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Inflammatory bowel disease (IBD) is a chronic lifelong condition which comprises 
Crohn’s disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified 
(IBDU). Around 8% of IBD cases diagnosed each year present in childhood (under 18 
years)(1) and can cause impairment of linear growth and pubertal development, affecting 
education and future employment. The incidence of paediatric IBD (PIBD) is increasing both 
within Scotland, as evidenced by previous publications, but also worldwide as 
demonstrated in a recent systematic review. As the number of cases are increasing, it has 
become critical that effective treatments are available to manage symptoms in this patient 
cohort. Anti-TNF alpha antagonists have been used to treat PIBD and shown in large single 
centre studies to be effective at the induction and maintenance of remission, however, 
these studies may not reflect the general PIBD patients’ clinicians treat daily so “real life” 
experience are needed to inform clinical practice. 
 
Aims 
The aims of my thesis were 1) to determine if the incidence and prevalence of PIBD 
continue to increase worldwide and to examine the durability of any incidence rise seen in 
Scotland, 2) to investigate in a nationwide population-based study the incidence and 
natural history of IBDU, 3) to examine the efficacy, safety and long-term effects of anti-TNF 
alpha drugs and lastly 4) to assess the long-term risk of PIBD on cancer and mortality rates 







Data was collected from all 4 PIBD centers across Scotland (Glasgow, Edinburgh, 
Aberdeen and Dundee) from 2009-2014 on new cases of IBD as well as those diagnosed 
with IBDU from 2003-2013, those treated with anti-TNF drugs from 2000-2012 and cases of 
cancer/deaths within the PIBD population from 2003-2013.  
Results 
Thirty-six studies from 18 countries were included in the incidence systematic 
review, most from North America and Western Europe. The highest incidence was 15.2 per 
100,000 in Nova Scotia, Canada with the lowest 0.47 per 100,000 in Saudi Arabia, for CD 
the highest incidence was 9.2 per 100,000 in Nova Scotia and lowest in Saudi Arabia at 0.27 
per 100,000 whilst for UC rates were highest in Finland at 8 per 100,000 and lowest in 
Saudi Arabia at 0.2 per 100,000. In the prevalence systematic review, 27 studies were 
included from 12 countries with the highest prevalence of 301 per 100,000 in Israel and 
lowest in Libya at 3.6 per 100,000. CD was highest in Sweden at 41 per 100,000 and lowest 
in Libya at 2.0 per 100,000 which was similar for UC with a high of 30.7 per 100,000 in 
Sweden and lowest at 1.36 in Libya. Most studies that reported on temporal trends saw an 
increase in PIBD, CD and UC. Significant heterogeneity existed in studies in both incidence 
and prevalence due to varying methodological approaches, age cut offs and diagnostic 
algorithms so meta-analysis was not performed. 
The incidence of PIBD in Scotland demonstrated a significant and sustained rise from 
430 cases in 2003-2008 with an incidence rate of 7.6 per 100,000 (95%CI 7.1-8.6) to 582 
cases in 2009-2014 and incidence of 10.6 per 100,000 (95%CI 9.8-11.5) (p<0.001); primarily 
due to an increase in paediatric Crohn’s disease. When compared with historical data there 
was a sustained and durable increase over the last 40 years, again mostly driven by 




20% of new PIBD cases in Scotland. Most children with this subtype had a relatively mild 
disease course, however 43% required immunosuppression and a small number escalated 
to anti-TNF therapy. 23% of IBDU patients had their diagnosis changed after endoscopic re-
evaluation, most 62%, to CD. A Scottish nationwide registry of all children treated with anti-
TNF drugs (infliximab (IFX) and adalimumab (ADA) was created from 2000-2012. 87% had 
improvement of their symptoms within 3 months post induction to IFX and 86% achieved 
remission with ADA. Growth was improved after one year of treatment with IFX but only in 
those children who responded after induction, had been diagnosed for over 2 years with 
IBD and were in the early stages of puberty (Tanner stage 1 and 2).  Anti-TNF agents were 
generally safe and well tolerated with only 13% having an acute adverse reaction to IFX, 
ADA was also well tolerated with 16/57 having an adverse event. Death in children with 
PIBD was a rare occurrence with only 3 cases over 10 years, 2 cases were PIBD related with 




The incidence and prevalence of PIBD is increasing worldwide with the highest 
incidence rates from Nova Scotia, Canada and highest prevalence rates from Israel, 
although there is a propensity of data from North America and Western Europe.  
In these population-based studies of paediatric-onset inflammatory bowel disease in 
Scotland, the number of new cases continue to rise with IBDU, as a subtype of IBD, more 
commonly diagnosed compared to other countries. Most children with IBDU had a mild 
disease course with 23% changing diagnosis following endoscopic reassessment most, 62% 
to CD. In Scotland, anti-TNF drugs are effective at managing symptoms of IBD with 




those treated with infliximab. Finally, cancer and death are a rare outcome in children with 
IBD in Scotland. The continued increase in incidence of PIBD with higher rates of IBDU 
observed in Scotland may suggest environmental factors, such as urbanization or latitude, 
influencing the onset of PIBD. Prospective case control studies can further explore these 
environmental risk factors taking advantage of the nationwide collaborative approach to 
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1. Introduction: Epidemiology of Paediatric-onset 
Inflammatory Bowel Disease 
Paediatric-onset Inflammatory Bowel disease (PIBD) is a chronic lifelong condition 
which comprises Crohn’s Disease (CD), Ulcerative Colitis (UC) and Inflammatory Bowel 
Disease Unclassified (IBDU). Around 8% of cases of inflammatory bowel disease present in 
children and young people(1).The worldwide incidence of PIBD is increasing, with countries 
which historically reported low incidence rates now reporting more cases, however, the 
highest rates continue to be from Northern Europe and North America (2). With increasing 
incidence, further research into pathogenesis and the advancement of therapeutic options 
is critical given the significant impact PIBD has on growth(3), puberty, employment and 
mental health(4). 
The observed increase in PIBD cannot be explained by genetics alone which evolve 
over thousands of years with no recent significant population shift to explain this. Many 
alternative theories have been postulated such as dietary and lifestyle factors, 
environmental triggers, epigenetics, alteration in the gut microbiota or improved methods 
of diagnosis(5). Epidemiological research can provide data on temporal trends and clues to 
pathogenesis and environmental risk factors which can then be more closely examined.  
 
1.1 - What is IBD? 
1.1.1 Crohn’s disease (CD) 
Crohn’s disease can affect anywhere in the GI tract from the mouth to the anus and 
is characterised by patchy transmural inflammation (6). Pathological findings include non-
caseating granulomata remote from a ruptured crypt (not always present) and focal 
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chronic inflammation including in the upper gastrointestinal tract. Macroscopic findings 
include linear or serpentine aphthous ulcers, cobble stoning, skip lesions, jejunal or ileal 
ulcers or strictures.  
Crohn’s is classified by the location (colonic, ileocolonic, terminal ileal or upper GI), 
disease behaviour (inflammatory, fistulising or stricturing), age at onset (less than 10 years 
or less than 17 years for paediatric patients) and with a qualifier of perianal disease or not 
(7). These criteria form the basis of the Paris classification  for CD which is a paediatric 
specific phenotypic classification(7). 
 
1.1.2 Ulcerative Colitis (UC) 
Ulcerative colitis affects mainly the colon although can affect the final part of the 
terminal ileum so called “backwash ileitis”. Differing from Crohn’s disease it is 
characteristically a continuous diffuse mucosal disease which is divided into pancolitis 
(proximal to the hepatic flexure), extensive colitis (affecting up to hepatic flexure), left 
sided colitis (affecting up to the splenic flexure) or ulcerative proctitis (affecting the final 
part of the colon only)(7). UC has the qualifier of clinical remission, mild, moderate or 
severe colitis. These criteria form the basis of the Paris classification  for UC which is a 
paediatric specific phenotypic classification(7). Histologically it displays architectural 
distortion, worsening disease distally, cryptitis and crypt abscesses whilst macroscopically 
there is superficial ulceration, friability, erythema and granularity.  
 
1.1.3 Inflammatory Bowel Disease Unclassified (IBDU) 
The diagnosis of IBDU has evolved over the years having been first described in 1978 
as Indeterminate colitis (IC),  a colitis with insufficient evidence to diagnose either Crohn’s 
disease (CD) or ulcerative colitis (UC), but macroscopic and microscopic findings suggestive 
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of chronic intestinal inflammation after infection had been excluded(8)(Table 1).  
Subsequently, IC was renamed colonic inflammatory bowel disease, type unclassified 
(IBDU) in the Montreal classification where it was first defined as a IBD subtype, requiring a 
clinical diagnosis made by clinicians following an inconclusive endoscopy rather than a 
temporary diagnosis made by pathologists (7, 9). However, the Montreal classification did 
not provide guidance on how to differentiate IBDU from UC/CD but did emphasise the 
importance diagnosing it due to the poorer prognosis than UC, including increased risk of 
chronic pouchitis following surgery. IBDU was ill-defined in terms of diagnostic criteria until 
recently when described by the Porto group as “Patients with definite IBD wherein 
inflammation is limited to the colon with features that make the differentiation between 
CD and UC uncertain even after a complete work up”(10). Despite this new definition, it 
remains a poorly understood and often underdiagnosed as clinicians doubt it is a sub type 
of IBD and do not diagnose it, patients are often labelled as CD/UC, even in the presence of 
atypical features. Figure 1 describes features which suggestive of CD, atypical UC and those 
which would trigger a diagnosis of IBDU. Evidence used to support the criteria could be 
improved upon as data is limited by small study numbers and short follow up.  
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Table 1 Classification of Inflammatory Bowel Disease Unclassified (IBDU) 
since first described in 1978 
Year Author Description of IBDU 
 
1978 Price(8) Colitis with insufficient evidence to diagnose CD 
or UC but macroscopic and microscopic findings 
suggesting chronic intestinal inflammation after 
infection has been excluded 
 
2005 Escher (Porto 
group)(11) 
Histology showing acute and chronic 
inflammation with architectural changes 
confined to the colon….. with normal small 
bowel follow through or enteroclysis where 









Further refined using serological and genetic 
markers as well as capsule endoscopy and other 
novel diagnostic tests 
 
2014 Levine (Porto)(10) Patients with definite IBD wherein inflammation 
is limited to the colon with features that make 
the differentiation between CD and UC 
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Figure 1- Diagnostic features suggestive of IBDU (13) 
TABLE 3. Diagnostic features in a child with untreated colitis phenotype at diagnosis  
Likelihood of 
occurring in UC Feature 
Diagnostic 
approach 
Class 1: Non -existent Well-formed granulomas anywhere in the GI tract, remote from 
ruptured crypt 
Deep serpentine ulcerations, cobblestoning or stenosis anywhere 
in the SB or UGI tract 
Fistulizing disease (internal or perianal) 
Any ileal inflammation in the presence of normal cecum (i.e., 
incompatible with backwash ileitis) 
Thickened jejunal or ileal bowel loops or other evidence of 
significant SB inflammation (more than a few scattered erosions) 
not compatible with backwash ileitis 
Macroscopically and microscopically normal appearing skip 
lesions in untreated IBD (except with macroscopic rectal sparing 
and cecal patch) 
Large inflamed perianal skin tags 
Diagnose as CD 
Class 2: Rare with UC 
(<5%) 
Combined (macroscopic and microscopic) rectal sparing, all 
other features are consistent with UC 
Significant growth delay (height velocity <2 SDS), not explained 
by other causes 
Transmural inflammation in the absence of severe colitis, all 
other features are consistent with UC 
Duodenal or esophageal ulcers, not explained by other causes 
(e.g., Helicobacter pylori, NSAIDs and celiac disease) 
Multiple aphthous ulcerations in the stomach, not explained 
by other causes (e.g., H pylori and NSAIDs) 
Positive ASCA in the presence of negative pANCA 
Reverse gradient of mucosal inflammation (proximal >distal 
(except rectal sparing)) 
Diagnose as IBD-
U, if at least  
1 class 2 feature 
exists 
Class 3: Uncommon 
(5%–10%) 
Severe scalloping of the stomach or duodenum, not explained 
by other causes (e.g., celiac disease and H pylori) 
Focal chronic duodenitis on multiple biopsies or marked 
scalloping of the duodenum, not explained by other causes 
(e.g., celiac disease and H pylori) 
Focal active colitis on histology in more than 1 biopsy from 
macroscopically inflamed site 
Non–bloody diarrhea 
Aphthous ulcerations in the colon or UGI tract 
Diagnose as IBD-U 
if at least  
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1.2 Classification of PIBD 
Accurate phenotyping of patients is essential to conduct research into disease 
pathogenesis and the genetic basis of disease to allow the comparison of the same types 
of patients. There have been several landmark papers which have demonstrated the 
evolving process of IBD phenotyping as our understanding develops in terms of the 
disease course, improved diagnostic tools such as small bowel enteroscopy and other 
imaging modalities, disease biomarkers both serological and faecal. The first classification 
of IBD was in 1991 by an international working group who reported from Rome a 
classification for CD which used disease location, behaviour, disease extent and operative 
history(14). This was then followed by the Vienna classification in 2000 (15) which 
simplified the 756 potential categories of the Rome criteria. In both of these publications 
UC was not considered, neither was IBDU, so in 2005 the Montreal criteria were then 
published (9). Unfortunately, the criteria did not consider the specific differences in 
paediatric-onset disease so paediatric gastroenterologists met and devised the Paris 
criteria which were published in 2011(7). The Paris criteria included disease severity, the 
increased propensity for disease extension(16), impact of disease on growth and further 
sub dividing ages to include a separate category for those under 10 years of age as 
opposed to 17 which had been the previous arbitrary cut off. The differences between 
with Montreal and Paris criteria are listed in Table 2.  
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Table 2 Montreal and Paris Classification for Crohn’s Disease and Ulcerative 
Colitis 
 Montreal  Paris 
Age at diagnosis A1: 0-16years 
A2: 17-40 years 
A3: >40 years 
A1a: 0-10 years 
A1b: 10-16 years 
A2: 17-40 years 
A3: >40 years 
Crohn’s disease   
Extent L1: Terminal Ileal 
disease +/- limited 
caecal disease 
L2: Colonic disease 
L3: Ileocolonic 
L4: Isolated upper GI 
disease 
L1: Distal 1/3 Ileum 
disease +/- limited 
caecal disease 
L2: Colonic disease 
L3: Ileocolonic 
L4a: Upper GI disease 
proximal to the 
ligament of Treitz 
 L4b: Upper GI 
disease distal to the 
ligament of Treitz and 
proximal to the distal 
1/3 ileum 




P= perianal disease 
modifier 





P= perianal disease 
modifier 
Growth n/a G0: No evidence of 
growth delay 
G1: Growth delay 
Ulcerative Colitis   
Extent E1: Ulcerative Proctitis 
E2: Left sided colitis 
(distal to splenic 
flexure) 
E3: Extensive 




E2: Left sided colitis 
(distal to splenic 
flexure) 
E3: Extensive (hepatic 
flexure distally) 
E4: Pancolitis 
(proximal to hepatic 
flexure) 
Severity S0: Clinical remission 
S1: Mild UC 
S2: Moderate UC 
S3: Severe UC 
S0: Never severe* 
S1:  Not ever severe* 
 
*Severe defined by Paediatric Ulcerative Colitis Activity Index (PUCAI) >65 
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1.3- Diagnosis of IBD 
The diagnosis of inflammatory bowel disease requires thorough history taking and 
examination, laboratory investigations of both blood and faeces as well as endoscopic 
evaluation with upper gastrointestinal endoscopy and full ileocolonoscopy with serial 
biopsies (See Figure 2) (10); clearly infective and other aetiologies should be excluded first. 
The symptoms of PIBD are varied so it is essential to maintain an index of suspicion in 
unclear cases(17), the commonest symptoms of abdominal pain, diarrhoea and weight loss, 
the so called “triad” only occurs in 25% of CD(18). CD can also present with pyrexia, 
unexplained anaemia or growth failure whilst UC more commonly presents with bloody 
diarrhoea (10). Extra-intestinal manifestations of IBD can occur at diagnosis including joints, 
ocular, liver and skin involvement (19, 20).  
The current guidelines recommend small bowel imaging, particularly in suspected 
CD, when ileal intubation was not possible or where IBDU is being considered. Imaging can 
be either MR enterography, barium meal or capsule endoscopy depending upon the 
facilities of the centre (10).  




Figure 2: ESPGHAN Revised criteria for diagnosis of IBD 
 
1.4 Treatment of PIBD 
The key treatment goals in PIBD are to induce and maintain remission, promote 
normal growth and pubertal development, minimise drug toxicity and improve quality of 
life (21). However, recent evidence would suggest that another key target, mucosal 
healing, should be achieved. By achieving mucosal healing after induction therapy in UC 
outcomes are improved including longer term remission, decreased colectomy rates and 
longer term corticosteroid free remission(22). A similar review was published for CD, 
again demonstrating longer duration of remission, decreased risk of surgery and longer 
term mucosal healing in those that achieve mucosal healing post induction therapy(22). 
Therapeutic options and strategies differ for CD and UC consequently separate 
guidelines exist for each. However, the evidence basis for many of the treatments used in 
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PIBD, for either CD or UC, is limited as few placebo controlled trials exist (23). 
Furthermore, given the ethical issues around withholding potentially effective treatment 
from children combined with the evidence that children often have an improved 
response to certain treatments, efficacy from adult data is often extrapolated to 
paediatric patients (24). Consensus guidelines exist for CD (21) and for UC (25), notably 
this guidance on UC does not include the management of acute severe colitis which was 
covered in a separate publication(26). 
 
1.4.1 Exclusive Enteral Nutrition 
Exclusive enteral nutrition (EEN) is used in Europe as the mainstay of induction of 
remission in paediatric CD and is recommended by European guidelines (21). There is no 
evidence of efficacy of EEN in UC. Systematic reviews have consistently proved that EEN is 
as effective as corticosteroids in inducing remission with additional benefits in terms of 
reducing adverse effects of corticosteroids, improving weight and nutritional status (27-29).  
The efficacy of EEN is independent of the luminal disease location (30) and has been shown 
to induce mucosal healing (31). However, only short term improvement in linear growth 
have been observed (32) with no evidence it does so in the long term(33).  
EEN is usually given over 6-8 weeks either orally or via nasogastric tube with both as 
effective at inducing remission; usually a polymeric (whole protein) feed is given to improve 
the palatability as it is equally as effective as elemental (amino acid based)(34, 35).  
 
1.4.2 Corticosteroids 
Corticosteroids can be used as induction treatment for either UC or CD, although 
most centres would reserve corticosteroids in CD for those not responsive to EEN or severe 
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presentations (21).  In UC, steroids are first line in the management of acute severe colitis 
and for moderately active UC with systemic features(25). Corticosteroids should not be 
used as a maintenance treatment for IBD(21, 25). Adverse effects associated with 
corticosteroid usage include poor long term growth which is well recognised and can be 
mitigated by single daily dosing in the mornings(36) and steroid sparing treatments which 
are preferred. Steroid dependency in paediatric UC can develop in 45% at one year when 
used as induction agent at diagnosis which is higher than reported in adults(37, 38) making 
it essential to introduce adjuvant therapies promptly to allow weaning.   
 
1.4.3 5- Aminoacylates 
5-aminosalycylates (5- ASAs) are mostly used in the induction and maintenance of 
remission in UC, there is limited evidence of efficacy in paediatric CD. In UC, oral 5-ASAs are 
recommended for induction in mild to moderate disease as well as for maintenance(25). If 
no response to 5- ASA is noted within the first 2 weeks of therapy escalation to oral 
steroids or adding in enema therapy is recommended. Enemas as an adjuvant in UC have 
been shown to be effective in improving disease activity in mild to moderate proctitis in 
children(39).  Although oral 5-ASAs are highly effective, their efficacy is enhanced when 
combined with rectal preparations, which is preferred above corticosteroid enema 
treatment.  Lifelong therapy with 5-ASA is recommended due to the relatively low risk of 
complications combined with the long term benefits including cancer prevention(25) with 
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1.4.4 Azathioprine /6-Mercaptopurine 
Thiopurines, 6- mercaptopurine (6-MP) or the pro drug azathioprine (AZA), are 
recommended for both UC and CD for the maintenance of steroid-free remission but not as 
an induction agent(21, 25). The full efficacy of thiopurines is not reached until 8-14 weeks 
after commencement which is why they should not be used as an induction agent. In the 
only placebo controlled trial of the use of thiopurines, relapse rates of 4 and 9% were given 
for those on mercaptopurine compared to 26 and 47% in the placebo arm(41). Additional 
benefits of AZA include a decreased risk of surgery(42), reduced corticosteroid use and 
fewer hospitalisation(43).  
A rare and serious complication associated with thiopurines is lymphoma; the 
relative risk is increased by 4 fold in patients on thiopurines with the risk is higher for males 
but the absolute risk remains low with 4.5 per 10,000 patient years(44). Furthermore, both 
AZA and anti-TNF therapy have been associated with the almost universally fatal 
hepatosplenic T cell lymphoma which occurs mainly in males in the teenage years or early 
20s(45). The evolution of this lymphoma has led to a change in practice with some 
physicians avoiding combination therapy with AZA and anti-TNF preferring to use 
methotrexate as a co-immunosuppressant or anti-TNF monotherapy.  
 
1.4.5 Methotrexate 
Methotrexate (MTX) can be used as an alternative immunomodulator and has been 
shown to be effective in the maintenance of remission for those with CD who have failed 
thiopurines(46, 47). Clinical practice varies, some centres would advocate MTX after failure 
of thiopurines, other would use as a first line immunosuppressant as single agent therapy 
whilst others would advocate its use as combination therapy with anti-TNF agents.  MTX 
can be given either subcutaneously or orally although most centres would choose 
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subcutaneously first line(48). In UC, the data regarding MTX use is sparse with one small 
trial demonstrating efficacy with 50% response/remission at 12 months. Due to the lack of 
evidence the current guidelines do not support its routine use suggesting only when there 
are a lack of suitable alternatives in those non responsive or intolerant to thiopurines(49). 
The most common reported side effects of MTX include nausea and vomiting, 
hepatotoxicity and myelosuppression. Folic acid supplementation is recommended but 
there is no clear evidence to support daily versus weekly administration(21). 
 
1.4.6 Anti-Tumour Necrosis Factor drugs 
1.4.6.1 Infliximab 
IFX, the first tumour necrosis factor-alpha antagonist (TNF-α) (50) gained UK licences 
for adult and paediatric CD in 2002 and  2010 respectively(51, 52) having been used off-
licence from the late 1990s(23) prior to RCTs in PIBD,(53-55) given the available high quality 
evidence for IFX use in adult IBD (56, 57). IFX is recommended for use in chronic active 
luminal CD after failure of immunomodulators, steroid dependency or steroid refractory 
disease and for first line in management of perianal fistulising disease in conjunction with 
both a surgical and medical approach(21).  It was first described in paediatric patients in a 
case series of by Hyams with refractory Crohn’s and was effective in inducing 
remission(58). When first licensed, IFX was used on an episodic or “as needed” basis to be 
administered when patients became symptomatic. However, after the ACCENT trial when 
episodic was compared to scheduled dosing in adult CD, it was shown to be superior so 
practice was changed with scheduled dosing as a standard practice; a similar study 
confirmed this in paediatric patients(55). The REACH study was the first large paediatric 
cohort which demonstrated both safety and efficacy of IFX in CD (53). The uptake for use in 
UC followed but was only published in 2012 for the management of acute severe colitis 
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(54), its use varied between countries and even between centres in each country 
depending upon expertise and familiarity with its use compared to ciclosporin. However, 
the recent ECCO/ESPGHAN guidelines recommend it as the first line biological drug of 
choice for both UC and CD and as a rescue treatment in acute severe colitis(25, 26). In 
addition to inducing and maintaining remission, IFX has been shown to improve linear 
growth and promote mucosal healing(59, 60).  
However, many issues have yet to be resolved in using anti-TNF drugs to treat PIBD 
including identifying patients likely to have a prolonged response to treatment and 
balancing the risk/benefit of combination therapy (anti-TNF and immunomodulator vs 
monotherapy with anti-TNF therapy alone) and the role of therapeutic drug monitoring. 
Therapeutic drug monitoring has evolved with evidence supporting a proactive approach to 
optimising levels rather than awaiting clinical response(61) yet more evidence supports 
higher trough levels for perianal disease(62). Loss of response to anti-TNFs is a key 
challenge for clinicians(50), initial loss of response can be regained with dose escalation 
unfortunately, this is often not maintained and remains a common reason for 
discontinuation of therapy(63, 64). Several risk factors have been identified including: 
isolated colonic crohn’s disease, lack of remission post induction, increased BMI, 
corticosteroid use at baseline and strictures(65-68). Despite being widely discussed in the 
literature, there is no consensus definition on loss of response making it difficult to 
compare results from various studies(69) and no clear protocol on how to manage although 
current evidence supports dose optimising and the addition of an immunomodulator if not 
currently receiving (61, 70). 
Anti-TNF therapy has been associated with an increased risk of opportunistic 
infections including reactivation of tuberculosis and other serious infections such as 
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abscesses and sepsis (50), and of malignancy, in particular hepatosplenic T cell lymphoma 
(HSTCL). However, the cases of HSTCL received concomitant thiopurines(71). 
Biosimilars to infliximab are now available, which are innovators of the 
biopharmaceutical products made by different companies once the drug licence has 
expired. This change has driven down dramatically the costs involved with no observed 
increase in side effects with similar efficacy(72). Currently studies are ongoing in paediatric 




Adalimumab (ADA) (Humira) is a fully humanised anti-TNF alpha agent which is 
administered subcutaneously every other week. ADA was initially used for primary or 
secondary loss of response to IFX to induce and maintain remission in adult CD and UC(73-
77)  with efficacy now confirmed by RCT in paediatric CD in 2012(78). ADA was licensed for 
UK paediatric CD use in 2013 but with prior widespread off-licence usage reported via a UK 
audit(79).  Few case reports exist in the use of ADA in UC which seem to suggest efficacy 
including UK and Irish data, but the numbers involved are small(79, 80). Less has been 
published on the side effects of ADA, however, similar risks exist of opportunistic 
infections(50) and increased malignancy, particularly with co-immunosuppression(50). 
 
1.4.6.3 Golimumab, Certolizumab pegol and other new drugs 
Other anti-TNF drugs are available such as golimumab and certolizumab pegol which 
are not yet licenced in paediatric use. Golimumab was effective in small paediatric UC 
trials(81) but not in CD(82),  it has a licence in adults for moderate to severe UC with 
certolizumab demonstrating efficacy in adult refractory CD only(83).  
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Further drug development is underway targeting other cytokines in the inflammatory 
pathway such as interleukin 12/23 with ustekinumab or anti integrins with vedolizumab. 
Both are becoming more common in adult practice with randomised control trials 
confirming efficacy but limited case reports are available in paediatric patients (84). Other 
more novel therapies are in development including mesenchymal stem cells for the 
treatment of perianal CD and the use of T regulatory cell and small molecule drugs (SMD) 
such as tofacitinib.  SMDs, are composed of smaller molecules which can be administered 
orally, a key benefit in PIBD, with Tofacitinib, a Janus kinase inhibitor, successful  in UC(85) 
but not for CD(86).  
 
1.5 Epidemiology of PIBD  
1.5.1  Systematic review on incidence 
Systematic reviews on the incidence of PIBD and adult-onset IBD have been 
published with data on prevalence reported in adults only (2, 87). In the paediatric review, 
there were key methodological flaws including variable age ranges used to defined PIBD 
from 14 to 19 years which impacts upon incidence rates the higher the age range as more 
patients are included. The review reports incidence from 139 studies from 32 countries 
which are mostly from Europe and North America with a paucity of data from developing 
countries (Figure 3), contrasting with the adult-onset IBD systematic review, which had 
data from countries which had not previously confirming the increasing incidence of 
IBD(87). Currently, there is no systematic review on prevalence of PIBD, however, there is 
an increasing trend in prevalence of adult- onset IBD suggesting a similar trend may be 
observed in paediatrics.   
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Figure 3 Worldwide map of countries reporting incidence of paediatric–
onset Inflammatory bowel disease(2) 
 
 
1.5.2  Systematic review prevalence 
The systematic review on adult-onset IBD demonstrated an increasing prevalence, 
which as with incidence, was highest in Europe/North America and lowest in Asia(87). 
There was a paucity of data in PIBD prevalence, however, increases have been observed in 
North America(88, 89).  
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1.5.3 Population–based studies in PIBD 
There are few population-based studies of incidence of PIBD compared to referral 
centre based due to data collection issues. Population-based studies suggest that PIBD is 
unevenly distributed throughout the world with the highest rates in more industrialised 
countries in Europe/North America which are (2). However, data is lacking from developing 
countries which will be discussed further in chapter 3. 
 
1.5.4 Temporal trends in incidence in PIBD 
Longitudinal incidence provides key messages about temporal trends and insight into 
potential environmental factors, informs service delivery and planning, yet few studies 
report it as evidenced by only 20% of papers in a recent incidence systematic review 
reporting it. 77%  of those reporting temporal data demonstrated an increase with none 
reporting a decrease (2), this is mirrored in adult IBD with increasing incidence for both CD 
in 43/57 (75%) and UC 30/50 (60%) in studies that reported data over at least 10 years(87) 
with none reporting a decrease. 
Within the UK, incidence rates have increased in Scotland(90-92), Wales(93-96) and 
Wessex(97), although the rates were highest in Scotland (Table 3). In Scotland, when PIBD 
incidence was first recorded in 1969, UC was the predominant IBD subtype, however, over 
the next 40 years the incidence of both has significantly increased with CD now the most 
common subtype(90-92). This phenomenon has been reported in other western 
countries(98-100) with UC the predominant subtype when IBD is first reported then CD 
becomes more common as countries become more westernised with Hong Kong an 
example(101) .  
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Table 3: Recent incidence data for Crohn’s disease (CD) ulcerative colitis 
(UC) in childhood in the UK (incidence rates are provided per 100,000) 




Barton(90) Scotland 1968 0-16 CD 0.7 UC 1.9* 





CD 2.5 UC 1.3 
Henderson(92) Scotland 2003-
2008 
0-15 IBD 7.82 CD 4.75  
UC 2.06 
Cosgrove(94) S Wales 1983-
93 
0-15 CD 2.2 UC 0.7 
Hassan(96) Wales 1995-
97 











0-16 IBD 2.7 
Sawczenko(102) UK 1998 0-15 CD 3.1 UC 1.4 
Ashton(97) UK, Wessex 2002-
2012 
0-16 IBD 6.39 CD 3.8 
UC 2.01 
*Rates for 6-16 years 
 
1.5.3 Geographical trends in incidence  
A North-South divide within countries has been described in both Europe (103) and 
North America where more northern states have higher incidences(89, 104, 105). However, 
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the North American studies are from insurance databases which are not population-based 
and may influence their results. Population-based studies, such as EPIMAD, have found 
increased cases in urban verses rural areas(106, 107).  In adult IBD, a population-based pan 
Europe study, an East-West divide was observed, paediatric patients were included but the 
numbers involved were small suggested incomplete accrual(108).  
 
1.5.4 Incidence of PIBD in Scotland 
Incident data for PIBD has been collected across Scotland since 1969 and has 
demonstrated a continued and sustained increase until 2008(90-92). When incidence data 
was reported in 1989, incidence rates of CD were higher than UC with a suggestion that 
rates of UC were decreasing. Disease distribution was similar to adult data with 38% of CD 
patients having panenteric disease and 50% of UC patients with extensive or pancolitis(90). 
Armitage reported in 2001 an increasing trend for UC although CD remained higher at 2.3 
per 100,000 compared to 1.3 per 100,000 for UC(91) with a 30% increase in IBD. By 2008, 
the incidence of IBD had continued to rise with  a 76% increase from the mid-1990s to 7.82 
per 100,000 with CD again more frequently reported with an incidence of 4.75 per 100,000 
(92) (see Figure 4).  Countries which reported higher incidence rates included Canada and 
Norway (109, 110) (111-113), both of whom have a northern latitude similar to Scotland 
(Figure 5). 
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Figure 4- Incidence of paediatric onset CD from 1969- 2008 in Scotland(92) 
 
Figure 5 – Temporal trends of worldwide incidence of paediatric-onset 
Inflammatory Bowel Disease(2) 
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1.6 Natural history of PIBD 
1.6.1 Evidence from population-based studies 
Few population-based studies examine the natural history of PIBD due to 
methodological challenges particularly related to the longitudinal follow up required, 
however, those that have provide key insights, and how this differs from adult onset 
disease. Different countries have shown similar and yet conflicting reports which may 
relate to numerous confounders including environmental factors, differences in diagnostic 
evaluation, treatment strategies and disease reassessments. However, a review of the 
published literature on UC reported 50% had disease progression as two thirds with a 
pancolitis by end of follow up and 20% required a colectomy by 10 years post diagnosis 
with 50% suggesting an aggressive phenotype (114).   
 
1.6.2 Cancer and mortality 
Cancer associated with PIBD is rare but studies report an increased rate in adults 
who were diagnosed with IBD in childhood(115). Deaths related to PIBD are also relatively 
low with the highest rates reported in earlier studies due to small or large bowel cancers 
which were hypothesised to be related to underlying disease activity(116). ESPGHAN 
published in 2014 European wide retrospective data showing that the leading cause of 
death was not malignancy as had been previously feared but, infection related to 
immunosuppression, follow then by cancer and uncontrolled disease(117); an important 
sequelae as chronic inflammation can lead to immune dysregulation with impaired tumour 
surveillance(118). The treatment of PIBD has changed significantly in recent years with 
more aggressive management including early immunosuppression in selected cases (21, 25) 
as evidenced by Scottish data with 45% of children with Crohn’s disease will be on 
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immunosuppression by 12 months(16). As the incidence of PIBD in both Scotland(92) and 
the rest of the world increases(2), the number of children on immunosuppression with the 
associated risks of opportunistic infections and malignancy will consequently increase.  
Further concern surrounds hepatosplenic T cell lymphoma (HSTCL), an almost universally 
fatal lymphoma which often occurs in young men with CD treated with thiopurines and/or 
anti-TNFs(119). 
EPIMAD published one of the few population-based studies into mortality and 
morbidity, reporting a mortality rate of 0.84% which did not differ from the background 
population. However, it did report a slightly increased risk of cancer which was not 
dependent upon age or gender, with 4 of 9 who developed cancer receiving prior 
immunosuppressants or anti-TNF. 1.3% of patients who developed cancer did so after a 
median follow up of 15 years, so in adult care, which was an increased risk compared to the 
general population(120). A national population-based study from Sweden supports this 
finding with an increased risk of gastrointestinal, hepatic, lymphatic and skin cancers in 
those diagnosed with IBD in childhood compared to those without IBD but with risk factors 
identified of a family history of cancer, long standing colitis and primary sclerosing 
cholangitis (121). Those diagnosed with IBD at a younger age had a higher mortality rate 
although the absolute risk remained low in a Danish population-based cohort(122). 
Studies presenting data on the risk of cancer in PIBD are listed in Table 4 with a 
summary of mortality studies not listed in a recent systematic review in Table 5.  
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449 (CD) 7077 12 (any 
cancer) 
8 (CRC) 
1.0 (0.5 to 
2.1) for CRC 














<15 363 (UC) 4220 13 (CRC) 3.1 (1.7 to 
16.3) 






<30 964(CD) 12025 5 (CRC) 0.4 (0.2 to 
0.9) 

















<20 4763 (UC, CD)  52100 18 (CRC) 0.3 (0.2 to 
0.5) 












698 (UC, CD) NR, median 
12 years 






























<17 5766 (UC, CD) 24543 15 (any 
cancer) 
9 (lymphoid) 






















3.3 (3.1 to 
3.6) 
0.6 (0.4 to 
0.9) 
























CD= Crohn’s disease, UC=ulcerative colitis, NA= not applicable, NR= not reported, CRC= colorectal cancer, CI=confidence interval, HR= hazard ratio, Thio= thiopurines 
*Standardised incidence ratio, unless otherwise stated; &- patient diagnosed <19 years but developed malignancy by 26 years; £- total number of malignancies 
reported; $-incidence reported per 1,000,000 patient years based on 33 cancer cases 
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698 (UC, CD) NR, median 
12 years 
















<19 55,036 192625 26 114  
CD= Crohn’s disease, UC=ulcerative colitis, NR= not reported, CI=confidence interval,  
*Standardised mortality ratio, unless otherwise stated 
 
1.7 Summary of thesis chapters 
Further understanding of the current trends in epidemiology of PIBD can be obtained 
through systematic review which will be explored via the incidence and prevalence in 
chapters 2 and 3. Temporal trend analysis of incidence provides information on the 
durability of rise or levelling out cases which is most effective in population-based studies 
such as Scotland which is seen in chapter 4. Few epidemiological studies have been 
performed on IBDU, the least common subtype of IBD, so a relative paucity of data exists 
on the natural history and efficacy of treatments which is explored further in chapter 5. 
Chapter 6 covers the natural history of anti-TNF therapy in PIBD in a population-based 
cohort, anti-TNFs are now commonly used despite initial concerns regarding safety and 
with proven efficacy. However, most studies are either single or multi-centre studies with 
few population-based studies which limits the generalisability. Lastly, mortality and 
morbidity are important outcomes to evaluate in PIBD, particularly given the high use of 
immunosuppression currently in use (Chapter 7) and to counsel families regarding long 
term course and side effects.




























2.1 Methodology for incidence and prevalence systematic reviews 
 
2.1.1. Search strategy for incidence and prevalence systematic review 
A systematic literature search was performed using a predetermined protocol 
(Tables 5 and 6) using MEDLINE (1950-2017), Ovid MEDLINE® In-Process & Other Non-
Indexed Citations (PREM), Embase (1950-2017), and Cochrane Library on the 17th July 2017. 
The initial search included all languages with abstracts and titles of all eligible studies were 
reviewed, full text was obtained if appropriate and references cross checked by hand.  
Finally, a “grey literature” search was performed by hand which involved searching through 
the abstracts for the previous 8 years (2009-2017) of the European Society of Paediatric 
Gastroenterology, Hepatology and Nutrition, United Gastroenterology Week, European 
Crohn’s and Colitis Organisation and North American Society of Paediatric 
Gastroenterology, Hepatology and Nutrition. Once all full text articles were available, they 
were independently reviewed by FC and DCW for eligibility.  A final search was performed 
using Google Scholar™ using search terms “paediatric” “incidence” “prevalence” and 
"inflammatory bowel disease” to ensure no relevant papers were missed.  
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Table 6- Full Medline search for journal article retrieval (1950 to October 2017) for 
incidence systematic review 
1. inflammatory bowel disease/ or colitis, ulcerative/ or crohn’s disease/ or 
((ulcerative adj2 colitis) or (inflammatory adj2 bowel) or crohn*).mp. 
2. morbidity/ or incidence.mp. [mp=title, abstract, original title, name of substance 
word, subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
3. 1 and 2 
4. inflammatory bowel disease/ep or colitis, ulcerative/ep or crohn disease/ep or 
(((ulcerative adj2 colitis) or (inflammatory adj2 bowel) or crohn*).mp. and ep.fs.) 
5. 3 or 4 
6. limit 5 to "all child (0 to 18 years)" 
7. (infan* or child* or teen* or adolescen* or paediatric* or pediatric*).ti,ab 
8. 5 and 7 
9. 6 or 8 
 
Table 7- Search strategy (OVID) for prevalence systematic review (1950-2017): 
1. exp Inflammatory Bowel Diseases/ 
2. Colitis, Ulcerative/ 
3. (inflammatory bowel disease* or ibd or crohn* or ulcerative colitis or indeterminate 
colitis).ti,ab 
4. 1 or 2 or 3 
5. Prevalence/ 
6. Cross-Sectional Studies/ 
7. prevalence.ti,ab 
8. ep.fs 
9. 5 or 6 or 7 or 8 
10. exp Infant/ or exp Child/ or Adolescent/ or Young Adult/ 
11. (infant* or newborn or neonate* or child* or adolescent* or teen* or young adult* or 
young person or young people).ti,ab 
12. 10 or 11 
13. 3 and 9  
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2.1.2 Inclusion and exclusion criteria for incidence systematic review 
A prior systematic review was performed on the incidence of PIBD, CD and UC which 
included studies published before 1.1.2010(2), this current review was designed as an 
update, focusing on longitudinal trends in incidence, to that no eligible studies from the 
previous search had been missed, the literature was searched from 1950-2017 on studies 
reporting incidence of PIBD (i.e. CD, UC or IBDU) from 1950-2017.  Inclusion criteria were 
studies with (1) a clearly defined method of diagnosing PIBD including, but not limited to, 
clinical history, radiological findings, histological changes, endoscopic appearances and 
physician-confirmed diagnosis (used for healthcare administrative databases); (2) a clearly 
defined cohort of patients under 18 years of age; (3) incidence data reported; (4) a full 
manuscript available for review and (5) not included in the previous systematic review. In 
some studies patients were identified using ICD 10 codes for IBD (K51.0, K51.1, K51.2, 
K51.3, K51.9, K50.0, K50.1, K50.8, K50.9) from insurance or hospital databases.  Studies 
were excluded (Figures 6)  if paediatric data could not be clearly differentiated from adult 
data, where data was presented in graphical form only with no clear numeric values, only 
male or female incidence reported, hospital-based incidence only, included in the previous 
systematic review or review articles where no original data was presented (the references 
were reviewed to ensure all eligible studies were included). Studies were included which 
reported “possible” and “probable” for two reasons:  firstly, to allow comparison with the 
previous systematic review where these studies were reported and to maximise the 
number of studies to improve generalisability of the results. Methodological appraisal was 
hampered by lack of information for certain studies therefore, authors were contacted via 
e mail to obtain clarification (corresponding author contacted twice, then first author (if 
different from corresponding author), contacted twice, then senior author if no reply from 
previous attempts). Five authors replied to provide further data. Eight papers were 
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excluded that gave no clear paediatric data.  Studies in languages other than English were 
translated using Google Translate™ and their abstracts reviewed, however, upon review 
none met the inclusion criteria. All eligible studies were included despite the varied 
methodological approaches to provide as wide a range as possible of the incidence of PIBD. 
 
 
















2.1.3 Inclusion and exclusion criteria for prevalence systematic review 
Studies were reviewed that reported incidence and/or prevalence of PIBD (i.e. CD, 
UC or IBDU). Inclusion criteria were the same as for the incidence systematic review other 
than prevalence data had to be reported to be eligible. Similar exclusion criteria were used 
(Figure 7) with studies excluded that did not include any paediatric specific prevalence 
data. The same age criteria and methods of contacting authors were applied to this review. 
3482 Unique references 
 
3446 excluded 
 36 Included studies 
 Reasons for exclusion 
• Did not meet 
inclusion/exclusion 
criteria-3401 
• Adult and paediatric data 
combined- 16 
• No numerical data- 8 
• Superseded by more 
recent publication- 7 
• No paediatric data-5 
• Non- population-based- 
3 
• No incidence rates -3  
• Review articles- 3  
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Three authors replied to provide further data with three other papers excluded as no clear 
paediatric data was provided.   
 




















2.1.4 Age criteria for inclusion 
Studies were included if there was a clearly defined population less than 18 year of 
age which is commonly accepted to define the paediatric population. The previous 
incidence systematic review included studies of patients under 19 years of age to increase 
the number included but did not consider how this influenced their results. Both incidence 
and prevalence increase with age so the rates reported may over report the incidence of 
PIBD. Ideally studies would compare those aged under 17 years according to the Paris 
4910 Unique references 
 
4883 excluded 
27 Included studies 
Reasons for exclusion 
• Did not meet 
inclusion/exclusion criteria-
4822 
• Adult and paediatric data 
combined- 30 
• Incidence only- 17 
• No paediatric data-6 
• Poor methodology- 3 
• No numerical data- 3 
• Superseded by more recent 
publication- 1 
• Non- population-based- 1 
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criteria(10), however, due to  the diverse methods of data collection if these criteria were 
strictly applied the number of eligible studies would reduce significantly.  
 
2.1.5 Data collection for incidence and prevalence systematic reviews 
Data collected included: incidence/prevalence rates for PIBD/CD/UC/IBDU, year of 
study, assessment of methodology, methods of disease diagnosis, sources of data and age 
range of the population included.  A time trend analysis was conducted over a 10-year 
period with a least 2-time points within that period for the incidence systematic review 
only. 
 
2.1.6 Summarisation of data for incidence and prevalence 
Studies were summarised in table format. Geographic maps of incidence and 
prevalence of IBD, CD and UC were created using Excel 13 (Microsoft Corporation, 
Redmond, WATM) with rates represented using colour intensity (darker colour indicates a 
higher incidence/prevalence rate). Incidence/prevalence rates for regions were only shown 
for United States of America, United Kingdom and Canada which could be clearly defined. 
In countries where more than one regional incidence/prevalence was reported, the highest 
rate reported was assigned to the entire country where rates were not reported. Where 
incidence/prevalence was reported over several time points, the incidence/prevalence was 
plotted on line graphs for IBD, CD and UC with rates plotted representing 
incidence/prevalence per 100,000 population.  If incidence/prevalence was reported over 
several years (i.e. 2000-2005) then data was attributed to the final year of that epoch. 
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2.2 Methodology for data collection of Scottish incidence data for 




Scotland has a population of 5.2 million people with approximately 17% aged less 
than 16 years old (916,103 in 2011) ; the majority of inhabitants are Caucasian(133). It is 
located in Northern Europe (latitude (550-600) and covers 30,500 square miles with four 
cities with a population over 100,000 people(133). In Scotland, specialist paediatric 
gastroenterology, hepatology and nutrition (PGHAN) is provided through three tertiary 
regional networks covering all four academic centres (Glasgow, Edinburgh, Aberdeen and 
Dundee) and all district general hospitals having paediatric units, thus forming a virtual 
Scottish national network as previously described(92, 134).  
 
2.2.2. Case identification  
Data was collected from 1969 to 2014 for all newly diagnosed patients with PIBD in 
Scotland under 16 years who were diagnosed within paediatric services. In Scotland, 
children are routinely cared for in paediatric centres until their 16th birthday when they are 
transitioned to adult services, so this age was used as a cut off. Historically children aged 14 
years or above may have been referred to adult gastroenterology or adult surgeons and 
managed solely in adult care. However, with the advent of an established PIBD network the 
usual referral pattern now would be to paediatric IBD centres via primary or secondary care 
if IBD is suspected or to adult services if over 16 years unless extenuating circumstances. 
Due to changes in recording of new diagnoses during the study period, different methods 
of data collection were employed. For the most recent cohort, from 1st January 2009 to 31st 
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December 2014 (hereafter known as Cohort 2), cases of PIBD were identified from each of 
the three-tertiary paediatric centres and two district general hospitals (Dundee and 
Inverness) prospectively from PGHAN department-held databases for two centres and 
retrospectively from the remaining centre. Prospective data was collected using a 
downloaded excel spreadsheet which was manually cross checked to ensure no duplication 
or missing data which needed clarification with the local centre. For the previous cohort in 
2003-2008, hereafter known as Cohort 1,  cases were reported using robust methodology 
to ensure complete accrual utilizing pathology records, PIBD clinic lists, endoscopy lists and 
local team knowledge(92). This data was validated in Aberdeen using endoscopy logs from 
theatre for all children undergoing ileocolonoscopy (all procedures were performed under 
general anaesthetic), IBD clinic lists, pathology records and local team knowledge. In 
Inverness, cases were validated using the same methodology with the addition of cross-
checking ICD-9 codes for CD/UC (K555-558) for those who would have been aged under 18 
years during the study period. The respective collection of data for cohort 2 was performed 
using the same methodology as for cohort 1, validating local team knowledge against IBD 
clinic lists, pathology records and endoscopy lists for the duration of the study period from 
2009-2013.  Data from 1969-1995 cohort was collected using the Scottish Hospital In-
patient Statistics which records admission to hospital and classified using the ICD-8/9 codes 
(CD- 555/0-555.9, UC 556.0). From 1981-1995, these records were all hand examined and 
validated to ensure diagnostic accuracy(91, 92).However, data from 1968-1983 were 
limited by the exclusion of those under 5 years with UC, lack of available case records for 
review and poor coding(90).  
Following case identification anonymized data was then collected from a hand 
search of written case notes/electronic records and entered onto a centrally custom-built 
database (Access 2007, Microsoft Corporation, Redmond, WA) held at the lead centre. 
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Cases were individually scrutinized to ensure no duplication from different areas of 
Scotland using unique identifiers with non-incident cases removed.  
When PIBD cases were first collected in 1969, IBDU as a distinct phenotype of PIBD 
did not exist, even in the later cohort of 1981-1995 the concept of IBDU was not widely 
accepted or used. In the 1981-1995 cohort, only 2 cases of IBDU was identified so were 
amalgamated with the UC patients. To allow a clear comparison with the historical cohorts, 
trend analysis over time and to avoid misclassification bias, two groups will be analysed: CD 
and non-crohn’s colitis (NCC). 
 
2.2.3. Exclusion criteria 
 Patients were excluded who were diagnosed outside of Scotland or were above 16 
years at age of diagnosis if diagnosed within a paediatric centre. 
 
2.2.4. IBD phenotyping 
Diagnosis was based on clinical symptoms, laboratory results, endoscopic, 
radiological and histological assessment in-line with the revised Porto criteria(13) for 
cohort 2, original Porto criteria(11) for cohort 1 and Lennard Jones(135)  for 1969-1995 by 
the local specialist PIBD team. Investigations performed to confirm the diagnosis of PIBD 
varied between centres with no unifying diagnostic algorithm but included ileocolonoscopy 
and/or upper gastrointestinal endoscopy and/or small bowel imaging dependent upon the 
macroscopic and histological findings. Small bowel imaging was performed by white cell 
scans, barium meal and follow through or wireless capsule endoscopies dependent upon 
the centre; MR small bowel was not routinely available in all centres. Faecal calprotectin 
was also not routinely available in all centres then only latterly in certain centres. Patients 
were diagnosed as either Crohn’s disease (CD), ulcerative colitis (UC) or inflammatory 
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bowel disease unclassified (IBDU) by the local centres. All ambiguous cases were discussed 
with senior clinicians (RKR and DCW), both of whom are the lead PIBD consultants in their 
respective region and have significant experience in IBD phenotyping, with involvement in 
developing the recent ESPGHAN guidelines on diagnosis of PIBD(13). Within both cohorts, a 
small number of cases that were diagnosed as IBDU were subsequently reclassified as 
either CD or UC after full endoscopic re-evaluation, therefore, only the most recent 
diagnosis was used. Additionally, all incident cases are continually reviewed to ensure the 
initial diagnosis was correct and non-IBD cases are removed.  
IBD phenotyping has evolved over the years with the first classification created in 
Rome in 1991 for CD based on disease location, behaviour, disease extent and operative 
history(14). Following the Rome criteria, further modifications were made and the Vienna 
classification was published in 2000, however, neither mentioned UC or IBDU(15). The  
Montreal criteria was published in 2005 and included all IBD subtypes with a 
separate paediatric IBD classification using age range of less than 17 years for paediatric 
cases(9). The Paris criteria was developed in 2011 which recognised the specific differences 
in PIBD verses adult onset disease including the propensity for disease extension, impact on 
growth and subdivided into those less than 10 years and less than 17 years(7).  
When classifying IBD subtypes, certain histological features are pathognomonic 
including granuloma and strictures in CD, whilst other features, such as ulcers, can be seen 
in both(11). The 2014 publication from the Porto group provided detailed guidance on 
differentiating CD/UC and features which would suggest a diagnosis of IBDU(10). The paper 
has features which are typical of CD/UC as well as atypical of UC but can occur in up to 10% 
including focal active duodenitis or aphthous ulceration in the colon or GI tract. If there are 
two or more features which are atypical of UC, a diagnosis of IBDU is suggested. This 
guidance will hopefully improve IBD phenotyping which, if inaccurate, will impair the 
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evaluation of treatments and the natural history as patients without similar diseases are 
compared.  
There is no one diagnostic pathway for PIBD as exemplified by the Eurokids registry 
which included 44 centres from 18 countries representing leading PIBD centres. Newly 
diagnosed patients were phenotyped according to the original Porto criteria, however, only 
64% underwent full endoscopic assessment of upper GI endoscopy and ileocolonoscopy, 
including 85% with IBDU who had an OGD(136).  This highlights that even in leading 
centres, recommendations are not always followed so a proportion of cases may have been 
misdiagnosed. Despite not following diagnostic algorithms, it is unlikely that cases of PIBD 
are missed but that the subtypes are incorrect, most commonly this would favour UC given 
the lack of consistent upper GI endoscopy. However, the PIBD subtype with the highest 
incidence remains CD(137) suggesting that this may not occur frequently. 
The Eurokids registry published data on IBDU where 16% of cases referred in from 
reporting centres as IBDU had features not compatible with this diagnosis, such as perianal 
disease and granuloma(138). Small bowel imaging was performed in 62% of IBDU 
patients(138) and histology was not reviewed in all due to high patient numbers without 
complete sets of biopsies, non-adherent to the revised Porto criteria (10). The challenges 
Eurokids registry faced reflects the daily dilemmas of clinicians in accurately phenotyping 
patients, some of whom are extremely complex. However, a full diagnostic evaluation 
including upper GI endoscopy, ileocolonoscopy with small bowel imaging will reduce the 
number of diagnostic challenges, this used in combination with endoscopic reassessment 
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2.2.5. Statistical analysis 
Information on the size of the paediatric population were obtained from the National 
Records of Scotland (NRS) for each year from 2009-2014(133). Allowance for the individual 
variation in the yearly at-risk population structure was performed by using standardised 
incidence rates calculated using the 2011 census data. Crude incidence rates were 
calculated per 100,000 paediatric population at risk per year and 95% confidence intervals 
were estimated assuming a gamma distribution(139). Trends on incidence over time were 
performed using Poisson regression using R v3.0.2 (R Foundation for Statistical Computing, 
Vienna, Austria).  For comparison with our previous published work, age groups of 0-5 
years (pre-school), 6-10 years (primary school age) and 11-15 years (secondary school age) 
were used throughout(92). 
 
2.2.6. Ethical considerations 
Ethical approval is not required in NHS Scotland for retrospective case record reviews 
with examination of departmental databases of service design/delivery as previously 
discussed as part of the Paediatric IBD Scotland Audit (PISA) (134).  
 
 
2.3 Methodology for data collection for Inflammatory Bowel Disease 
Unclassified 
 
2.3.2. Case identification 
Cases of IBDU were identified from each of the three-tertiary paediatric centres and 
two district general hospitals (Dundee and Inverness) from 1st January 2003 to 31st 
December 2013 with follow up until 30th June 2014 as described in Methods section 2.2.2 
then IBDU cases were selected. Context for the number of IBDU cases diagnosed was made 
to the total PIBD incident cases from 2009-2013 and diagnosis of those under 5 years was 
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compared to data from a recent systematic review on IBDU(140). Following case 
identification, data was then collected from a hand search of written case and electronic 
records and entered onto a centrally custom-built database (Access 2007, Microsoft 
Corporation, Redmond, WA) as per Methods section 2.2.2.   
 
2.3.2. Inclusion criteria 
Patients were included who were less than 16 years old and in paediatric services 
when a diagnosis of IBDU was made between 01/01/2003 until 31/12/2013 with a 
minimum of 6 months follow up. 
 
2.3.4. Exclusion criteria 
 Patients were excluded whose case notes were not available (n=1) or were 
diagnosed outside of Scotland or in adult centres. 
 
2.3.5. IBDU phenotyping 
Diagnosis was based on clinical symptoms, laboratory results, endoscopic, 
radiological and histological assessment in-line with the revised Porto criteria(13) by the 
local specialist PIBD team; the same approach as for all PIBD cases (further detail in section 
2.2.4). Disease extent was defined as per the Paris criteria(7). Ileal intubation was defined 
as clinician report of visualization of ileal mucosa with or without ileal biopsy.  
 
2.3.6 Data collection 
Data collected included age at diagnosis, diagnostic and ongoing assessment, 
treatments including corticosteroids, thiopurines, methotrexate and anti-TNF-α therapy 
(either infliximab [IFX] or adalimumab [ADA]), response to treatment, natural history, 
surgery and change of diagnosis. 
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2.3.7. Natural history 
Disease course was defined as either: quiescent, very mild, mild, moderate or 
chronically active as assessed by the lead researcher using definitions as listed below (141). 
Quiescent disease was disease in continuous clinical and biochemical remission (e.g. 
normal calprotectin and C-reactive protein [CRP] as defined by normal reference ranges for 
the hospital laboratory). Very mild disease was mild infrequent disease flares, usually less 
than twice per year and no evidence of inflammation on laboratory markers (e.g. normal 
calprotectin and CRP as defined by normal reference ranges for the hospital laboratory). 
Mild disease involved raised inflammatory markers, mild disease flares only with no 
escalation of treatment, occurring less than twice a year. Moderate disease was defined as 
more than two disease flares per year or disease flare requiring escalation of therapy (such 
as to a thiopurine or methotrexate) with laboratory evidence of inflammation including but 
not limited to raised faecal calprotectin, CRP, erythrocyte sedimentation rate [ESR] and 
white cell count. Chronically active disease was frequent severe disease flares requiring 
escalation of treatment, including anti-TNF-α therapy or the need for surgery. 
Response to treatment was divided into remission, response but not yet reached 
remission and no response. Remission was defined as improvement in physician global 
assessment (PGA) to inactive disease by the attending physician(142); response but not yet 
reached remission was defined as improvement in symptoms and/or laboratory 
parameters (e.g. ESR, CRP and faecal calprotectin) but continued ongoing disease activity. 
PGA was assessed through history, clinical examination, anthropometry and laboratory 
values by the clinician after induction treatment. 
Steroid dependency was defined as inability to wean steroids despite continuous 
therapy/rapid recommencement after weaning within 16 weeks; and steroid resistance as 
no clinical effect despite high doses (maximum 2mg/kg). Thiopurine (azathioprine or 
Chapter 2 Methodology 
62 
 
mercaptopurine) and methotrexate intolerance was deemed to have occurred when 
reproducible symptoms (e.g. headache, nausea, fatigue) or adverse drug reaction led to 
discontinuation. Thiopurine and methotrexate primary non-response were defined as lack 
of clinical response despite 16 weeks of therapy. Loss of response to thiopurines and 
methotrexate was considered when therapeutic effect was lost after initial remission with 
possible dose escalation. Loss of response to anti-TNF-α therapy was defined as initial 
clinical response to IFX maintenance treatment but need for surgery or withdrawal of IFX 
(recurrent acute infusion reactions)  and a switch to other medical treatment(143). Primary 
non-response to anti-TNF-α therapy was defined as no significant clinical improvement 
when assessed at 10 weeks post first induction dose for IFX and subsequent removal of 
therapy(143).  
 
2.3.7. Statistical analysis 
Paediatric population data were obtained from National Records of Scotland for each 
year from 2003-2013(133). Incidence rates were calculated per 100,000 paediatric 
population at risk per year and 95% confidence intervals were estimated assuming a 
gamma distribution. Trends on incidence over time were performed using Poisson 
regression using R v3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).  
 
2.3.8. Ethical considerations 
Ethical approval is not required in NHS Scotland for retrospective case record reviews 
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2.4 Methodology for data collection for Scottish Biologicals Registry 
 
2.4.1 Case identification 
All PIBD patients within paediatric services were included if aged <18 years at 
biological therapy start from 01/01/2000 to 31/12/2012 with 10 weeks minimum follow up. 
Patients were identified using PGHAN department-held records and databases (prospective 
and/or retrospective), pharmacy lists, nurse practitioner records, and case note review. 
Patients were given IFX for fistulating CD outside of the licenced indications. Excluded 
patients were those whose main reason for biological was not primarily IBD (e.g. arthritis or 
uveitis).  
 
2.4.2. Drug administration  
IFX induction dosing was 5mg/kg at 0, 2, and 6 weeks. Prior to 2006, some received 
episodic IFX dosing (as required, unscheduled) following induction. Maintenance IFX was 
5mg/kg administered 8 weekly; dose escalation (increased dose and/or shortened 
frequency of dosing) and de-escalation occurred. Adalimumab induction comprised 2 doses 
(160mg/80mg, 80mg/40mg, 40/20mg or 24mg/m2) followed by fortnightly maintenance 
dosing (80mg, 40mg, 20mg or 24mg/m2); dose escalation and de-escalation occurred.  No 
agreed protocol was followed in any of the units regarding dose escalation and was based 
on clinician’s discretion with IFX/ADA levels were not routinely available in all centres and 
only latterly used in a small number of cases. 
 
2.4.3. Data collection 
Not all centres maintained prospective patient databases, data was collected 
periodically via proforma and entered on the Scottish PIBD biological registry database 
(held in University of Edinburgh). Data were collected at study end (31/12/2013; transition 
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to adult services; emigration from Scotland).  Demographic information included disease 
phenotype(9); biological schedule and regimen (induction only; induction-episodic; 
induction-episodic-maintenance; induction-maintenance); medications (including steroids, 
thiopurines and methotrexate) and surgery before, at and after biological start. Response 
to treatment by IFX/ADA was divided into steroid-free remission, remission, partial 
response, loss of response and no response. Physician global assessment (PGA) was 
assessed through history, clinical examination, anthropometry and laboratory values after 
induction treatment. Remission was defined as improvement to inactive disease(142), 
partial response as improved symptoms but continuing disease activity, and loss of 
response where initial remission required later surgery or anti-TNF withdrawal during 
maintenance, and switch to another medication, including second anti-TNF agent(143).  
The paediatric ulcerative colitis activity index (PUCAI) and the paediatric Crohn’s disease 
activity index (PCDAI) scores were collected at defined timepoints when available (144, 
145); PGA was collected and defined as remission, mild and moderate/severe disease 
activity for all.   
Acute infusion reactions occurred during or within one hour of infusion stopping. All 
serious adverse events (resulting in hospitalisation during or within 90 days of stopping 
treatment, prolonged hospitalisation, life-threatening or death) and adverse events which 
investigators thought possibly related to biological therapy were recorded. 
 
2.4.4. Ethical consideration 
Ethical approval is not required in NHS Scotland for retrospective case record reviews 
with examination of departmental databases of service design/delivery, such as in PISA 
(Paediatric-onset IBD Scottish Audit, comprising epidemiology (2) and biologicals 
register(134)).Most, but not all patients/families gave written consent for anti-TNF therapy; 
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this was due to different start points for written consent in two of the networks plus one 
regional network using mainly oral consent throughout the thirteen year period. 
 
2.4.5. Statistics 
Descriptive statistics were median (range) for non-normally distributed continuous 
results and number (%) for categories. Normally distributed continuous data was displayed 
as means and standard deviations. Twelve-month CD remission rate was compared with 
duration of illness and immunomodulator use at baseline by Chi-squared analysis, 
significance defined as p<0.05 using SPSS version 19 IBMTM.  
 
2.4.6. Growth cohort 
Patients were included who had growth data available for a minimum of 24 months; 
12 months prior to commencing anti-TNF therapy and for 12 months after treatment 
commenced, if further growth data was available this was also captured.  One patient was 
excluded as was receiving recombinant human growth hormone as growth promoting 
treatment.  
Height and weight data were collected for IFX for all PIBD subtypes (CD, UC, IBDU) at 
the following time points: 12 months prior to commencing IFX (T-12), at start of IFX (T0), 12 
(T+12),24 (T+24) and 36 (T+36) months post IFX start. Due to transition and variable length 
of follow up for each patient, a smaller cohort had growth data available for 24- and 36-
months post start of IFX. For ADA, height and weight data were collected over 24 months: 
at 12 (T-12) and 6 months prior to commencing ADA (T-6) at start of ADA (T0), 6 (T+6) and 
12 months (T+12) post ADA. Satisfactory growth data reflects 12 months prior to 
commencing anti-TNF therapy to 12 months after start date whilst extended growth data 
covers data collected up to 36 months after starting anti-TNF therapy. 
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 Height was measured using wall mounted stadiometers according to Frankfurt plane 
position and weight measured wearing minimal clothing using calibrated seat scales to the 
nearest 100g. These data were converted to standard deviation scores for height (Ht SDS), 
weight (Wt SDS) and BMI (BMI SDS) using 1990 British childhood standards(146, 147), then 
Δ height SDS (Δ ht SDS) and height velocity(HV) were calculated for T0 and T+12. Delta ht 
SDS at T0 was calculated by subtracting the ht SDS at T0 from ht SDS at T-12, for delta ht 
SDS at T+12 then ht SDS at T12 was subtracted from ht SDS at T0.  Pubertal staging was 
assessed using either a validated self-assessment  form(148, 149) or by clinical examination 
and was documented at baseline, 12, 24 and 36 months where available.  
 
2.4.7. Growth cohort statistical analysis 
Descriptive statistics are presented as median with 90th percentiles. Wilcoxon was 
used to examine differences in height, weight and BMI SDS scores. A standard significance 
level of 0.012 was adopted due to multiple comparison testing and was calculated using a 
Bonferroni correction. Analyses were carried out using SPSS (IBM 19, Chicago Ill) IBMTM. 
Multiple logistic regression was performed using R v3.0.2 (R Foundation for Statistical 
Computing, Vienna, Austria) and all patients with satisfactory growth data were combined. 
Confounders including type of IBD, small bowel involvement, azathioprine use, 
methotrexate use, duration of disease, Tanner pubertal staging, remission, corticosteroid 
use at baseline, PGA at baseline, height SDS at baseline and whether patients received 
maintenance therapy with anti-TNF were entered into the model. There was a degree of 
duplication in the data as certain patients received both IFX and ADA so for those patients, 
one of the treatment periods was randomly excluded to ensure a robust model with no 
autocorrelation.  A general linear model was used; a correction was performed to minimise 
the effect of missing Tanner staging data using the adjusted general linear model. 
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2.4.8. Dependency cohort 
Patients who were under 18 years at start of anti-TNF therapy and received at least 
12 months of either IFX or ADA in paediatric services in Scotland were included.  Patients 
were excluded for the following criteria: received episodic dosing, did not proceed onto 
maintenance therapy and those who received anti-TNF therapy for less than 12 months. 
Dependency was defined as repeated infusions and/or injections to maintain good clinical 
response per the caring physician for at least 12 months(143). Patients could become 
dependent on either first or second course of either IFX or ADA. Loss of response (LOR) was 
defined as initial clinical response to IFX but discontinued maintenance treatment due to 
need for surgery, recurrent allergies or switch to other medical treatment due to sub 
optimal clinical response(143). Planned withdrawal was defined as in clinical remission 
only, clinical remission with normal blood parameters including faecal calprotectin or 
clinical and endoscopic remission with normal blood parameters including faecal 
calprotectin classed as “deep” remission. 
 
2.4.9. Dependency cohort statistical analysis 
Descriptive statistics were median (range) for non-normally distributed continuous 
results and number (%) for categories. Differences between groups were analysed using 
student’s T test. Time to loss of response was calculated using Kaplan Meir analysis using 
SPSS (version 19 IBMTM), patients were censored on date of last drug administration. 
Variables associated with loss of response were in the dependent cohort were assessed 
using Cox proportional hazard modelling using SPSS version 19. Variables included in 
multivariate analysis were gender, disease duration, corticosteroid usage, perianal disease, 
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3. The incidence of Paediatric-onset Inflammatory 




Inflammatory bowel disease is a chronic relapsing  lifelong condition affecting the 
gastrointestinal tract with around 8% diagnosed in childhood(1) with a more extensive 
phenotype than adult onset disease(16).  The aetiology remains elusive but current 
hypotheses suggest genetic susceptibility, environmental factors(150) and changes in the 
gut microbiota resulting in maladaptive responses in the innate and adaptive  immunity are 
involved(151).  A comprehensive systematic review of the incidence of paediatric-onset 
inflammatory bowel disease (PIBD) was performed from 1950 -2009 which included 139 
studies from 32 countries(2).  In 70% of countries that reported incidence an increase was 
observed, but only 28 reported temporal trends. Increases were seen in 7/9 for IBD, 15/25 
for crohn’s disease (CD) and 4/20 for ulcerative colitis (UC) suggesting the increase in IBD is 
driven mainly by an increase in paediatric CD. Data was mainly obtained from 
“westernised” countries with a paucity from developing countries which mirrored the 
systematic review of adult-onset IBD(87). After this systematic review was performed on 
1.1.2010, other large nationwide cohort studies have reported new incidence data 
including the SPIRIT registry from Spain, Scotland and Ireland(92, 152, 153) so an update 
was required.  
 
3.1.1. Aims and hypothesis 
The hypothesis is that the incidence of PIBD continues to rise and the increase is 
driven mainly by an increase in paediatric-onset CD. This review aims to determine if the 
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incidence of PIBD worldwide continues to increase, if it is becoming more common in 
countries that have not yet reported data and to assess longitudinal trends. 
3.2 Methods 
Details of the methods used are presented in chapter 2, section 2.1.  
3.3 Results 
 
3.3.1. Search results 
Three thousand four hundred and eighty-two unique references were found using 
the search strategy in Table 8, of those 153 abstracts were reviewed to assess for eligibility 
with thirty-six included in this review from eighteen countries (see Figure 6); 4 of which had 
not been included in the previous review(93, 132, 154, 155). 24/36 (67%) reported only 
paediatric incident data(92, 97, 132, 137, 152, 153, 156-173) with the remaining 12/36 
(33%) reporting both adult and paediatric data(93, 154, 155, 174-182). Most data were 
obtained prospectively in 21/36; prospective physician survey in 5/36, prospective patient 
recruitment in 5/36, government registry in 4/36, national database in 5/36, prospective 
case review in 1/36 and an insurance database in 1/36.  The remainder, 12/36, were 
collected retrospectively; 8/36 from retrospective case note review, 3/36 hospital database 
or retrospective physician survey in 1/36. Three studies obtained data from two sources, 
two used both retro and prospectively case note review(92, 178) whilst the other 
combined government registry data with prospective physician survey(132). 
 
3.3.2. Incidence rates  
Incidence rates of PIBD varied from 0.47 per 100,000 in Saudi Arabia to 15.2 per 
100,000 in Nova Scotia Canada(137, 159), whilst for CD incidence ranged from 0.27 per 
100,000 in Saudi Arabia to 9.2 per 100,000 in Nova Scotia, Canada (137, 159) and for UC 
0.20 per 100,000 in Saudi Arabia to 8 per 100,000 in Finland(159, 173). Figure 8 A, B and C 
Chapter 3. The incidence of Paediatric-onset Inflammatory Bowel Disease: An updated 
systematic review of longitudinal trends 
72 
 
demonstrate world maps of the incidence of PIBD, CD and UC respectively in countries 







Table 8 Summary of included studies for updated incidence systematic review organised by Continent and Country of origin (incidence rates are 
provided per 100,000) 



















Tuzla region 1995-2006 0-14 RCR   0.4 Trend analysis 
Jakobsen 
2011(165) 
Denmark East Denmark 2007-2009 0-15 PPS 6.4 3.2 3.1 Multiple time periods 






1998-2006 0-15 GR, PPS 4.7 3.1 1.6 Trend analysis, multiple 
time periods reported 
Mertz Norgard 
2014(174) 
Denmark  1995-2011 for CD 
1995-2011 for UC 














Finland  1987-2003 0-18 ND 9.6   Trend analysis, multiple 
time periods reported 
Jussila 
2012(183) 
Finland  2000-2007 0-14 ND  CD (M, F) 
0-7 1.8    1.4 
8-14 7.5    5.2 
UC (M, F) 
0-7 2.5    2.5 










1988-2011 0-17 PPS 1988-1990-3.0 
2009-2011- 6.3 
  Multiple time periods 






















































Trend analysis, multiple 





2002-2006 0-19 PPR  0-10- 0.5 0-10 1.6  
Muller 
2013(164) 
Hungary  2007-2009 0-18 PPS 7.48 4.72 3.82  
Agnarsson 
2013(167) 
Iceland 1951-1989 1951-1989 0-16 RCR 5.0 2.3 2.4 Trend analysis, multiple 
time periods reported 
Hope 
2012(153) 




  Trend analysis 
Urlep 
2014(161) 
Slovenia North Eastern 2002-2010 0-18 RCR 7.6 4.6 2.8 Trend analysis 
Martin-de-Carpi 
2012(152) 












2002-2007 0-16 PPR 12.8 9.2 2.8 Multiple time periods 
reported, trend analysis 
Ronnblom 
2010(178) 
Sweden Uppsala 1945-2007 0-19 PCR, RCR   1965-1983  
0-9 years -4.3  
Trend analysis not 
specific to paediatrics 
Sjoberg 
2012(177) 
Sweden Uppsala 2005-2009 0-17 PCR   8.9 Trend analysis not 
specific to paediatrics 
Ashton 
2013(97) 
UK Wessex 2002-2012 0-16 HD 6.39 5.85 2.67 Multiple time periods 
reported, trend analysis 
Gunesh 
2007(93) 
UK  Cardiff, Wales 1996-2005 0-16 RCR  2.7   
Yapp  
2000 (154) 





























UK Scotland 1990-95 
2003-2008 












1996-2006 0-18 ID  2.7 3.2 Trend analysis 
Adamiak 
2013(157) 
USA Wisconsin 2000-2007 0-18 PPS 9.5 6.6 2.4  
Benchimol 
2017(137) 
Canada  1999-2010 0-17 GR 9.7 6.5 2.4 Multiple time periods 
reported, trend analysis 
Benchimol 
2014(180) 
Canada Ontario 1999-2008 0-19 GR 0-10- 2.9 0-10- 1.3 0-10- 1.3 Multiple time periods 
reported, trend analysis 
Benchimol 
2014(169) 









Multiple time periods 
reported, trend analysis 
El-Matary 
2014(160) 
Canada Manitoba 1978-2007 0-17 GR 2003-2007- 6.77 2003-2007-4.68 2003-2007-1.64 Multiple time periods 
reported, trend analysis 
Al-Qabandi 
2011(163) 
Kuwait  1998-2008 0-15 RCR 2.16 1.53 0.6 No trend analysis 
El Mouzan 
2014(159) 
Saudi Arabia  2003-2012 0-14 RCR 0.47 0.27 0.2 Trend analysis 
Studd 
2016(181) 
Australia Barwon 2010-2011 0-14 PPR 6.8    
Schildkraut 
2012(172) 





China Shanghai 2000-2010 0-18 HD 5.5 2.9 2.5 Trend analysis 
Hilmi 
2015(176) 
Malaysia Kinta Valley 2011-2013 0-16 PPR 0.63 0.42 0.21 No longitudinal trends  
Methods of case ascertainment: ID- Insurance database, ND- National database, RCR- Retrospective case note review, PPS- Prospective physician survey, RPS- Retrospective physician survey, PPR-
Prospective patient recruitment, GR- Government registry, Hospital database




Figure 8(A) Worldwide IBD incidence rates for countries reporting incidence after 2000. (B) Worldwide 
CD incidence rates for countries reporting incidence after 2000. (C) Worldwide UC incidence rates for 
countries reporting incidence after 2000.   
(A)  
(B)    
(C)   
Footnote- except for Canada, United States of America and United Kingdom where a province is reported (i.e. city, state, region) the incidence is extrapolated to 








3.3.3. Temporal trends 
Of the included studies, 18/36 (50%) reported temporal trends using a variety of statistical methods to assess 
the trend. Four studies reported trend data but gave no p value, all studies reported increasing trend in CD and 
UC(137, 162, 166, 171). Poisson regression was the most commonly used statistical test in 10/18, other methods 
included linear regression 2/18, chi square 3/18, not specified in 2/18 and Cochran Armitage in 1/18. Temporal trend 
analysis for IBD in 12/13 had a significant increase in incidence with only one study reporting no increase. For CD 
12/15 had a statistically significant increase 2/15 had an increase and 1/15 had a decrease. In UC, 11/16 reported a 
significant temporal increase with 3/16 reporting an increase and 2/16 reported a decrease with 1/16 reporting no 
change. 
Two studies that combined adult and paediatric data reported an increase in UC and IBD respectively(162, 
174). One study reported a temporal increase in UC and CD but no p value (166). Figure 9 A, B and C demonstrate 
temporal incidence rates for IBD, CD and UC respectively with multiple time periods displayed independent of the 
authors performing statistical trend analysis. 
  




Figure 9A Temporal trends of incidence rates for Paediatric-onset inflammatory bowel disease in studies reporting 
incidence at multiple time points. (Where year range is reported, incidence in reported for the final year of the range (ie 2000-2010 is 




Figure 9B Temporal trends of incidence rates for Paediatric-onset crohn’s disease in studies reporting incidence at 






































































































Figure 9C Temporal trends of incidence rates for Paediatric-onset ulcerative colitis in studies reporting incidence 
at multiple time points 
     
Nine studies reported temporal trends for both IBD subtype and age. In Scotland, a significant increase in  
incidence was observed for all IBD subtypes in males aged 6-10 years and 11-15 years whilst for females there was 
only a significant increase in CD in those aged 11-15 years and in IBD/IBDU for those aged 6-10 years(92). Data from 
Saudi Arabia demonstrated a significant increase in IBD, CD and UC in those aged 10-14 years compared to a 
significant increase in IBD and CD in those aged 5-9 years,  finally only an increase in CD was seen in those aged 0-4 
years(159). Ontario, Canada had similar results with an increase in IBD, CD and UC in those aged 10-17 years and 6-9 
years compared to an increase in IBD only in those aged 0-5 years(169). Another study from the Ontario group 
reports a significant  increase in IBD, CD and UC in those aged 10-19 years compared to an increase in IBD and UC 
only in those aged 0-10 years(180).  An increase in UC was reported from Finland with increasing incidence in older 
age groups with a ratio of 1.1 for those aged 0-10 years increasing to 1.4 in 11-15 years and 1.6 for those aged 16-19 

























































A nationwide Canadian study reported a significant increase in the 6 months to 5 years age category with no 
significant increase in the older age ranges(137).  
 
3.4 Discussion 
The increasing incidence of PIBD persists in this updated systematic review with a propensity of data from 
North America and Western Europe confirming the hypothesis. The highest incidence of PIBD was 15.2 per 100,000 
in Nova Scotia, Canada, the highest to date, with the highest incidence reported so far for UC in Finland at 8 per 
100,000. Previously the highest rate of CD was 13.2 per 100,000 in Quebec (2), however, the age range was 0-19 
years contrasting with current data from Nova Scotia which was under 18 years meaning the current study may 
represent a higher incidence.  Age ranges varied from under 15 years to 19 years, as the incidence of IBD is higher in 
those aged 16 to 18 years, the incidence rates reported in Table 8 may over or underreport current figures. Most 
studies reporting on longitudinal trends described an increase in PIBD, CD and UC. However, one study reported a 
decrease in CD(156) and one study reported a decrease in UC which (132). This contrasts with the previous 
systematic review where, the increase in IBD was thought to be primarily driven by paediatric CD with the rates of 
UC appearing to level off(2). It is difficult to draw significant conclusions from the relatively few temporal studies 
published, particularly as the majority from North America and Europe. However, comparison with adult-IBD can be 
made which has shown that although IBD continues to increase, the rate of rise is not as steep as previously 
seen(87, 184).  
The systematic review by Benchimol (2) on the incidence of PIBD worldwide provided evidence of the increase 
observed by clinicians with an insight into the globalisation of PIBD. However, wide variation in methodologies were 
used, a variety of age cut off for paediatric patients from 14 years and under to 19 years were used and differences 
defining the diagnosis of IBD. By using different age ranges in a condition which varies with age affects incidence 
rates. All studies that reported on PIBD incidence, regardless of the methods used, so a huge heterogeneity of were 
cases reported, including “possible” and probable” IBD diagnoses. Although included studies were meant to be 
population-based, the review included those from insurance databases which may not be a true reflection of the 




cases within that geographical area (158). Four studies were identified (2 from the UK, 1 each from Denmark and 
Bosnia(154, 155)) (93, 132)which were not included within this review but were included within this update. 
Health administrative database used to collect cases in Ontario demonstrates a good, robust approaches to 
collecting incidence data.  The database is a mandatory reporting system allowing the treating physicians to be paid, 
the authors use a variety of database algorithms to collect data then validate their results to ensure full capture of 
cases. Clear criteria were used to confirm the diagnosis of PIBD which was then validated for a selected period to 
ensure correct administrative coding. Not all countries have an insurance database but can still collect good 
nationwide incidence data such as Ireland, Iceland and Scotland. In Iceland, cases were identified retrospectively for 
the initial part of the study (1951-1989), with charts and pathology specimens reviewed by an investigator to 
confirm IBD, then cases were prospectively identified (1990-2010).  Investigators contacted paediatricians and 
gastroenterologists to confirm complete accrual of cases and reported on the investigative approach to diagnose 
IBD. By current recommendations(10) the diagnosis of historic cases was not robust and there may be some 
diagnostic uncertainty which the authors acknowledge (cases before 1980 did not have an upper GI endoscopy and 
not all had full ileocolonoscopy)(167). There is a paucity of data from middle eastern countries so the study from 
Saudi Arabia is crucial to understanding the globalisation of PIBD, however, methodological issues make interpreting 
this data challenging. Although incidence figures are reported up to 14 years, the authors acknowledge that those 
aged 13-14 years may be treated by adult gastroenterologists and estimate that they included only 70% of 14 year 
olds(159). Unfortunately, it is not reported if they tried to contact adult gastroenterology colleagues to identify 
these cases or private clinics who may have treated these patients. In addition, it is not clear how patients were 
diagnosed including what investigations or histopathology samples were taken These methodological issues would 
only increase the incidence rates and support the assertion that PIBD is increasing worldwide.  
This review builds on these reports a further increase in PIBD, CD and UC, of which CD continues to 
predominate. New countries from Europe have reported incidence but, crucially countries from Asia and the Middle 
East such as Malaysia and Kuwait, have been published supporting the assertion that PIBD is becoming a global 
disease. However, the highest rates continue to be in Europe and North America which may relate to improved 




access to healthcare with robust reporting systems allowing easy capture of new cases within well-established 
research protocols. The increase in countries which are becoming more “westernised”, such as Malaysia, supports 
the assertion that environment plays a key role in the pathogenesis of PIBD, but specific triggers have yet to be 
elucidated. 80% of studies in CD and 69% in UC reported an increased incidence contrasting with 60% for CD and 
20% for UC in the previous review. The increased rates of UC may reflect the newer countries reporting data or less 
robust diagnostic accuracy, however, it was not consistent. 
 
Methodological assessment 
As with the previous systematic review, methodological issues influence the conclusions drawn from the data 
presented.  A key difficulty for epidemiological research is the definition of IBD and the robustness of initial 
diagnostic assessment. Few studies reported on diagnostic approach, often relying on data collected for 
hospital/insurance/government registries so difficult to assess the criteria for obtaining a diagnosis. A historical issue 
is the use of “probable” and “possible” CD(175). Accurate phenotyping is essential to ensure appropriate 
comparisons of patients, the publication of ESPGHAN guidance on diagnosis of PIBD(10) will surely improve the 
process but many of these studies report data collected prior to its publication.  
Only studies which contained a clearly defined cohort of paediatric patients under 18 years of age were 
included so the data accurately reflects paediatric practice. Age ranges reported varied from less than 14 to less than 
18 years depending upon the country with differing healthcare systems using varying age cut offs. For example, 
within Scotland patients are cared for in paediatric IBD centres until the age of 16 years before transitioning to adult 
services, this contrasts with North America where patients can continue in paediatric services until 19 years of age. 
The difference of three years affects the incidence rates in a condition which increased with age, potentially North 
American countries may not have a higher incidence if only those under 17 years were included. Ideally the Paris 
classification should be used to present incidence of those under 10 years and under 17 years. 
Incidence rates for regions within a country were generalised to the entire country, both in this and the 
previous review to facilitate comparisons between different countries which may have resulted in either over or 




under representation of the true incidence. Certain studies contacted adult gastroenterologists whilst others did not 
which may result in an underestimation of incidence as teenagers may be seen in adult centres.  
Temporal trends were reported in thirty-six studies with almost all reporting increases in PIBD, CD and UC 
incidence rates. A decrease in CD was observed in Sweden with rates decreasing from 10.8 per 100,000 in 2002-
2004 to 7.6 per 100,000 in 2005-2007 which is not likely to be significant due to the relatively short time period, this 
is confirmed by the combined incidence rate of 9.2 per 100,000 from  2002-2007(156) and the increasing prevalence 
rate(185).Trend analysis was not performed on the results of this review due to the heterogeneity of the data, the 
various time points used and lack of consistent methodology.  
A strength of this study is that newer countries such as Kuwait and Malaysia have been added as have other 
national registries from Spain, Scotland and Ireland broadening of the current data. More population-based cohorts 
are included improving generalisability and evidence of the sustained increase in PIBD incidence. Methodological 
flaws persist of retrospective study design and hospital/regional cohort studies yet he advent of centralised methods 
of data collection will undoubtedly improve collection of incidence data. A paucity of data reported in Asia, South 
America and Africa continues where the potential role of environmental and genetic factors could be further 
developed and comparison with European/North American cohorts could be made. 
 
3.5 Conclusion 
The incidence of paediatric-onset IBD, CD and UC continue to rise in almost all countries reporting data most 
studies from North America and Northern Europe yet more data are now emerging from Asia, Africa and South 
America improving the generalisability of the results. However, considerable variation and heterogeneity still exists 
amongst data collection, age ranges and analysis. Prospective national databases in countries that have not 
previously reported data will enhance knowledge on the globalisation of PIBD and provide insights into 
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4. Prevalence of Paediatric Inflammatory Bowel Disease: A 
Systematic Review of trends 
 
4.1 Background 
Inflammatory bowel disease (IBD) is a chronic relapsing condition consisting of Crohn’s disease (CD), ulcerative 
colitis (UC) and inflammatory bowel disease unclassified (IBDU) with recent data suggesting approximately 8% of 
cases present in childhood(1). A recent systematic review of adult-onset disease studying incidence and prevalence, 
found both indices were increasing worldwide, with the highest prevalence in developed countries (particularly in 
Europe), low prevalence in Asian nations and an increasing trend in developing nations that traditionally had low 
prevalence rates(87). The incidence of paediatric-onset IBD (PIBD) is increasing worldwide (2, 92) and, although 
prevalence rates are likely to mirror this increase, accurate data is lacking. Prevalence data is crucial for service 
planning and delivery to ensure that adequate services provide care exist for children and families with PIBD, it also 
assesses the burden of disease and facilitates research by allowing accurate power calculations to be performed. 
Prevalent data is often more challenging to collect due to the changing of the population moving into and out of the 
catchment area requiring regular monitoring to ensure it is correct.  
By understanding why areas have high IBD prevalence it could help uncover environmental factors involved in 
aetiopathogenesis such as increased urbanisation causing changes to microbial exposures (186) through 
epidemiological research. Key areas to examine would be developing nations where IBD is becoming more common 
to identify other changing environmental or dietary factors.   
 
4.3.1. Aims and hypothesis 
The hypothesis was that given the significant increase in incidence of PIBD, prevalence rates would show a 
similar increase. A systematic review of the literature was performed focusing on the prevalence of PIBD worldwide, 
describing the patterns seen in different geographical areas and where possible assessing temporal trends.  
 




Methods for this chapter are discussed the Chapter 2 Methodology section 2.1. 
4.3 Results 
 
4.3.1. Search results 
4190 references were found during the initial search with 138 abstracts scrutinized. Following this, 53 full 
papers were reviewed and 26 excluded as they did not meet the inclusion criteria leaving 27 were included from 12 
countries (Figure 7). 14 studies had data on the prevalence of PIBD, (Table 9) twenty (54%) on CD whilst 21 (57%) 
had data on UC, (3 (11%) on IBD alone, 3 (11%) on UC only and 4 (15%) on CD alone) (Table 9). Twelve studies (44%) 








Table 9 Summary of included prevalence studies of paediatric-onset inflammatory bowel disease, Crohn’s disease and ulcerative 
colitis (prevalence rates are reported per 100,000) 














Population at risk 
Benchimol 
2017(137) 
Canada  1999-2010 0-16 HD, RCR 38.2 25.5 10.7 Prevalence rates given for 5 
provinces (Alberta, Manitoba, 



















IBD prevalence figures given for 
each year from 1994-2005. 
Population <15yrs- 936,514 
El Matary 
2013(160) 
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BC 5.2 
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NS 4.0 
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ID  12.0 19.5 Population given for age ranges 
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ID  5.63 (3.76-8.38) 
12.6 (10.4, 15.2) 
46.5 (42.5,51.0) 
106.3 (98.8, 114.5) 
5.4 (3.6,8.1) 
10.9 (8.9, 13.4) 
29.4 (26.2, 33) 





















































Population at risk 
Jussila 
2012(183) 
Finland  1993-2008 0-14 
 






Population at risk give as whole 




























1983-1993 0-16 RCR 20.2 16.6 3.42 Approx. 90,000 
Levi 
2013(192) 
Israel  1998 
2010 
17 GR 149.4 
301.0 





Israel Tel Aviv-Jafo 1971-2 0-14 
 
RPS   3.93 76,397 
Krawiec 
1984(194) 




RPS  2.1  95,827 
Jacobsohn 
1986(195) 
Israel Jerusalem 1973-78 0-14 
 





Libya  1997-2006 0-<15 RCR 3.62 2.0 1.36 441,371 
Higashi 
1988(197) 



















Japan  1986-1998 0-9 GR  Male- 0.2 
Female 0.1 
 Total population given not age 
breakdown 






Canterbury 2004-2005 0-4 
5-9 
10-14 








 2015 0-16 PPR 21.7 16.5 3.3 
Studd 
2016(181) 
Australia  2010-2011 0-14 PPR 33   
HD- Healthcare database, ND- National database, RCR- Retrospective case note review, PPS- Prospective physician survey, RPS- Retrospective physician survey, PPR-Prospective patient recruitment, GR- 
Government registry 
*Mean prevalence averaged over 2 years 





4.3.2. Data collection and diagnosis 
Significant variation was evident in the methods of patient identification between 
studies and was as follows: national healthcare insurance databases 6 (22%), government 
registries 5 (19%), retrospective case note review 6 (22%), private healthcare insurance 
database 3 (11%), prospective physician survey 3 (11%), retrospective physician survey 2 
(7%) and prospective patient recruitment 2 (7%) (Table 9).  Government registries are used 
in certain countries to allow reimbursement of medical expenses for certain chronic 
conditions such as IBD. Physicians diagnose patients according to specific criteria 
completing a medical certificate which is then passed to the government so some or all 
costs of medications are reimbursed to the patient or family. The method of diagnosis is 
usually robust as clear criteria must be met to receive the benefits but was often not clearly 
specified. Dependent upon the registry the robustness of the methodology applied varied, 
with some registries using validation techniques (111-113, 180). Prospective registries have 
been set up in certain countries, usually involving a specific geographical area, which 
include both paediatric and adult gastroenterologists to capture all cases(188-190). 
Healthcare insurance databases allow prospective accrual of data as records indicate if the 
patient has the condition when they join the organisation or develop during the 
coverage(89, 105, 158). Most studies were retrospective and several combined methods 
including adverts in newspapers/in clinics and local charities(199). The most common 
retrospective method for data accrual involved searching hospital records for relevant ICD 
8/9 codes for IBD/CD/UC with subsequent case note review(94, 187, 193-196). 
There was a wide variation in the diagnostic criteria used to define CD and UC which 
included: clinical history, endoscopic appearances, radiology findings and pathological 
changes suggestive of IBD. Certain authors used a strict definition to define “definite” and 
“probable” IBD (187, 190, 193, 195) whilst others used disease classification criteria such as 





Lennard Jones, Porto and NASPGHAN (158, 181, 188, 194, 199, 200). Insurance and 
national databases used diagnostic codes such as ICD 8/9, however, diagnostic criteria 
were not always provided for these and it was unclear how the diagnosis was made. 
Healthcare databases, either insurance or government, were searched using diagnostic 
codes specific for CD/UC for hospital discharge diagnosis or pharmacy claims for 
medications related to IBD (89, 105, 111-113, 137, 158, 160, 180, 182, 185, 192, 197). Some 
studies did not define the criteria used to diagnose IBD but referred to clinical, radiological, 
pathology and endoscopy findings (94, 160, 189, 191, 196, 198). Some studies used the 
results of their database search and case note review to validate their search strategy(182, 
197, 198), whilst others used previously validated methods to verify(89, 105).  
Further variation was seen in the age ranges used across studies (Table 9), with a 
total of eight different ranges used. Most reported in either 5- or 9-year age brackets (89, 
105, 111, 112, 137, 158, 180, 187, 197-199, 201) but some defined paediatric patients as 
being aged below 14 to 17 years (94, 160, 181, 182, 185, 188, 189, 191, 193-196, 202). Levi 
reported prevalence in adolescents attending for obligatory medical assessment for 
eligibility for military service and defined age as “close to the age of 17” (192) with a mean 
age of 17.3 +/- 0.5 years. 
 
4.3.3. Prevalence 
The prevalence of PIBD ranged from 3.6-301.0/100,000, CD from 2.0-28.8/100,000 
and UC from 1.36-30.7/100,000 (Table 9). There was a preponderance from developed 
countries:  nine from North America(89, 105, 111-113, 137, 158, 160, 180), eight from 
Europe(94, 182, 185, 187-191), four from the Middle East(192-195), three from 
Australasia(181, 199, 202), two from Asia(197, 198) and one from Africa(196) (Figures 10 A, 





B and C). Prevalence rates of PIBD were highest in Israel at 301 per 100,000 and Sweden at 
75 per 100,000 with the lowest in Libya at 3.62 per 100,000.  
Figure 10A Prevalence of paediatric-onset inflammatory bowel disease (rates per 
100,000) 
 
Figure 10B- Prevalence of paediatric-onset crohn’s disease (rates per 100,000) 
 
Figure 10C-Prevalence of paediatric-onset ulcerative colitis (rates per 100,000) 
 
Notes: Most recent prevalence rate was used in countries which provided temporal trends. Except 
for United States of America, Canada and the United Kingdom where a jurisdiction is reported (e.g. 
city, province, geographically defined region) the prevalence is extrapolated to country level. Studies 
not included where prevalence rates were presented by age breakdown only or by gender only. 





Gender differences were observed in certain studies with 5 CD was common in males 
than females (105, 112, 158, 197, 198), although only in ages 0-9 years (199) and 6 months 
to 4 years (111) in 2 respective studies. In UC, the data showed greater variation with two 
studies demonstrating higher prevalence in males (111, 197) yet two other studies showed 
a higher female prevalence(112, 158). 
4.3.4. Statistical methods 
Few statistical methods were performed on prevalence rates and the results were 
predominantly descriptive. Six studies performed statistics to assess temporal trends and 
all used Poisson regression (111, 137, 160, 180), however, in one study this covered the 
whole population and was not limited to paediatric data(182).  One studies used a different 
method to calculate z score to assess trends (196). Kappelman reported a significant 
variation in prevalence with a North/South divide in the United States of America with 
more cases in the Northeast compared to the West, with a higher prevalence in males than 
females(89, 105). Conversely, Bernstein found higher prevalence among females with 
significantly higher rates in certain provinces (p<0.0001) (113). In New Zealand, prevalence 
was higher in the South Island compared to the North which was statistically 
significant(202). 
 
4.3.5. Temporal trends 
Only six studies provided temporal trend analysis which showed an increase in PIBD 
prevalence (see Figure 11A, B and C). In Libya a significant increase in PIBD prevalence was 
seen over a 5 year period from 2002-2006(196). In Ontario, Canada, a significant increase in 
CD and UC over 12 years was reported,  from 42.1/100,000 in 1994 to 56.3/100,0000 in 
2005 for CD and 16.2/100,000 to 19.7/100,000 for UC)(111) which was maintained in a 
follow up study (180). Another Canadian prevalence study from Manitoba province 





reported increasing prevalence in IBD and all subtypes from 3.1 per 100,000 for CD in 1982 
to 14.9 per 100,000 in 2002 whilst for UC an increase from 0.7 per 100,000 to 12.7 per 
100,000 over a similar time periods was observed (160).  In Israel an increase in PIBD from 
149.4 per 100,000 in 1998 to 301.0 per 100,000 in 2010 was observed(192). In Eastern 
Denmark, an increase was reported in PIBD with an increase in both CD and UC which 
peaked in 2003 at 28.3 per 100,000 then decreased in 2004 to 24.2 per 100,000(188). 
Figure 11A Temporal trends of prevalence of paediatric-onset inflammatory 
bowel disease (prevalence rates per 100,000)
 
Figure 11B Temporal trends of prevalence of paediatric-onset crohn’s disease 








































































Figure 11C Temporal trends of prevalence of paediatric-onset ulcerative colitis 




This systematic review examined the prevalence of PIBD worldwide indicating a 
higher prevalence of PIBD in developed countries in North America and Europe with the 
addition of Israel, confirming the hypothesis. The highest prevalence rates were in Israel for 
PIBD with 301.0 per 100,000, Sweden for CD with a prevalence rate of 28.8 per 100,000 
and for UC 30.7 per 100,000. The results are similar to adult data which demonstrated 
higher rates in North America and Europe(87). The increase in PIBD prevalence is to be 
expected given the increasing incidence in systematic reviews in both adult and paediatrics 
(2, 87). The increase in PIBD incidence has been driven by increase in CD more than UC (2) 
which again is similar to adult data (87).  Temporal trends were difficult to assess as few 
studies separated paediatric from the adult data including the Finnish study which 
demonstrated a three-fold increase in the prevalence of IBD over 15 years with the highest 
prevalence was seen in the 35-44 age category (182). A significant increase in paediatric 








































contrast, in  Libya a significant increase in paediatric prevalence was observed over an eight 
year period showing yearly increase from 0.53 per 100,000 in 1998 increasing to 3.62 in 
2008(196). Similar increases in prevalence rates have been reported in Sweden, Denmark, 
Canada and Israel over varying epoch lengths (5-26 years), with variable rates of rise seen 
(111, 185, 188, 190, 192). 
All eligible studies were included regardless of the methodology used or age cut offs 
to ensure a range of countries and data were represented.  The methods of data collection 
were diverse and included: national registries, insurance databases and physician’s survey. 
One study used a variety of sources involving charities, newspaper advertisement and 
posters at clinics in hospitals then cross checking patients thought to have IBD with 
pathology and radiology specimens and reports(199). The lack of consistent robust 
methods of data accrual may suggest that prevalence rates may be under representative of 
the actual rates. Few studies reported on Indeterminate Colitis or Inflammatory Bowel 
Disease Unclassified (IBDU) as an IBD subtype, probably as it was not described until the 
Montreal classification in 2005 before many of the current studies were published. These 
cases were often excluded or potentially misclassified and as IBDU accounts for 9% of new 
diagnosis of PIBD(136), if not included then there is potentially a significant under 
estimation.  
Many studies were carried out in the 1970-90s with half from 2000 onwards during 
which time rates have increased dramatically in both adults and paediatrics suggesting that 
prevalence has also increased. Most prevalence results included in this review are 
historical, particularly those from 1970-1990, and are not likely to be true representations 
of the current rates in their countries.  Furthermore, most countries improved access to 
diagnostic procedures which could result in increasing numbers due to improved diagnosis. 





Most studies were hospital based, particularly in developing countries which is often due to 
centralising of paediatric services. It would be uncommon in most countries for primary 
care to make and treat IBD in children without secondary or tertiary involvement, 
therefore, although not population-based, rates may well accurately reflect the population.  
 Diverse age range were used varying from under 14 to 19 years whilst others broke 
down further e.g.  5-9, 10-14 years. PIBD prevalence increases with age which influences 
the prevalence rates reported, for example, studies that used a cut off 17 years could have 
a higher prevalence rate than those with a cut off 14 years, but, if the same age cut off 
were used prevalence rates could be similar. Future studies would benefit from using a 
recognised age cut off, such as 17 years as per the Montreal/Paris classifications(9, 10). 
However, this may prove challenging as healthcare systems in different countries care for 
children of certain ages from 14 years to 21 years. A database of all prevalent cases of PIBD 
regularly updated would aid these problems allowing of those under a certain age to be 
reported whilst removing those that are no longer eligible for inclusion. Another challenge 
is patients who present under 2 years with very early onset IBD who often have genetic 
mutations such as IL-10 deficiency (203) with a different phenotype to IBD, so it is essential 
to differentiate them which is not clear from some studies.  
In adults, as in children, the highest prevalence exists in Northern Europe and North 
America, with increasing incidence in countries that are becoming more Westernised.  
Rises in adult prevalence have been reported in Asian countries such as Japan where 
prevalence has increased 4-fold in 12 years and in developing countries such as South 
Korea which has seen a similar increase in 8 years(198, 204). The exception to 
predominance in Europe and North America is Israel which has the highest prevalence of 
PIBD, this may be due to the age used, 17 years compared to <16 or <14 years in other 





studies as more cases were included with an additional 3 years or may be a true reflection 
of the increased rates in that country.  The robust methodology used in the Israeli study 
ensured good capture of potential patients using government registry for recruitment into 
national service with only 13.4% excluded on religious grounds(192). The high prevalence 
rates are consistently increasing over the 13-year study period with the largest number of 
PIBD cases from Western origin, those living in urban locations and high socioeconomic 
status.  Few studies considered ethnicity which Israel did and found a lower rate of CD in 
the Arab population compared to the Israeli Jewish population (205). However, others have 
found higher prevalence’s among European/Americans and Asian/African populations 
respectively when other areas of the country have been studied(195). These studies 
illustrate the variety that occurs among different within ethnic groups in the same country 
suggesting genetics as well as environmental triggers are involved. Canada demonstrates 
an increase in CD and UC in paediatric patients of South Asian origin compared to non-
South Asian with an increasing incidence in this group over the 20 year study period (206).  
Causation for the increase in PIBD remains unclear with many theories postulated 
relating to environmental triggers. Both Canada and Israel have demonstrated a higher 
incidence of PIBD in families with fewer siblings and residing in an urban environment(107, 
201). However, other Canadian studies reported different results with less overcrowding in 
cases of CD than in controls(207). Latitude has been associated with an increase rate of 
Crohn’s disease within a country such as France where an increased rate of Crohn’s disease 
was noted in the North and confirmed by other studies in Northern Europe (91, 182). The 
same French study found an increased rate of Crohn’s in urban areas and those with poor 
sanitary house equipment, further supporting the hygiene hypothesis(106, 208).  





The role of environment in the development of PIBD is supported by the assertion 
that individuals who immigrate to an area of high incidence of IBD take on the increased 
risk of developing the condition with the most critical time being childhood(209). Rates of 
CD were higher in children of non-immigrants compared to immigrants with the age of 
entry into Canada a critical risk factor with increasing age at arrival associated with a 
decreased risk of developing IBD(88).  Further evidence for an environmental factors can be 
seen in adults in the United Kingdom where higher rates of UC have been reported in South 
East Asians, particularly in second generation migrants, compared to the UK population 
(210) . Increased risk with emigration would suggest that environment, in particular 
industrialization, may play a significant role in the development of the disease as well as 
genetic predisposition(211).  
Limitations of this study include is that only full published articles in were reviewed 
so data presented in solely abstract form was not included due to insufficient data to 
confirm eligibility. The lack of data available from developing countries limits the 
generalizability of the results; one study from Africa, none from South America and only 
two from Asia which. Furthermore, the diagnostic criteria to diagnose PIBD varied 
enormously, although most studies attempted to verify diagnosis using either physician 
survey or case note review. The gold standard for diagnosis of PIBD is ileocolonoscopic and 
upper GI endoscopy(13), however, it is unclear from the paper who underwent these 
investigations and, particularly in the earlier cohorts and in developing countries, it is 
unlikely. Diagnosis may be incorrect which is more likely to favour a diagnosis of UC than 
CD and the degree of certainty varied with “probable” CD/UC based on case record review 
used in older studies. 
 





4.5 Conclusions  
This comprehensive systematic review on the prevalence of PIBD has shown a wide 
range from 3.8-301 per 100,000 with most data provided by countries in North America 
and Europe. There is a paucity of data on temporal trends of prevalence consequently it is 
difficult to assess whither the increase in incidence rates of PIBD has led to an increase in 
prevalence. However, in studies temporal trends were assessed, an increase was observed 
but numbers were limited, and the methods differed significantly limiting the 
generalizability.  
Significant methodological heterogeneity exists between studies rendering the 
results unsuitable for meta-analysis. Key methodological differences issues include 
different age ranges, variations in diagnostic assessments used/diagnostic criteria used and 
data mainly from Europe and North America. A clearer understanding of prevalence trends 
of PIBD must include updated from countries with existing data figures ensuring similar 
diagnostic criteria and methodological are used. 
There are many potential environmental factors associated with PIBD which are 
often not consistent or easily relatable; the challenge now is to unite these different 
theories through nationwide epidemiological study, particularly comparing developed and 
developing countries. By studying countries which have seen a sharp increase in PIBD, 
environmental factors can be sought out such as vitamin D and urbanisation. Paediatric 
patients present a unique opportunity to enhance our understanding as children have had 
shorter exposure to environmental triggers. Accurate prevalence figures could result in 
better provision of services to support to patients and families with PIBD thereby improving 




























5. The incidence of Paediatric Inflammatory Bowel 
Disease in Scotland demonstrates a sustained rise over 
the last 40 years- 1969-2014 
 
5.1 Background 
  The incidence of paediatric-onset inflammatory bowel disease (PIBD) has been 
increasing worldwide according to a recent paediatric systematic review(2), however, the 
reasons for this remain elusive. Current hypotheses for the pathogenesis of IBD suggests that 
in genetically susceptible hosts there is an immune mediated process leading to gut dysbiosis 
and so the development of IBD(212).  
Scotland has the highest reported incidence within the United Kingdom (UK) of PIBD 
with a rate of 7.82 per 100,000 reported in 2012 in those under 16 years (92). Other areas of 
the UK and Ireland have also reported an increasing incidence(93, 97, 153). Scotland also has 
one of the highest reported rates worldwide with only Canada, Sweden and Finland reporting 
higher rates with an incidence of 23 per 100,000 in Finland(137, 156, 173).However, only 
Sweden has reported rates in the under 16 year age group with Finland reporting under 19 
years of age, and Canada under 18 years which will have contributed to the higher rates 
reported. Crohn’s disease (CD) is the predominant form of PIBD in Scotland (sustained since 
1995), where previously ulcerative colitis (UC) had been more common(90) which is unlike 
other countries that have reported a predominance of UC (162, 167, 171, 182, 213). 
 
5.1.1. Aims and hypothesis 
As the incidence of PIBD continues to increase worldwide, the hypothesis is that 
incidence of PIBD in Scotland would continue to increase. PIBD incidence data has been 




collected and collated in Scotland since 1969, so the aim was to calculate the incidence of PIBD 
in Scotland from 2009-2014 and to compare that to the historical data from 1969 to ascertain if 




 Methods are explained in Methodology chapter 2, section 2.2. 
 
5.3 Results 
5.3.1. Incidence of PIBD continues to rise in Scotland in all sub types  
 
In total, 430 patients were diagnosed with PIBD between 2003-2008 (cohort 1) (269 CD, 
118 UC, 43 IBDU) compared to 582 children between 2009-2014 (cohort 2) (355 CD, 147 UC, 80 
IBDU) (Table 10). Crude incidence of IBD was 10.6 per 100,000 [95% CI 9.8,11.5], CD 6.6 per 
100,000 [95%CI 6.0,7.3], UC 2.7 [95% CI 2.3,3.2] and for IBDU 1.3 per 100,000 [95%CI 1.0,1.6].  
Adjusted age-sex incidence rate for IBD increased between cohort 1 and cohort 2 from 
7.9/100,000/year [95%CI 7.1-8.6] in cohort 1 to 10.6/100,000/year [95%CI 9.6-11.5] in cohort 2 
(p<0.001). A significant increase was also seen for CD (4.7/100,000/year [95%CI 4.2-5.4] in 
cohort 1 compared to 6.6/100,000/year [95%CI 6.0-7.3] [p<0.0001]) for cohort 2 and with UC 
which increased from 2.1/100,000/year [95%CI 1.7-2.5] to 2.7/100,000/year [95%CI 2.3-3.3] in 
cohort 2 (p=0.03). There was an increase in IBDU from 0.8/100,000/year [95%CI 0.6, 1.0] in 
cohort 1 to 1.3/100,000/year [95%CI 1.0, 1.6] in cohort 2 (p=0.15). There was a slight decrease 
in the population under 16 years from cohort 2 to cohort 1 (See Table 11) 
 
 




Table 10- Crude incidence of paediatric-onset inflammatory bowel disease 













IBD 247 183 354 228 
CD 158 111 229 134 
UC 66 52 85 64 
IBDU 23 20 40 30 
Population at 
risk* 
474,299 452,369 467,290 446,027 
*Mean number of population <16 years of age at risk for each year of the cohort. IBD- Inflammatory Bowel Disease; CD- Crohn’s 
Disease; UC- Ulcerative Colitis; IBDU- Inflammatory Bowel Disease Unclassified.  
# Cohort 1, $ Cohort 2 
 













5.3.2. Incidence of PIBD by gender 
 The incidence of PIBD significantly increased in both males and females from cohort 
1 to cohort 2 (p<0.001 for males and p=0.03 for females see Table 12), although when further 
analysed, the significant increase observed in males was due predominantly to the increase in 
male CD. The highest incidence in cohort 2 was males with an age-adjusted incidence of 13.4 
per 100,000 [95% CI 12.0,14.8] compared to 9.0 per 100,000 [95% CI 7.9,10.2] for females with 
IBD. Incidence was also higher in males in all IBD subtypes: for CD, 8.6 per 100,000 [95% CI 
7.5,9.8] in males vs 5.2 per 100,000 [95%CI 4.4,6.2] for females, for UC 3.2 per 100,000 [95% CI 




2.5,3.9] vs 2.5 per 100,000 [95%CI 1.9,3.2] for females and 1.5 per 100,000 [95% CI 1.1,2.1] for 
IBDU in males against 1.2 per 100,000 [95%CI 0.8, 1.7] for females. When compared to cohort 
1, the incidence of all PIBD subtypes has increased but a significant increase was only seen in 
males with IBD and CD, this contrasts with cohort 1 where a significant increase was observed 
in CD, UC and non-Crohn’s colitis (NCC) (see Table 12). In cohort 2, females with IBD showed 









Table 12 Age adjusted incidence of Paediatric-onset inflammatory bowel disease demonstrates sustained increase since 
1990 for all males and for females with IBD 
 
 Males      Females     



















































































































IBD- Inflammatory Bowel Disease; CD- Crohn’s Disease; UC- Ulcerative Colitis; IBDU- Inflammatory Bowel Disease Unclassified. Incidence rates are per 100,000 population at risk.  # 
Cohort 1 $ Cohort 2






5.3.3 Incidence by age subgroups 
 Incidence rates were calculated by age subgroups for both males and females then 
compared from Cohort 1 against Cohort 2. The median age at diagnosis was similar for both 
males and females with a median age at diagnosis of 12.3 years (range 1.23-15.92) for males 
and 12.2 years (range 1.26-15.91) for females. Although increasing numbers of IBD cases were 
diagnosed under 6 years of age, this did not achieve statistical significance for males or 
females. However, the incidence of IBD and CD in males aged 11-15 years continued to 
increase from cohort 1 to cohort 2 with incidence of IBD 16.0 per 100,000 [95% CI 13.60,18.16] 
in cohort 1 to 26.9 per 100,000 [95%CI 23.60,30.56] in cohort 2 (p<0.0001) and for CD 10.5 per 
100,000 [95% CI 8.59,12.80] in cohort 1 increasing to 17.4 per 100,000 [95% CI 14.72,20.32] in 
cohort 2 (p=0.001). There was an increase in UC in males aged 11-15 years with incidence of 
4.4 per 100,000 [95%CI 3.21,6.00] in cohort 1 and 6.5 per 100,000 [95% CI 4.93,8.40] in cohort 
2 (p=0.11). For IBDU in the older age range of 11-15 there was a significant increased from 1.03 
[95% CI 0.5,1.91] to 3.07 [95% CI 2.03,4.48] (p=0.04). For females, there was a significant 
increase in IBD in those aged 6-10 years and those aged 11-15 years, in those aged 11-15 years 
incidence increased from 11.6 per 100,000 [95% CI 9.53,14.04] in cohort 1 to 17.3 per 100,000 
[95% CI 14.58,20.31] in cohort 2 (p=0.01).  For females aged 11-15 years there was a significant 
increase in CD from 7.3 [95% CI 5.65,9.26] in cohort 1 to 10.2 [95% CI 8.12,12.55] in cohort 2 
(p=0.05). There was a significant increase in rates of NCC in those aged 11-15 years from 4.3 
per 100,000 [95% CI 3.09,5.90] in cohort 1 to 7.1 per 100,000 [95% CI 5.43,9.16] in cohort 2 








Table 13A: Standardised incidence of PIBD by gender, IBD subtype and age at diagnosis demonstrates continues 
increased from cohort 1 to cohort 2 
 
 
£- Previous cohort IBDU did not feature. IBD- Inflammatory Bowel Disease; CD- Crohn’s Disease; UC- Ulcerative Colitis; IBDU- Inflammatory Bowel Disease Unclassified; NCC- non-Crohn’s 






 Males               
Age 
(years) 























































































































































Table 13B: Standardised incidence of PIBD by gender, IBD subtype and age at diagnosis demonstrates continues increased 
from cohort 1 to cohort 2 
 
£- Previous cohort IBDU did not feature. IBD- Inflammatory Bowel Disease; CD- Crohn’s Disease; UC- Ulcerative Colitis; IBDU- Inflammatory Bowel Disease Unclassified; NCC- non-Crohn’s 
colitis. Incidence rates are per 100,000 population at risk.  # Cohort 1 $ Cohort 2
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5.3.4 Longitudinal trends from 1969-2014 
In Scotland, the incidence of PIBD demonstrates a continued and sustained increase 
since 1969 to 2014 for all IBD (Figure 12a) which is driven by paediatric CD (Figure 12b) 
continuing to show a steep increase. Comparison with historical data from before IBDU was 
introduced and commonly used has been performed by combining UC and IC creating non-
Crohn’s colitis, which has increased but only latterly has achieved significance (Figure 12c). 
 
Figure 12A- Incidence of paediatric-onset IBD demonstrates sustained increase in 
incidence from 1969-2014 (incidence rates per 100,000) 
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Figure 12B- Incidence of paediatric-onset CD demonstrates sustained increase in 
incidence from 1969-2014 (incidence rates per 100,000) 
 
 
Figure 12C- Incidence of paediatric-onset NCC (non-Crohn’s colitis) demonstrates 
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The incidence of paediatric-onset inflammatory bowel disease in this nationwide 
cohort study demonstrates a sustained and durable increase with a persistent increase in 
paediatric-onset CD from 1969-2014. Comparing the two most recent cohorts, cohort 2 
(2009-2014) and cohort 1 (2003-2008), there was a significant 27% increase in all PIBD 
incidence, yet the only significant increase in IBD subtypes was in CD in males which has 
shown an enduring increase since 2003(92). The IBD incidence rate of 10.7 per 100,000 for 
those under 16 years in Scotland remains one of the highest worldwide and the highest in 
the UK(97, 153).  
In a recent systematic review on the worldwide incidence of PIBD, 70% of countries 
described an increase, however, few countries reported such a durable rise as observed in 
Scotland(2). Australia and Sweden also have continued and durable rises in UC over a 60 
year period, again with the most significant increases at the end of the study period(172, 
178). Both studies compared 20-year epochs (i.e. 1950-1969 vs 1990-2009 in Australia), 
which if further broken down into 5-year epochs, the incidence may more closely reflect 
that seen in Scotland. Australian incidence is presented annually in graphical form (no 
numerical data) where rates vary annually with peaks in 2007-2008 and lower levels in 
2006/2009(172). In the Swedish study patients were included up to 19 year which may 
explain their increase (177). Potential changes in diagnostic pathways or better accrual of 
data may also explain the increases seen whilst in Scotland these pathways have remained 
relatively stable over many years with clear established referral pathways. 
Ontario Canada has had a sustained increase over a shorter period from 9.5 per 
100,000 in 1995 to 13.2 per 100,000 in 2009(111, 180) but includes those under 19 years. 
More recent Canada-wide incidence data from 2010 included those less than 18 years and 
reports incidence rate of 9.7 per 100,000(137), which still includes an additional 2  years of 
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incident data from the Scottish cohort.  Unlike our cohort, the Ontario group reported 
significant increases in all IBD subtypes although, did not report on IBDU, in those aged 6-9 
and 10-17 years with a slight decrease in CD in those aged 0-5 years(180). EPIMAD confirms 
the increases in incidence of CD in those aged 10-19 years with a significant increase from 
3.4 per 100,000 in 1988-90 compared to 5.9 per 100,000 in 2006-07 (p<0.001), which was 
not influenced by gender or region(175). A further example from Canada, this time from 
Manitoba, incidence in PIBD increased from 1.2 per 100,000 in 1978 to 4.68 per 100,000 in 
2007 (p<0.001). Finland reported incidence over 28 years via a national registry for those 
under 19 years which increased from 7 per 100,000 in 1987-1990 to 23 per 100,000 in 
2011-2014 (173). This is significantly higher than Scotland, however, the additional 3 years 
of patients from aged 16 to 19 years may explain the higher rates. 
Adult systematic review data supports paediatric findings with higher incidence rates 
reported in Europe and North America(87). Temporal data from this review demonstrates 
an increasing trend with 56% of CD and 29% of UC studies since 1980 reporting a significant 
increase, however, 6% of UC studies reported a decrease compared with none for CD. The 
rate of rise seen at the end of the 20th century in adult IBD has not been maintained (87, 
184) and it is possible this may happen in PIBD. The decrease in UC may be related to 
diagnostic approach with a more robust process associated with an increase in CD,  the 
assertion that in developing countries ulcerative colitis is a more predominant subtype(5) 
or environmental exposures. Environmental factors have been implicated for many reasons 
including that as countries become more “westernised”, the incidence of IBD increase, as 
demonstrated in the Asia-Pacific Crohn’s Colitis Epidemiological Study,  where UC is twice 
as likely to be reported than CD(101). IBD is increasing in those who immigrate from low 
risk to high risk countries in either first or second generation exemplars include Canada, UK 
and Denmark(150, 206, 210, 214) further supporting the role of environment in the 
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aetiology of IBD. In PIBD, an age related effect was observed with the highest risk of 
developing IBD in those immigrating at a younger age (88) and potentially the role of the 
microbiome(215) as infants have higher susceptibility to microbial change in response to 
environmental factors(216). Immigration is unlikely to have influenced the incidence in 
Scotland as there is relatively low rates with only 4% of the population belonging to an 
ethnic minority (16). 
Observational cohort studies have suggested several associations with PIBD including 
cigarette smoking (increases risk in CD) (217), antibiotic usage during childhood (increased 
risk in Westernised population)(218), breastfeeding (protective)(219), appendectomy 
(protective against UC)(220), air pollution (increased risk)(221), latitude and urbanisation 
(89, 221-224). Data from Finland suggests higher incidence in more sparsely populated 
areas contrasting with Manitoba, Canada which suggests higher rates in urban areas(160, 
224, 225) and is supported by Danish data that reported for every 5% increase in 
urbanisation the odds of having CD compared to UC increased by 34%(208).  The hygiene 
hypothesis may explain the increase and theorizes that childhood infections and poor 
hygiene are protective against developing CD. Poor hygiene allows the host to develop 
tolerance or immunity to potential agents that could trigger CD in later life and is been 
supported by case-control studies(201). Factors found to be protective against IBD support 
this including having pets, larger family size and greater number of siblings(113, 226). 
Evidence on the role of diet is conflicting with a recent systematic review, including only 
one paediatric study, showing an association between high dietary fibre and intake of fruit 
with a decreased rate of CD(227). In PIBD at diagnosis new CD patients had lower intakes of 
fruits and vegetables than controls(228) which supports the previous findings. However, 
caution must be exercised when interpreting these studies are recall bias may influence the 
results and the effect of confounders cannot be excluded i.e. children restrict their diet as 
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this influences their symptoms.  Another key environmental factor is latitude with a clear 
north south divide seen in both Europe and North America, including Scotland (89, 106, 
223). Scotland has reported higher incidence rates in the North than South for CD only 
although this may have been confounded by the inverse relationship between 
socioeconomic status and risk of IBD(223). In the United States of America, higher 
incidence was reported in Northern states(105), however, this data is not population-
based. The diverse results reported illustrate that no single environmental factor can 
explain the rising incidence which is likely to be a complex interaction between genetics, 
environment and unknown microbial influences. The effect of the gut microbiota in the 
pathogenesis of IBD has yet to be fully understood but is associated with innate immunity. 
Microbial diversity is reduced in IBD when compared to healthy individuals, particularly in 
CD(229). Additionally, certain types of bacteria are reduced in CD such as Faecalibacterium 
prausntizii  which has been shown to have anti-inflammatory properties(230).  
The incidence of very-early onset IBD, those aged less than 6 years, remained stable 
during the study period in our cohort confirmed by the EPIMAD group which also reported 
a stable incidence from 1988-2011(170). However, this contrasts with other studies which 
report increasing trend in this age compared to older children(137, 169). EPIMAD reports a 
stable rate of 5% of all PIBD cases in those under 6 years, similar to a study of 5 Canadian 
provinces with data collected through health administrative databases. However, there was 
variation between the Canadian provinces with Alberta reporting 12.5% of all PIBD cases in 
those under 5 years contrasting with Quebec which reports only 2.4%. IBD diagnosed under 
2 years is likely to  have a monogenetic cause including IL10 receptor defects and XIAP(231, 
232) while those under 6 years are hypothesised to be related to environment(137). The 
genetics of IBD remains poorly understood, yet recent advances have greatly enhanced 
knowledge with 200 risk loci now identified suggesting involvement of the adaptive and 
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innate immunity, autophagy, intestinal epithelial barrier function and microbial defence 
pathways(151). Genetic shifts evolve over thousands of years and heritability cannot fully 
explain the risk suggesting that other factors are involved in the increase in IBD including 
epigenetics. Epigenetic changes occur with increasing age caused by environmental 
factors(233) and are thought to affect interaction with the intestinal microbiome(234) and 
immune response(235). Interestingly, differences are reported in DNA methylation 
between adult and paediatric IBD; 26 dysregulated miDNA associated with PIBD and only 8 
overlap identified in adults(234) which is supported by a recent systematic review.   
The strengths of our nationwide cohort study are that our most recent cohort was 
prospectively obtained using the same rigorous and robust methodology used in previous 
studies(91, 92). The well-established virtual healthcare network set up in Scotland covering 
all district general hospitals allows for accrual of all cases less than 16 years of age. The 
established database based in a single centre ensures that cases are regularly reviewed and 
IBD subtypes are changed if needed after endoscopic re-evaluation and discussion with the 
lead for IBD for each centre ensuring the phenotyping is robust and evolving. As in our 
previous study, we have not approached adult colleagues for under 16-year olds who have 
been diagnosed in adult practice, as there are significantly more adult IBD centres where 
patients could be seen. A different approach to data collection is required such as a 
national database to identify cases which would then need to be validated by researchers 
to confirm the age of diagnosis and the IBD subtype.  However, given the well-established 
paediatric gastroenterology service which is now in place nationwide and has not changed 
for many years, most cases are seen within this service and the minority are seen in adult 
service. As these patients are not included, it will only increase the incidence rates 
observed supporting the assertion that PIBD continues to increase in Scotland.  Previous 
hypotheses the increase was due to improved methods of diagnosis and accrual of data via 
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the national network of care, are not enough as the current investigations strategies and 
referral pathways have been in place for sustained period without change, necessitating 
another explanation for the rise. It is possible that these pathways reduce time to diagnosis 
through increased awareness and improved access to services but not for the increase in 
actual numbers diagnosed. 
 
5.5 Conclusion 
This population-based nationwide study of incidence of paediatric-onset IBD 
demonstrates a 27% increase in IBD from 2003-2008 to 2009-2014 which is driven by a 
sustained and durable increase in paediatric-onset CD, maintained by the increase in males, 
predominantly aged 11-15 years. The incidence of 10.7 per 100,000 of PIBD under 16 years 
to our knowledge remains the highest reported in the UK and one of the highest 
worldwide. Further epidemiological research is needed to establish and explore potential 
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6. Paediatric Inflammatory Bowel Disease 
Unclassified: a nationwide population-based incidence 
and natural history cohort study 
 
6.1 Background 
IBDU is the least common subtype of PIBD accounting for around 10% of cases (102) 
yet there is a paucity of population-based data on the incidence with reported incidence 
figures ranging from 0.03 per 100,000 to 1.0 per 100,000 (152, 236) which has increased 
over time(152, 188) with United Kingdom incidence in 1999 0.6 per 100,000(102). There is 
a lack of  evidence on the natural history of IBDU but studies do suggest that  patients have 
a rapidly progressing disease in both paediatric and adult patients(237, 238) which evolves 
over time into CD or UC although with differing frequencies (116, 138). Further research is 
needed to assess and understand the natural history of paediatric IBDU to gain insight into 
the disease course and outcomes including efficacy of treatment options. 
 
6.1.1. Aims and hypothesis 
The hypothesis was that the rates of IBDU are increasing within Scotland and that 
most cases have a mild disease course with a similar response to treatments as UC. The aim 
was to determine the incidence and temporal trends of paediatric IBDU in a well-defined, 
population-based cohort in Scotland, and to describe their natural history, diagnostic 
assessment and treatment outcomes. 
 
6.2 Methods 
Methods are explained in Methodology chapter 2, section 2.3. 
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6.3.1. Basic characteristics 
115 patients met the inclusion criteria (66 male; 8% under 5 years old, 36% 6-10 
years and 56% 11-15 years) with a median age at diagnosis of 11.4 years (range 2.3-15.9). 
The median follow-up time was 2.8 years (range 0.5-9.6). 476 cases of PIBD (i.e. CD, UC and 
IBDU) were diagnosed between 2009-2013; 65 (14%) were IBDU.  
Most patients had extensive disease at presentation (Table 14) and progression was 
noted in all categories (Table 15). The majority had a relatively mild disease course (when 
assessed at last follow up; Figure 13), however, 16% had severe disease requiring anti-TNF-
α therapy and/or surgery. In those that had severe disease at presentation, all remained 
IBDU at last follow up with 2 requiring surgery with 4/10 having chronically active disease, 
all of whom required IFX. 
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Table 14 Baseline characteristics at diagnosis of patients diagnosed with IBDU 
Male (%) 66 (57) 
Median age 11.4 years 
Disease extent (%) 
-Pancolitis 
-Disease distal to hepatic 
flexure 




















-MRE and barium 





















Table 15- Progression of disease in those that remained IBDU at last follow up 
using Paris Classification 
 





Disease extent at 
last follow up 
Number of 
patients   IBDU at 
last follow up 
(n=89) (%)  
E1 5 (4) E1 2 (2) 
E2 12 (11) E2 6 (7) 
E3 8 (7) E3 9 (10) 
E4 90 (78) E4 72 (81) 
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Figure 13 Longitudinal disease course in IBDU demonstrates than most patients 




In 2013, 21% (21/98) of all incident cases of PIBD in Scotland were diagnosed with 
IBDU, with a crude incidence rate of 1.2/100,000 across the entire study period (2003-
2013). Age-sex adjusted incidence rate for 2003-2008 was 0.9/100,000 (95% CI 0.6, 1.2) 
compared to 1.7/100,000 in 2009-2013 (95% CI 1.3, 2.6) (p=0.04) (Figure 14). Following re-
evaluation 89/115 had a diagnosis of IBDU at last follow up giving an adjusted 2003-2013 
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Figure 14- Incidence of Inflammatory Bowel Disease Unclassified in Scotland 2003-
2013 shows significant increase in time between 2003-2007 and 2008-2013 
(incidence rates per 100,000) 
 
 
6.3.3. Baseline investigations 
All children underwent colonoscopy at diagnosis and 112 (97%) underwent upper 
gastrointestinal (GI) endoscopy (Table 14). Three children did not receive an upper GI 
endoscopy. Two were initially investigated in Scottish adult hospitals and on suspicion of 
IBD were transferred to paediatric services. One was in clinical remission and the other had 
acute severe colitis which required a colectomy within one month of diagnosis; both 
patients have subsequently undergone an upper GI endoscopy which was normal both 
macroscopically and microscopically. The third child did not have an upper GI endoscopy at 
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6.3.4. Induction therapy 
75 (65%) received corticosteroids (either intravenous and/or oral) with 65 (87%) 
achieving remission. Two children received Infliximab (IFX), one child who responded to 
oral steroids but did not achieve remission and one child who failed to respond at all. 
Following IFX, one child achieved remission whilst the other had an improvement but 
subsequently underwent a colectomy.  
Exclusive enteral nutrition (EEN) was used in 15 (13%) thought initially to have 
Crohn’s disease based on macroscopic appearances but microscopically suggestive of IBDU. 
Only two (15%) children achieved remission with EEN one of whom was subsequently 
reclassified as CD. 5- ASAs were used in 58 (50%) cases; of these 32 (55%) achieved 
remission and 21 (36%) subsequently received a course of corticosteroids resulting in 
remission/response in all but one child.  
6.3.5 Maintenance therapy 
Most children were commenced on a 5-ASA for maintenance 107 (93%). However, 
with 52 (45%) went on to receive azathioprine and 16 (14%) methotrexate (Table 16). Anti-
TNF therapy was required in 14 (12%), all initially had IFX and five required ADA after 
failure of IFX (Table 16). Of the 14 patients who received IFX, 11 were discontinued:  two 
for primary non-response, five for loss of response and four as a planned drug 
discontinuation (two received IFX as a bridge to surgery, one as a bridge to 
immunosuppression and one entered clinical and endoscopic remission). Five patients 
changed from IFX to ADA (one primary non-responder and four loss of response), two then 
had primary non-response to ADA. 
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Table 16 Prior medications for maintenance for all IBDU patients 









Azathioprine/6-MP (N, %)  
-Primary non-response 







Methotrexate (N, %) 
-Primary non-response 







Infliximab (N, %) 
-Primary non-response 
-Loss of response 
-Bridge to 
immunosuppression/surgery 













6.3.6. Reclassification to alternative IBD subtype from IBDU 
Sixty-three patients (55%) had a repeat upper GI endoscopy after a median of 1.5 
years (range 0.2-9.6) (Figure 15).  A further two (2%) underwent repeat upper GI 
endoscopy for reasons other than IBD (recurrent dyspeptic symptoms despite optimum 
medical treatment and recurrent H. pylori infection) and did not undergo colonoscopy. 2 
(2%) underwent repeat colonoscopy only.  18/65 (28%) underwent repeat imaging with 
one child undergoing a repeat barium follow through then MRE. The most commonly used 
imaging for reassessment was MRE in 10 (53%) then barium follow through in 6 (32%) then 
2 (10%) had wireless capsule endoscopy and 1 (5%) had a white cell scan.  
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Sixty-five patients underwent 106 colonoscopies most commonly for disease 
reassessment in 54 (51%), relapse of symptoms in 33 (31%) or steroid dependency in 14 
(13%).  41 (36%) had one endoscopic re-evaluation, 16 patients underwent two, three 
patients had a third re-evaluation, three had four and two had six re-evaluations. One 
patient who had six re-evaluations had difficult to control disease with a polypoid lesion in 
his transverse colon which required endoscopic surveillance; he remained IBDU at 
transition to adult services. Another patient who underwent six re-evaluations had a 
colectomy and end ileostomy then underwent closure of the loop ileostomy; her colectomy 
sample was consistent with UC and went on to develop chronic pouchitis and stenosis of 
her anal pouch.  
26 (23%) changed their diagnosis, all after endoscopic re-evaluation, most commonly 
to CD in 16 (62%) and UC in 10 (38%) after a median of 1.5 years (range 0.6, 5.9) (Figure 
15). Most, 21 (81%), changed their diagnosis after one endoscopic re-evaluation (14 to CD 
and 7 to UC). Three patients changed diagnosis after their second endoscopic re-
evaluation, one to UC and two to CD. One patient changed to UC after his third endoscopic 
re-evaluation and one after 5 endoscopies also changed to UC. In those that changed to CD, 
5 (31%) did not have ileal intubation at diagnosis but all had small bowel imaging and upper 
GI endoscopy.
 












N=2 no small bowel imaging (no small bowel disease 
seen when diagnosis changed)
N=9 barium meal and follow through
N=4 MRE
N=1 white cell scan



















3 ADA (all post IFX)
Outcome:























N=6 ileum not visualised (all had subsequent 
small bowel imaging)
N=18 had OGD
N=8 barium meal and follow through
N=1 no small bowel imaging (Had OGD)





























Figure 15 Outcome and treatment for patients who remained IBDU at last follow up 
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Figure 16 Outcome and treatment for patients who remained IBDU at last follow up
 
6.3.7 Surgery 
Seven (6%) patients underwent IBD-related surgery after a median of 2.1 years 
(range 0.1-5.4). The most common procedure was colectomy and end ileostomy in 6 of 7 
with the final procedure a small bowel resection for a patient who had a changed diagnosis 
to CD prior to surgery. A further 3 patients had a change of diagnosis; 2 prior to surgery 
changed to UC whilst 1 had a change of diagnosis to CD following reassessment post 






N= 2 had no OGD














N=2 EEN (1 remission and 1 response)
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6.4 Discussion 
In this Scottish population-based cohort of patients with IBDU, a significant increase 
was reported over an 11-year study period with an extensive phenotype at presentation, 
yet a relatively mild disease course, with only 6% requiring surgery and 14% requiring anti 
TNF therapy. There was a low threshold for re-investigation with 57% having a repeat 
endoscopy but, despite a high rate of re-assessment, only 40% (26/65) who had a repeat 
endoscopy changed diagnosis, most commonly to CD in 62% after a median of 1.5 years. 
The incidence of paediatric IBDU significantly increased in our cohort over 11 years, 
as demonstrated in other countries(152, 188). The increase may reflect a more 
comprehensive diagnostic assessment in this cohort as patients were not labelled CD or UC 
due to insufficient evidence.  All patients in this study underwent colonoscopy and 97% had 
an upper GI endoscopy, compared to 98% and 89% respectively in the Eurokids 
registry(138), with 89% of IBDU patients here undergoing small bowel imaging compared to 
62% in Eurokids (138). Furthermore, all Scottish patient’s histology was reviewed to 
confirm IBDU prior to inclusion, difficult cases were reviewed by senior IBD clinicians in 
each centre to confirm eligibility, but biopsies were not reviewed in the Eurokids study. The 
variation in diagnostic approach may be explained by guidance not being published until 
2005 on a recommended approach, when upper and lower GI endoscopy including ileal 
intubation with multiple biopsies, and small bowel imaging irrespective of ileal disease at 
endoscopy were recommended (11). Biopsies are crucial for a diagnosis of IBDU with the 
Porto group defining changes as “histology showing acute and chronic inflammation with 
architectural changes confined to the colon…. With normal small bowel follow through or 
enteroclysis”(11). In 2014 further clarification on what which would be considered IBDU 
and atypical features of UC/CD were published including a child with colitis with significant 
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growth delay (height velocity <-2SDS), multiple aphthous ulcerations in the stomach not 
explained by another cause (e.g. non-steroidal anti-inflammatory drugs or H. pylori ), 
aphthous ulcers in the oesophagus or duodenum not explained by another cause (e.g. H. 
pylori or coeliac disease) or reverse gradient of mucosal inflammation (i.e. worse right-
sided mucosal inflammation)(13).Further validation work on these features have been 
performed to produce a clearer diagnostic algorithm (239). 
A systematic review on the incidence of PIBD(2) did not include IBDU and few other 
epidemiological studies have covered this area, potentially  due to inherent methodological 
difficulties and relatively recent subclassification. The methodological challenges with any 
paediatric epidemiological study (heterogeneous data collection techniques, variable age 
limits defining paediatric populations and diagnostic misclassification) are compounded by 
the historical lack of diagnostic criteria for IBDU which leads to varying diagnoses of IBDU 
among countries and even amongst centres within the same country(137). The Eurokids 
registry exemplifies this, with cases reported from leading European centres yet 16% who 
were initially classified as IBDU had features more compatible with CD (more likely in those 
that did not undergo full diagnostic work up)(138). Furthermore, a patient who could have 
been diagnosed as IBDU previously may now be given a diagnosis of atypical UC(13). True 
population-based cohort studies such as this, excludes the referral bias inevitable with 
single centre studies, and with full IBDU accrual the full spectrum of disease severity, from 
the mildest to the most severe is seen. 
In this cohort 8% were diagnosed under 5 years and it became more common with 
increased age, contrary to the Spanish cohort where IBDU was diagnosed more at a 
younger age (152). The median age of diagnosis in our cohort was 11.3 years similar the 
literature (188, 240) yet younger than Eurokids at 12.3 years(138). A systematic review on 
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IBDU, in adults and paediatrics reported it was more common in younger children with up 
to 20% of children diagnosed under 5 years of age(116). However, numbers in this age 
group are small and the diagnosis can often be challenging(140). Heyman performed 
multivariate regression and demonstrated that compared to CD, children aged below 8 
years were 3.5 times more likely to be diagnosed with IC(241). 13% were identified as IBDU 
in this cohort but it is unclear what diagnostic work-up they underwent (13). Conflicting 
evidence exists regarding gender propensity in IBDU, we found IBDU to be more common 
in males whilst Lindberg reported it to be more common in females (240) and others have 
found no difference(102, 138). 
IBDU can evolve over time into either CD or UC and a challenge for paediatric 
gastroenterologists is that patients transfer to adult care so are often lost to follow up. In 
our study 23% changed their diagnosis after a median of 1.5 years, is higher than previously 
reported and mostly reclassified to CD, which is similar to other studies (156, 188). In the 
Eurokids study, 33% changed diagnosis, most commonly to UC, however, only 44% of the 
whole cohort of 265 patients were included in this aspect of follow up(138).  A different 
longitudinal cohort study followed IBDU cases for a mean of 3.5 years, 23% of patients 
changed diagnosis after a median of 4.1 years: 8 (44%) to CD, 5(28%) to UC and 5 (28%) as 
non IBD. Of the 30% who remained IBDU, 55% reported no symptoms and were on no 
medication at last follow up with only 30% confirmed IBDU (242). It is not clear from the 
methodology what baseline investigations were performed or if patients had small bowel 
imaging which may explain the increased numbers reclassified as CD. Many patients ended 
up with a non-IBD diagnosis which promotes the need for endoscopic re-evaluation. The 
importance of longitudinal follow up is illustrated in another single centre study, 33.7% of 
paediatric patients were reclassified after a median of 1.9 years(237), however, if follow up 
was extended to 8 years, up to 80% of adult patients had their diagnosis revised(243).  
Chapter 6. Paediatric Inflammatory Bowel Disease Unclassified: a nationwide population-
based incidence and natural history cohort study 
133 
    
 
Further support is provided in a systematic review that there was in increase in CD and 
decrease in indeterminate colitis with time(116). However, this review mentions a decrease 
in UC s in some studies but not all, so it is then unclear if the increase in CD and decrease in 
IBDU reflects changes to CD, UC or both.  
In those that remained IBDU at last follow up in this cohort, 76% had extensive 
disease at diagnosis rising to 81% at maximal follow up which is similar to a previous study 
of Scottish children where74% of UC  patient had pancolitis at diagnosis which increased to 
82% after a median of 3.9 years(16).  The rapid disease progression is especially relevant 
given the increased risk of surgery in those with extensive disease(13). Disease progression 
has been observed in both UC and CD in PIBD (16) but little is known about progression in 
IBDU, recent  evidence suggests that it is a genetically different subtype differing from both 
UC, colonic and ileal CD with a genetic continuum from ileal CD to UC(244). In a single 
centre study in North America of paediatric IBDU, nearly 80% had pancolitis at diagnosis 
rising to 100% after 6 years of follow up suggesting rapidly progressing disease(237). In In 
the Eurokids cohort, 58% had extensive disease at presentation with no comparator at end 
of follow up although repeat colonoscopy was performed in 50%(138).  
The natural history of IBDU in relation to medications is largely unknown as these 
patients are not included in large studies of immunomodulators or anti TNF therapy. In our 
cohort, 45% IBDU patients require immunomodulation, mostly azathioprine, and 14% 
required anti TNF therapy an aggressive disease phenotype. However, 5-ASAs were 
effective at inducing remission with most patients continuing onto maintenance therapy 
suggesting a proportion have a milder disease course. Treatment responses are similar to 
others in the literature with 12% requiring anti-TNF therapy and nearly 90% receiving 5-ASA 
at diagnosis (245).  Future studies would benefit from including these patients to provide 
Chapter 6. Paediatric Inflammatory Bowel Disease Unclassified: a nationwide population-
based incidence and natural history cohort study 
134 
    
 
further guidance on how medications should be used in paediatric IBDU and evidence of 
efficacy. 
There were several methodological difficulties in conducting this study which may 
influence the results. Only children less than 16 years who were diagnosed and managed in 
paediatric services were included so the number may be an underrepresentation.  Patients 
were identified from either prospective or retrospective databases; however, all data was 
collected using a standardized proforma by a single researcher to ensure a standard 
approach. During the 13-year period, practice changed on appropriate diagnostic 
techniques, so no one standardized approach was used and significant diagnostic 
heterogeneity exists.  However, this study is population-based incidence providing analysis 
of trends over time with a median of 2.8 years of follow up providing an insight into 
investigation and treatment of paediatric IBDU. The importance of endoscopic re-
evaluation to monitor disease progression and potential evolution to CD or UC has been 
shown which is not often mentioned in relation to a change in diagnosis(156). The impact 
of the revised Porto criteria and new diagnostic algorithms may impact upon the incidence 
of IBDU given more structured diagnostic criteria(13, 239) which may result in an increasing 
number diagnosed. 
6.5 Conclusion 
In this national population-based study on the incidence of paediatric IBDU a 
significant rise over an eleven-year study period was found with 23% changing in diagnosis 
after endoscopic re-assessment, mostly to Crohn’s disease. Low rates of surgery and anti 
TNF therapy were observed with most patients having a mild disease course despite high 
rates of extensive disease at presentation and disease extension observed during a median 
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follow-up of 2.8 years. Further longitudinal follow up is needed to determine if more 
patients will be reclassified or have further extension of their disease.
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7. The natural history of anti-TNF therapy use for 
paediatric inflammatory bowel disease treatment in 
Scotland 
7.1 Summary  
• ADA/IFX were safe and effective at inducing remission in all subtypes of PIBD with 
remission in 58% of IFX and 83% response/remission of ADA patients 
• Safety- 30 (15%) patients had 35 acute infusion reactions to IFX (either on the first 
or second course); 2 had anaphylaxis. 21 had an adverse reaction with 14 
experiencing toxicity who required hospitalisation. 15 had adverse effects with ADA 
with 5 hospitalisations. No deaths or anaphylaxis were reported.  
• 93% of IFX patients commenced maintenance therapy which they received for a 
median of 0.9 years (range 0.1-3.7); 56% still receiving IFX at 12 months. The most 
common reason for discontinuation under 12 months was primary non-response.  
• 56/57 commenced ADA maintenance with 34/57receiving at 12 months, the most 
common reason for discontinuation was primary non-response in 5/11 who 
stopped before 12 months  
• IFX/ADA dependency occurred in 50% of ADA and 34% of IFX patients. Despite dose 
escalation, 43% discontinued due to secondary loss of response with 56% were still 
on IFX and 74% on ADA at last follow up. 27% IFX and 39% ADA patients had a 
planned drug withdrawal, mostly for clinical remission.  
• Remission, early stages of puberty (Tanner 1, 2 and 3) and disease duration ≥ 2 
years at induction were associated with improved linear growth in IFX 
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• Significant improvement in linear growth was associated with males, moderate 
disease at induction of IFX, induction then maintenance and AZA. Corticosteroids at 
baseline were associated with an improvement in linear growth at 12 months.  
• For ADA, improvement in linear growth was in those in the early stages of puberty 
(Tanner 2 and 3)  
7.2 Background 
Biological therapy in PIBD is increasing worldwide with Infliximab (IFX) (Remicade, 
MSD), and Adalimumab (ADA) (Humira, Abbvie) licensed for PIBD use in the UK. Despite 
widespread usage, no complete nationwide data exist as the UK PIBD audit, a national 
report on biological therapy, had incomplete reporting both within and amongst UK PIBD 
centres (246). 
 
As anti-TNF usage has increased,  the evidence on long-term efficacy has improved 
(63, 247) showing reduced inflammation, improved mucosal healing and reduced disease 
relapse/corticosteroid usage, however improvement in long term linear growth, a key 
outcome target, has proven more elusive(53, 248, 249). The presence of poor growth and 
short stature in PIBD, and more specifically, Crohn’s Disease (CD) has been described for 
some time; this can lead to a significant impact on final adult height with varying reports of 
20-30% of children with CD having a reduced adult height(250). Evidence on the efficacy of 
Infliximab (IFX) on short term growth is generally supportive with several studies showing 
clear benefit (59, 65, 251-253) however other published studies have shown no beneficial 
effect (33, 254-256). The long term effect of IFX on growth is less widely reported yet a 
recent retrospective study demonstrated improved height SDS in the short term with 3 
year follow up but final adult height at the lower range of their target (257). Fewer growth 
data exist on ADA, but it does demonstrate an improvement in the short (258)and longer 
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term growth(78) which is more pronounced in those who have remission/response post 
induction(259-261).  Despite a significant increase evidence on efficacy and benefits of anti-
TNF therapy, most data is provided by clinical trials which do not represent the “real life” 
clinical dilemmas faced by clinicians limiting the generalisability of the results as patients 
are selected to participate, often from tertiary referral centres, with not all PIBD subtypes 
included(262). 
Dependency was first reported in paediatric CD in 2007 and occurs in 42-66% of CD 
patients who required repeated infusions to maintain remission (254, 263, 264).  In adults 
on maintenance IFX, relapse on discontinuation is common despite immunomodulator 
therapy so dependence on anti-TNF to maintain remission is often seen(265). Evidence for 
ADA dependency is not as clear, possibly related to the length of time it has been available 
having only recently been licenced for use in paediatric patients with CD in the UK(52).  
  
7.2.1. Aims and hypothesis 
The aim of this study was to characterise biological usage, growth and dependency in 
a population-based cohort of children with all types of IBD, treated with ADA and/or IFX 
between 2000-2012 in Scotland using data from the Scottish PIBD biologicals register. The 
hypothesis was that anti-TNFs were safe and effective in all subtypes of PIBD. 
 
7.3 Methods 
Methods are covered in chapter 2, section2.4. 
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7.4 Efficacy of anti-TNF drugs 
7.4.1. All IBD patients receiving anti-TNF agents (IFX and ADA) 
One hundred and ninety-five patients were treated with 240 courses of therapy with 
a biologic, 164 (85%) had CD, 28 (14%) had UC and 3 (1%) IBDU. Most, 115 (60%) were boys 
with a median age of 11.2 years (range 2.7-17.2) at diagnosis. 191 received IFX and 57 
received ADA (4 received ADA alone) (Table 17 and Table 18).  
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Table 17 Baseline characteristics of patient on IFX 
 Crohn’s Disease (CD) Ulcerative Colitis (UC)  Inflammatory Bowel 
Disease Unclassified 
(IBDU) 
Number of patients 160 28 3 
Female (%) 63 (39)  11 (39) 2 (66) 
Median age at diagnosis 
(range, years) 
11.0 (2.74- 17.2) 12.2 (5.2-14.8) 13.2 (12.0-14.8) 
Median duration from 
diagnosis to start of IFX 
(range, years) 
2.6 (0.02-11.5) 1.34 (0.01-7.7) 0.01 
Median age at start of IFX 
(range, years) 
14.0 (5.96-17.5) 13.5 (5.3-17.6) 13.2 
Montreal classification 
(%) 
L1 and L4 2 (1) 
L2 28 (18) 
L2 and L4 25 (16) 
L3 36 (23) 
L3 and L4 67 (42) 
L5 2 (1) & 
E3- 25 (89) 
E2- 3 (11) 
E3-3 (100) 
Indications to start IFX (%) -Luminal CD 124 (78) 
-Immunomodulator failure 
102 (64) 
-Steroid dependency 40 (25) 
-Bridge to therapeutic 
immunosuppression 29 (18) 
-Perianal disease 29 (18) 
- Acute severe colitis 17 (61) 
-Chronic active colitis 11 (39) 
-Steroid dependency 12 (43) 
-Immunomodulator failure 9 
(32) 
- Acute severe colitis 2 
(66) 
-Chronic active colitis 1 
(33) 








- Methotrexate  
- Primary non-
response 
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Table 17 Continued Crohn’s Disease (CD) Ulcerative Colitis (UC)  Inflammatory 
Bowel Disease 
Unclassified (IBDU) 


































Post-IFX surgery  51 patients had 95 
procedures 
-30 Colectomy and end 
ileostomy 
-1 Small bowel resection 
-6 Right hemicolectomy 
-3 Left colon resection 
-8 Defunctioning stoma 
-10 perianal/fistula surgery 
-14 Colectomy and end 
ileostomy 
-1 Defunctioning stoma* 
-1 perianal surgery ** 
-1 Colectomy and end 
ileostomy 
 
&= isolate perianal disease only *family request **subsequently reclassified as CD 
.  
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Table 18 Baseline characteristics of patient on ADA 







Number of patients 53 3 1 
Female (%) 23 (43)  0 0 
Median age at diagnosis (range, 
years) 
10.9 (4.8- 14.9) 12.1 (9.5-12.3) 14.7 
Median age at start of ADA (range, 
years) 
14.5 (6.8-18.3) 13.6 (12.2-14.6) 15.5 
Duration from diagnosis to start IFX 
(yrs) 
3.86 (0.04-8.3)  0.8 
Montreal classification (%) L2 11 (21) 
L2 and L4 14 (26) 
L3 8 (15) 
L3 and L4 20 (38) 
E3- 2 (67) 
E2- 1 (33) 
E3-1 (100) 







































40/25mg- 1  
40/20mg 2  
24mg/m2 2  
40mg 5  
160/80mg 3 80/40mg-1 
Number of patients on previous IFX 
(%) 
48 (91) 3 (100) 1 (100) 
Reason for IFX discontinuation (%) 16 (33) Primary non-
response 
26 (54) Loss of 
response 
6 (13) Allergy 
2 (66) loss of 
response 
1 (33) allergic 
reaction 
1 Loss of response 
Post-induction response at 4 weeks 
- Remission 
-Partial response 













Maintenance 40mg 49 
25mg 1  
20mg 1  
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Table 18 Continued Crohn’s Disease 
(CD) 
Ulcerative 















-Loss of response 
-Intolerance 















































Post ADA surgery (n=12) 12 had 16 procedures 
-9 Colectomy and end 
ileostomy 
-1 dilatation of rectal 
stricture 
-1 right hemicolectomy 
- 1 SB resection* 
-1 defunctioning 
stoma** 
-1 EUA Labia 
 
-2 Colectomy and end 
ileostomy 
 
-2 Colectomy and end 
ileostomy 
*Small bowel resection ** had defunctioning stoma prior to colectomy 
 
7.4.2. Details of all patients receiving IFX  
7.4.3. Baseline IFX characteristics of all patients 
191 patients were treated with IFX, 160 (84%) patients had CD, 28 (14%) had UC and 
3 (2%) had IBDU (see Table 17). Figure 17 demonstrates the outcome of all patients treated 
with IFX.  IFX was commenced at a median of 13.8 (range 5.35 to 17.2) years, 2.20 (range 
0.01-11.5) years post-diagnosis at 11.2 (range 2.74 to 17.2) years; 115 were male (Table 
17). Patients received a median of 6 (range 1-41) doses over a median of 5.2 (range 0.67-
14.2) years of follow up, a cumulative national total of 1701 doses. Prior corticosteroids, 
thiopurine and methotrexate had been received by 168, 143 and 58 respectively. 
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Figure 17 Outcome of patients treated with Infliximab 
  
191 patients received IFX 
-160 CD 
-28 UC 
-3 IBDU  
63 received induction only 
-46 CD 16 UC 1 IBDU 
128 received induction then 
proceeded maintenance 
-114 CD 12 UC 2 IBDU 
9 received episodic- all CD 
4 received other maintenance 
dosing schedule 
78 patients received >12 months (11 
on second course) 
-74 CD 
- 3 UC 
-1 IBDU 
 
63 stopped post induction 
-31 Primary non-response 
-23 Planned drug withdrawal 
-1 Loss of response 
- 2 Allergic reaction 
-3 Adverse event 
- 3 transitioned post induction prior 
to maintenance 
35 stopped (33 CD and 2 UC) 
-17 loss of response 
-12 long drug holiday 
- 5 Allergic reaction 
-1 Primary non-response 
 
-52 stopped <12 mths 
  -17 primary non-response 
  15 loss of response 
  15 planned drug 
withdrawal 
  2 allergic reaction 
  3 adverse events 
Patients remaining on IFX: 
2 yrs- 25 patients 
3 yrs 15 patients 
4 yrs 6 patient 
5 yrs 2 patients 









  -4 stopped <12mths 
    1 planned drug 
withdrawal 
    1 loss of response 
    2 Primary no 
response 
Long term FU of all patients 
2 yrs- 22 patients 
3 yrs 14 patients 
4 yrs 5 patients 
5 yrs 1 patients 
 
-11 on IFX at last follow up 
received <12 mths (2 on 
second course) 
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7.4.4. Planned drug discontinuation 
51 (27%) discontinued IFX due to planned drug withdrawal, 23 (47%) received 
induction only and stopped after a median of 0.3 years (range 0.1-3.5). The most common 
reason for planned drug withdrawal was clinical remission (clinical examination and 
biochemical parameters) in 28 (55%) followed by planned withdrawal after achieving 
therapeutic immunosuppression in 18 (35%). Other reasons were IFX used as a bridge to 
surgery in 2 (4%) and deep clinical remission (clinical, endoscopic and biochemical) in 2 
(4%).  One patient with UC discontinued having responded to induction therapy but 
stopped due to lack of approval for use of maintenance IFX in paediatric UC. Most patients, 
30 (59%) were male, and 38 (74%) had CD, 12 (24%) UC and 1 (2%) IBDU. 13 (25%) 
restarted IFX, 2 failed a second course of IFX and were changed to ADA.  
7/18 had planned withdrawal for ADA, all discontinued in clinical remission; 2 of 
whom relapsed and subsequently restarted ADA, one stopped post colectomy and one 
remained in remission on anti TNF therapy at study end. 
 
7.4.5. IFX use in Crohn’s disease  
128 (67%) had further IFX post induction, including 9 (7%) with CD who had episodic 
dosing, 119 went onto maintenance initial induction (Figure 17) and had a median time to 
discontinuation was 0.9 years (range 0.1-3.7). 67(56%) were still receiving IFX at 12 months; 
9 (8%) continued IFX at last follow up but had not yet received IFX for 12 months and 43 
(36%) had discontinued. The most common reason for discontinuation under 12 months 
was primary non-response in 13 (30%), followed by planned withdrawal in 12 (28%), loss of 
response in 14 (32%) and allergic reaction in 2 (5%) and adverse event in 2 (5%). 
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Fifty-five required dose escalation; 45 had shortened infusion schedule – most 
commonly 7 weeks (n=18), then 6 weeks (n=18), 5 weeks (n=2) and 4 weeks (n=1). Thirty 
subsequently discontinued due to: loss of response in 20, primary non-response in 4, 
planned withdrawal in 4 and 2 related to infusion reactions. Three patients had their 
schedule lengthened to 12 weeks, 5 to 10 weekly and 1 to 9 weekly. Thirty-four had 
increased dose; twenty-three had increased dose and frequency, 11 increasing dose alone. 
Maximum doses were 10mg/kg (n=25) with 2 each receiving 7mg/kg and 6.5mg/kg. 84 
patients underwent surgery either pre- or post-IFX (Table 17). 
 
7.4.7. IFX use in UC  
Twenty-eight UC patients received IFX with fifteen progressing to surgery (Table 17) 
and 1 having IFX as a bridge to immunosuppression. Twelve had maintenance IFX; 1 
continued IFX in remission but 11 discontinuing (2 primary non-response after partial 
response, 2 loss of response (1 dose increase to 10 mg/kg) and 6 planned withdrawals in 
sustained remission in 5 with mild disease in one by study end. One stopped due to an 
adverse event with paraesthesia which resolved upon discontinuation of IFX.  
 
7.4.8. IFX use in IBDU  
Three patients required IFX, 2 for acute severe colitis and the other for chronic active 
colitis (Table 17). The patient with chronic active colitis entered remission post induction 
after a bridge to azathioprine but lost response despite dose optimisation so was changed 
to ADA but unfortunately, they still failed to respond so underwent a colectomy. Two 
patients with acute severe colitis had IFX, one responded after induction with IFX used as a 
bridge to azathioprine then entered a prolonged remission on azathioprine monotherapy, 
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the other patient entered remission post induction with loss of response on maintenance 
which responded to dose escalation (10mg/kg) and was in remission at study end 
continuing IFX. 
7.4.9. Basic demographics of all ADA patients 
57 patients were treated with ADA, 52 (91%) previously received IFX, 53 (93%) had 
CD, 3 (5%) UC and 1 (2%) IBDU (see Table 18). The median age at the start of ADA was 14.5 
years (range 6.8-17.2), and patients diagnosed at 10.9 years (range 4.8-17.9), 34 were male. 
18 (44%) stopped ADA after a median of 0.9 years (range 0.1-4.6), most commonly for 
primary non-response in 8 (44%) and planned drug withdrawal in 7 (39%) (See Figure 18). 
Figure 18 Outcome of patients treated with Adalimumab 
  
57 patients received induction 





33 patients received >12 months 
-33 CD 
13 patients still on at last FU 
received ADA<12 months 
 
11 stopped <12 mths 
 
-2 UC- primary non-response 
- 1 IBDU- primary non-response 
-8 CD 
• 5 primary non-response 
• 2 lost response 
• 1 planned drug withdrawal 
 
 
9 stopped  
-6 planned drug withdrawal 
-2 loss of response 
- 1 primary non-response 
27 patients on ADA at last FU (1 
for JIA not PIBD) 
Long term FU 
2 yrs- 15 patients 
3 yrs 9 patients 
4 yrs 8 patients 
5 yrs 3 patients 
6 yrs 1 patient 
4 had a second course of ADA 
-2 became dependent 
-2 received ADA for <12mths 
at last FU 
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7.4.10. ADA use in CD 
17/53 gained remission post-induction (Table 17) and 22/36 achieved remission on 
maintenance after 0.33 (range 0.10-1.1) years, totalling 39 achieving remission. Thirty 
required dose escalation: 5 dose increased to 80 mg and 29 increased to weekly dosing 
(6/29 increased frequency and dose) with 7 reversing escalation. Fifteen discontinued ADA 
after 0.94 (range 0.18-4.6) years; 5 primary non-response, 3 loss of response and 7 planned 
withdrawal. Thirty-eight continued ADA for 1.48 (range 0.1-6.8) years at study end; 22 in 
remission (17 on co-immunosuppression).  Ten of 16 (63%) with primary IFX non-response 
to IFX gained remission on 2nd biological compared to 21 of 26 (81%) with loss of IFX 
response. Twenty-six patients underwent surgery. 
 
7.4.11. ADA use in UC 
Three patients received ADA, all male for acute severe colitis and were on IV steroids 
at baseline. One patient who lost response to IFX despite dose optimisation, responded and 
achieved remission post induction so was commenced on maintenance which continues. 
One patient stopped IFX due to an acute infusion reaction whilst receiving MTX co-
immunosuppression, unfortunately he had no response to ADA so underwent a colectomy 
and stopped ADA. The final patient had a primary non-response to IFX then had a response 
to ADA induction but did not achieve remission yet continued maintenance ADA, however, 
subsequently underwent a colectomy and stopped ADA. 
 
7.4.12. ADA in IBDU 
One patient received ADA who had lost response to IFX despite dose optimisation. 
The patient was on low dose CS and AZA at the start of ADA but failed to respond so 
stopped ADA and underwent a colectomy.  
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7.5.1. Demographics of the infliximab growth cohort 
Satisfactory 24-month growth data were available for 93/191 (49%) (see Figure 19); 
57 (61%) were boys and 86 (92%) had CD, the remaining 7 (8%) had UC. Median age at 
diagnosis was 10.4 years (range 2.7-15.2) and median age at start of IFX was 13.8 years 
(range 5.9-17.6). The most common disease location in CD was panenteric in 28 (33%) with 
inflammatory the most common behaviour in 76 (88%) whilst 86% had extensive UC. The 
commonest indication for starting IFX in CD was active luminal disease followed by 
immunomodulator failure whilst for UC it was chronic active colitis followed by 
immunomodulator failure (see Table 18). At treatment start 18% had Ht SDS <-2, improving 
to 15% then 7% at 1 year and 2 years respectively after treatment with IFX (p>0.05). Forty-
one patients underwent surgery (18 pre IFX); all of whom had CD. Most patients had 
disease for greater than 2 years (n=62) with a median duration of 3.5yrs prior to starting 




















65  had 12 
month 
growth data
25 had 24 
month 
growth data
15 had 36 
month 
growth data
45 still on at 
last follow up
21 had 12 
month 
growth data
40 had 24 
month 
growth data
24 had 36 
month 
growth data
Inflammatory Bowel Disease 
Unclassified
n=3
2- induction plus 
maintenance
1- induction only





12- induction plus maintenance
16 induction only
8 stopped
5 had 12 
month 
growth data
2 had 24 and 
36 month 
growth data
4 still on at 
last follow up
2 had 12 
month 
growth data








35 still on at 
last follow up
20 had 12 month 
growth data available
11 stopped





No 12 month  
growth data
Ulcerative Colitis n=2
No 12 month 
growth data
Figure 19 Status of patients in Scottish National biologicals registry over study period (2000-2010) 







Table 19 Baseline characteristics of 93 patients requiring Infliximab and 28 patients receiving ADA with full growth data for 24 
months; results are expressed as median (range) and number (%)  
 
 IFX- Crohn’s disease (CD)  Ulcerative colitis (UC) ADA- Crohn’s disease (CD) Ulcerative colitis 
(UC) 










Median age at diagnosis (range yrs.)  10.5 (2.72-15.1) 10.2 (8.48-14.7) 10.3 (4.89-14.9) 12.1 
Median Age at start of IFX (range yrs.) 13.8 (5.9-16.9) 13.7 (9.2-17.6) 13.4 (6.8-17.2) 13.7 
Median Duration from diagnosis to start 
IFX (range yrs.) 
2.86 (0.15-9.45) 2.66 (0.78-5.6)  3.4 (0.04-8.4) 1.5 
Montreal classification 
 
L1 and L4 2 (2%)           B1 75 (87%) 
L2 15 (17%)                 B2 9 (10%) 
L2 and L4 12 (14%)      B3 2 (2%) 
L3 20 (23%) 
L3 and L4 36 (42%) 
L5 1 (1%) 
E1 0 
E2 1 (14%) 
E3 6 (86%) 
L2 9 (32%)                    B1 20 (71%) 
L2 and L4 3 (11%)       B2 5 (18%) 
L3 6 (21%)                    B3 3 (11%) 




E3 1 (100%) 





















Indications to start IFX/ADA (more than 1 
indication is possible) 
 
 Active Luminal disease 72 (84%) 
 Immunomodulator failure 65 (76%) 
 Bridge to immunosuppression 12 (14%) 
 Perianal disease 16 (19%) 
Growth+/- pubertal delay 4 (5%) 
Chronic active UC 5(71%) 
Acute severe colitis 2 (29%) 
Steroid dependency 3 (43%) 
Immunomodulator failure 4 
(57%) 
IFX primary non-responder 12 (41%) 
Loss of response to IFX 10 (36%) 
Allergic reaction 1 (3%) 
Family choice 2 (7%) 
Previous JIA 2 (7%) 
Possible JIA at CD diagnosis 1 (3%) 
IFX primary non-responder 1 
(100%) 
 




















Response post induction -Steroid free remission 35 (33%) 
-Remission 20 (24%) 
Response not remission 27 (31%) 
No response 9 (10%) 
-Steroid free remission 3(43%) 
Remission 1 (14%) 
Response but not yet remission 2 
(29%) 
No response 1 (14%) 
-Steroid free remission 1 (4%) 
-Remission 4 (14%) 
Response but not yet remission 17 (61%) 
No response 6 (21%) 
-Steroid free remission 0 
-Remission 0 
Response but not yet remission 
0 
No response 1 (100%) 


















Small bowel resection 4 (5%) 
Right hemicolectomy 2 (2%) 
Left colonic resection 3 (3%) 
Defunctioning stoma 1 (1%)  
Perianal surgery 12 (14%) 
Colectomy and end ileostomy 0 
 
Small bowel resection 0 
Right hemicolectomy 4 (5%) 
Left colonic resection 2 (2%) 
Defunctioning stoma 5 (6%) 
Perianal surgery 7 (8%)  













Defunctioning stoma 1 (14%) 
Colectomy and end ileostomy 
3 (43%)  
 
Small bowel resection 0 
Right hemicolectomy 0 
Defunctioning stoma 0 
Perianal surgery 7 (25%) 
Colectomy and end ileostomy 0 
 
Small bowel resection 1 (4%) 
Right hemicolectomy 1 (4%) 
Defunctioning stoma 1 (4%) 
Perianal surgery 1 (4%) 









Colectomy and end 
ileostomy 1 (100%)  
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Sixty-five patients within this growth cohort received further IFX post induction, 
including 6 patients who received episodic dosing prior to 2007, with 42 subsequently 
discontinuing maintenance IFX after a median of 1.0 years (range 0.2-3.2) receiving a 
median of 8 doses (range 1-25) (see Figure 19). The most common reasons for 
discontinuation of maintenance IFX were loss of response in 15, planned drug withdrawal 
in 13, primary non-response in 8, allergic reaction in 5 and 1 had an adverse event. Thirty 
(45%), all with CD, required dose escalation, most commonly increased frequency in 23 
(77%) whilst 22 (73%) had an increased dose. 
In the 93 children with satisfactory 24-month growth data, median Ht SDS at T-12 
was -0.7 (-2.2, -0.7), worsened to median Ht SDS -0.8 (-2.5, -0.5) at T0 and remained similar 
with a median Ht SDS -0.8 (-2.3,0.7) at T+12 (p<0.001). Median Δ Ht SDS was -0.2 (-0.6,0.3) 
at T0 and increased to a median Δ Ht SDS at T+12 of 0.1 (-0.4,0.6) (p<0.001). Median HV at 
T0 was 3.5 (1.0, 7.2) cm/yr. and which increased to 4.4 (1.2,9.1) at T12 (p=0.003). No 
further sustained improvement in linear growth was seen beyond 12 months post-anti-TNF 










Table 20 Long term follow up to 36 months shows no further improvement in height velocity and delta height SDS beyond 12 months with 
improvement seen in weight and BMI SDS at 12 months post-IFX treatment. 
 
 T-12 (n=42) T0 (n=42) P value 
for T-12 
vs T0 
T+12 (n=42) P value 
for T0 vs 
T+12 
T+24 (n=42) P value 
T+12 vs 
T+24 
T+36 (n=42) P value 
For T+24 
vs T+36 




P<0.0001 -1.1 (-2.6, -
0.03) 





Δ ht SDS n/a -0.25 (-
0.7,0.2) 










-0.6 (-1.9,1.1) p=0.001 -0.4 (-2.0,1.2) p=0.002     
BMI SDS* 0.1 (-1.6,1.5) -0.3 (-1.9,1.7) p=0.05 0.1 (-1.5,1.9) p=0.003     
HV= height velocity *n=94 
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7.5.2. Factors affecting growth 
Achieving remission was associated with a significant improvement in median Ht 
SDS, Δ Ht SDS and HV (see Figure 20). Early stages of puberty, Tanner stages 1-3, were 
associated with an increase in Δ Ht SDS and HV (see Figure 21).  22/94 were Tanner stage 4-
5 and showed no significant change in Ht SDS and Δ Ht SDS and a decrease in HV; Ht SDS at 
T0 -0.2 (-1.8,1.1) to -0.3 (-2.0, 1.1) at T+12 (p=0.78), Δ Ht SDS at T+0 -0.14 (-0.5, 0.9) then Δ 
Ht SDS at T+12 -0.01 (-0.5, 0.9) (p=0.78) and HV at T0 3.5(1.0,9.8) decreased to 2.1 (0.2, 4.4) 
at T+12 (p=0.001).  60 (65%) of those treated with IFX had a disease duration greater than 2 
years at the start of their treatment with IFX and had increased Ht SDS, Δ Ht SDS and HV at 
T+12 compared to those with disease duration less than 2 years (see Table 21).    
 
Figure 20- Improvements in linear growth are seen at 12 months in those treated 
with Infliximab who achieve remission post induction (n=56) 
A. Improvement seen in median ht SDS at T+12 compared to T0 
 
     
 
 p<0.001 
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B. Improvement seen in Delta ht SDS at T+12  
  
 





















       T0        T+12 
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Figure 21. Tanner stage 1-3 shows improvement in height velocity and delta height SDS at 
T0 to T+12 without improvement in height SDS (n=24) 
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Table 21 Improved growth parameters seen at 12 months in those treated with IFX (n=93) 
 Ht SDS T-12 
Median (IQR) 





Ht SDS T+12 
Median (IQR) 
P value 
For T0 vs 
T+12 
Delta Ht SDS T0 
Median (IQR) 
Delta Ht SDS T+12 
Median (IQR) 



































-0.3 (-0.8, 0.3) 
 
-0.1 (-0.6,0.3) 
0.03 (-0.5, 0.6) 
 




3.3 (0.8, 6.9) 
 
3.6 (1.1,7.2) 
4.1 (0.9, 9.4) 
 








































Moderate disease at 
baseline 
































































































































































Surgery -0.74 (-2.4,0.6) -0.8 (-2.3,0.5) P=0.006 -1.0 (-2.6,0.3) P=0.15 -0.20 (-0.7,0.3) -0.1 (-0.5,0.4) P=0.065 3.4 (0.9,7.1) 4.0(1.0,8.0) P=0.17 
No surgery -0.7 (-2.2,0.8) -0.8 (-2.5,0.8) P=0.002 -0.8 (-2.2,0.8) P=0.001 -0.17 (-0.6,0.3) 0.1 (-0.3,0.6) P<0.001 3.5 (1.1,7.3) 4.9 (1.3,9.5) P=0.005 
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Boys growth improved compared to girls, with boys Δ Ht SDS and HV increasing 
significantly whilst girls only increased Δ Ht SDS (see Table 21). In those with moderate 
disease, improvement was noted in Δ Ht SDS and HV (see Table 21). 82 (88%) were on 
immunomodulators (IM) at baseline and increase in Ht SDS, Δ Ht SDS and HV at T+12 was 
noted in this cohort compared to no improvement in those not on IM. Further analysis was 
performed on type of immunomodulator, 42 patients were on azathioprine (AZA) and 40 on 
methotrexate (MTX); there was no significant difference between the AZA and MTX groups 
in Δ Ht SDS at T+12 (p=0.64, 95%CI -0.2, 0.1). Azathioprine usage was associated with 
increased Ht SDS, Δ Ht SDS and HV compared to only improvement in Δ Ht SDS and HV in 
those on MTX (see Table 21).  
Patients who received induction and maintenance (n=66 (I&M)) showed 
improvement in Ht SDS, Δ Ht SDS and HV compared to those who received induction only 
where only Δ Ht SDS increased (n=37 (I only)).  Patients who were established on 
maintenance IFX for greater than 12 months from first induction dose had significantly 
increased Δ Ht SDS and HV (see Table 21). Corticosteroid use at baseline was associated 
with significant improvement in Ht SDS and Δ Ht SDS (see Table 21). Increase was noted in 
Ht SDS, Δ Ht SDS, and HV in those who did not have surgery (n=68) whilst no significant 
improvement was observed in those who underwent surgery post-IFX (n=25) (see Table 
21). No improvement in Ht was observed in those with Ulcerative Colitis. 
 
7.5.3. Demographics of the Adalimumab cohort 
Growth data for 12 months were available for 28 patients treated with ADA; 12 
(43%) were girls, 27 (96%) with CD (see Table 18) and 18 of whom had IFX growth data 
analysed previously. All patients treated with ADA increased Δ Ht SDS at 12 months only 
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(see Table 22). Early stages of puberty (Tanner stage 2 and 3) were associated with 
increased Δ Ht SDS and HV with improvement also seen in Δ Ht SDS in males (see Table 23).  
No improvement was seen in those who were not on corticosteroids at baseline (n=16) or 
those who achieved remission at week 4 (n= 5).  
 
Table 22 Adalimumab is associated with improved Δ ht SDS at 12 months (n=28) 
 T-12 T0 P value 
for T-12 
vs T0 
T+6 P value 
for T0 vs 
T+6 
T+12 P value 
for T0 
vs T+12 








































p=0.66 0.1 (-1.6, 
1.9) 
p=0.58 0.1 (-1.3, 
2.3) 
p=0.72 










Table 23. Adalimumab is associated with improved Δ ht SDS and HV in those in early puberty and improved Δ ht SDS in males 
(n=28) 
 

























Δ Ht SDS T0 
vs Δ HtSDS 
T+6 




Δ HtSDS T0 
vs Δ HtSDS 
T+12 
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7.5.4. Multiple regression  
Multiple regression models were used to determine associations of therapy and 
disease on Δ Ht SDS at T+12 for both IFX and ADA combined. The following variables were 
inserted into both models: Δ Ht SDS T0, remission, Tanner staging of puberty, azathioprine 
use, methotrexate use, corticosteroid usage at baseline, type of IBD, PGA at baseline, small 
bowel involvement, maintenance therapy given and duration of disease until anti-TNF 
commenced. In the final model, only corticosteroid use at baseline was associated with an 
improvement in Δ Ht SDS at 12 months (p=0.02) (95%CI 0.03,0.39). 
7.6. Dependency cohort 
7.6.1. Demographics of IFX dependency cohort 
Dependency was defined as repeated infusions and/or injections to maintain good 
clinical response for at least 12 months(143). 77 (40%) patients developed dependency, 73 
(95%) had CD, 3 (4%) had UC and one IBDU. 29 (38%) were female and they received IFX for 
≥12 months at last follow up. The median age at diagnosis was 10.6 years (range 4.7-15.5) 
which was less than those in the non-dependency cohort (p>0.05) (see Table 24). Patients 
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Table 24 Comparison of demographic of dependency vs no dependency patients 
on IFX 
 Dependency (n=77) Non-dependency (n=131) $ 
Type of IBD (%)  -CD 73 (95) 
-UC 3 (4) 
-1 IBDU (1) 
- CD 103 (79) 
- UC 26 (20) 
- IBDU 2 (1) 
Median age at diagnosis (range, years) 10.6 (4.8-15.5) 11.5 (2.7-17.2) 
Median age at start at IFX (range, years) 13.8 (6.1-16.9) 14.0 (5.3-17.6) 
Median disease duration prior to IFX (range, years) 2.8 (0.01-10.7) 2.4 (0.03-11.5) 
Female (%) 29 (38) 57 (44) 
Montreal Classification (%) L1 and L4 1 (2) 
L2 12 (17) 
L2 and L4- 17 (23) 
L3 12 (17) 
L3 and L4 31 (42) 
 
B1 65 (89) 
B2 7 (1O) 
B3 1 (1) 
E3 4 (100) 
L1 and L4 1 (1) 
L2 17 (17) 
L2 and L4- 12 (12) 
L3 28 (27) 
L3 and L4 43 (41) 
L5 2 (2) & 
B1 84 (82) 
B2 15 (14) 
B3 4 (4) 
E2 3 (11) 
E3 25 (89) 
Steroids at baseline (%) 44 (57) 75 (57) 
Immunomodulators at baseline (%) 68 (88) 112 (85) 
Surgery (%) 25 (32) 
-20 (80) pre IFX had 24 procedures 
  -15 (63) Perianal procedures 
  -3 (13) small bowel resection 
 -4 (18) Right hemicolectomy 
 -1 (4) Left colon resection 
- 1 (4) Colectomy and end 
ileostomy 
-6 (24) post IFX (4 pre-and post IFX) 
  -  2 (33) Perianal procedures 
-2 (22) small bowel resection  
  - 2 (22) Colectomy 
  -1 (11) Left colon resection 
68 (52) 
23 (33) pre IFX had 25 procedures 
- 17 (68) Perianal procedures 
 -3 (12) small bowel resection 
-3 (12) Right hemicolectomy 
 -2 (8) Left colon resection 
51 (75) post IFX had 60 procedures 
 -  11 (18) Perianal procedures 
 - 31 (52) Colectomy & end ileostomy 
 -8 (13) Defunctioning stoma 
-6 (10) Right hemicolectomy  
-1 (2) small bowel resection 
-2 (4) Left colon resection 
PGA at induction (%) Mild 25 (26) 
Moderate 55 (71) 
Remission 3 (4) 
Mild 24 (18) 
Moderate 104 (79) 
Remission 3 (3) 
PGA post induction (%) Remission 56 (77) 
Response 17 (23) 
No response 0 
Remission 51 (44)  
Response 49 (37) 
No response 21 (16) 
Reasons for discontinuation of IFX (%) Primary non-response 1 (3) 
Loss response 17 (49) 
Planned withdrawal 12 (34) 
Allergy 5 (14) 
Primary non-responders 51 (44) 
Long drug holiday 39 (33) 
Loss of response 17 (14) 
Allergic reaction 5 (4) 
Adverse reaction 6 (5) 
Previous medication (%) 
-EEN 
-Corticosteroids 
      -Steroid resistance 
      -Steroid dependency 
      -Side effects 
-AZA/6-MP 
    -AZA resistance 
   - AZA loss of response 
    - AZA side effects 
-Methotrexate 
    -MTX resistance 
     - MTX loss of response 





























& isolated perianal disease only $- n=131 includes those who did not develop dependency on either first or second course of 
IFX 
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7.6.2. Crohn’s disease and dependency- Induction in dependency cohort 
At induction 51 (70%) had moderate to severe disease, 19 (26%) had mild disease 
and 3 (4%) were in remission (see Table 24). At baseline, 40 (55%) were on corticosteroids, 
30 (41%) on Azathioprine and 36 (49%) on Methotrexate. The most common indications for 
commencing IFX was luminal disease in 62 (85%), immunomodulator failure in 48 (66%), 
steroid dependency in 16 (22%) and perianal disease in 11 (15%) (see Table 24). 
 
7.6.3. Post induction and dose escalation in dependency cohort 
Post induction, 17 (23%) had a response and 56 (77%) were in remission. All patients 
who received induction proceeded onto maintenance therapy. 46 (62%) required dose 
alteration with 39 (85%) having a frequency adjustment; 11 (28%) decreased to 7 weekly, 
17 (44%) to 6 weekly, 2 (5%) to 5 weekly and 1 (3%) to 4 weekly. 4 (10%) had their dose 
extended to every 10 weeks and 4 (10%) to 12 weekly. Dose was increased in 25 (54%); 19 
(76%) to 10mg/kg, 2 (10%) respectively received 6mg/kg, 6.5mg/kg and 7mg/kg. 16 (34%) 
had reversal of dose escalation. Of those who required dose escalation, 20 (43%) stopped 
IFX most commonly due to loss of response 15 (75%) followed by planned withdrawal 3 
(15%) and allergic reaction in 2 (10%). 
 
7.6.4. Outcome of CD dependency patients  
At 12 months, 47 (64%) were in remission, 16 (22%) had mild and 10 (14%) moderate 
disease but by 24 months, only 51 (70%) were still in paediatric follow up; 32 (63%) were in 
remission, 11 (21%) had mild disease and 8 (16%) had moderate disease respectively. By 36 
months, 33 (45%) remained in paediatric follow up and 21 (64%) were in remission, 6 (18%) 
each had moderate and mild disease.  
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At last follow up 41 (56%) continued IFX with 33 (45%), stopping after 12 months, 
most commonly due to loss of response in 16 (47%) (see Figure 17) and 2 then having 
surgery (colectomy and small bowel resection). 18 (50%) received ADA, one of whom had 
undergone surgery after ADA was started.  




The median time to discontinuation of IFX was 2.8 years (range 2.0-3.6) (see Figure 
22) which was not affected by either immunomodulator usage (p=0.43) or by duration of 
disease prior to IFX commencing (p=0.76). Median follow up for those that discontinued 
was 1.3 years (range 0-5.5) years who had received a median of 11 doses (range 8-25). 
Patients on IFX at last follow up, received a median of 2.3 years (range 1.0-5.6) with 28 
(70%) were on immunomodulators at last follow up. 
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7.7.5. UC and dependency 
Three patients with UC received IFX for greater than 12 months with a median age at 
diagnosis of 9.5 years (range 6.0-13.4); 2 were male. All commenced IFX for acute severe 
colitis at presentation of UC and failed to improve with intravenous corticosteroids.  After 
induction, all were in remission and commenced 8 weekly maintenance therapy. Two had 
dose extensions to every 10 weeks and one child received an increased dose of 7.5mg/kg. 
One child then stopped IFX as a planned drug withdrawal in clinical remission from their 
disease whilst the other 2 continued until end of follow up. No adverse reactions or 
infusion reactions were observed with none requiring surgery. 
 
7.6.6. IBDU and dependency 
One patient with IBDU received IFX for over 12 months due to chronic active disease 
and immunomodulator failure having suffered severe side effects secondary to chronic 
corticosteroid usage. The patient achieved remission post induction but has required 
subsequent dose escalation to maintain response. Despite repeated endoscopic re-
evaluation, the patient has remained IBDU and continues IFX at last follow up.  
 
7.6.7. Demographics of ADA dependency cohort 
34 (60%) patients, all with CD, 13 (38%) were female, received ADA for ≥12 months 
at last follow up (see Table 25). Thirty had previously received IFX with one patient 
developing ADA dependency in their first and second course. Those that had received IFX 
had a median of 7 (3-22) doses, and 9 (30%) had received a dose escalation.  At induction, 
23(69%) received 80/40mg, 4 (13%) received 40mg, 2 (8%) received 160/80mg, 40/20mg 
and 24mg/m2 respectively and one received 40/25mg.  
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Table 25 Comparison of demographic of dependency vs no dependency patients on 
ADA 
 Dependency (N=34) Non-dependency (n=27)$ 
Median age at diagnosis 
(range, years) 
10.6 (4.9-14.9) 12.1(4.8-14.8) 
Median age at start at ADA 
(range, years) 
13.5 (6.8-17.2) 15.2 (9.1-18.4) 
Female (%) 13 (38) 12 (48) 
Type of IBD (%) 34 (100) CD 23 (85) CD 
3 (11) UC 
1 (4) IBDU 
Montreal Classification (%) L2 8(23) 
L2 and L4 7 (21) 
L3 7 (21) 
L3 and L4 12 (35) 
 
 
B1 25 (74) 
B2 8 (24) 
B3 1 (2) 
L2 5 (22) 
L2 and L4- 8 (35) 
L3 2 (8) 
L3 and L4 8 (35) 
E3- 3 (75) 
E2 1(25) 
B1 17 (74) 
B2 5(22) 
B3 1 (4) 
Steroids at baseline (%) 14 (41) 15 (56) 
Immunomodulators at 
baseline (%) 
20 (59) 17 (63) 
PGA at induction (%) Mild 11 (32) 
Moderate 23 (68) 
Mild 10 (37) 
Moderate 17 (63) 
PGA post induction (%) Remission 11 (32) 
Steroid free remission 1 (3) 
Response 16 (47) 
No response 6 (18) 
Remission 4 (15)  
Steroid free remission 2 (7) 
Response13 (48) 
No response 8 (30) 
Previous IFX (%) 31 (91)  25 (93) 
Reasons for discontinuation of 
IFX (%) 
Primary non-response 12 (39) 
Loss response 17 (55) 
Allergy 2 (16) 
Primary non-response 6 (24) 
Loss response 14 (56) 
Allergy 5 (20) 
Previous medication (%) 
-EEN 
-Corticosteroids 
      -Steroid resistance 
      -Steroid dependency 
      -Side effects 
-AZA/6-MP 
    -AZA resistance 
   - AZA loss of response 
    - AZA side effects 
 
-Methotrexate 
    -MTX resistance 
     - MTX loss of response 































Surgery (%) 17 (50) 
-9 (53) pre-ADA had 11 procedures 
  - 7 (64) Perianal surgery 
  - 1 (9) Colectomy 
  -1 (9) Defunctioning stoma 
  -1 (9) Left colon resection 
 -1 (9) right hemicolectomy 
8 (47) post ADA had 12 procedures 
  -  2 (17) Perianal surgery 
  -6 (50) Colectomy 
  -1 (8) Defunctioning stoma 
  -1 (8) Right hemicolectomy  
- 2 (17) Dilatation of anal stricture 
15 (56) 
-6 (40) pre-ADA 
 - 3 (50) Perianal surgery 
- 2 (33) Small bowel resection 
-1 (22) Right hemicolectomy 
13 (87) had 17 procedures post ADA 
- 11 (64) Colectomy 
-2 (12) Perianal procedures 
-1 (6) Defunctioning stoma 
 -1 (6) Small bowel resection 
-2 (12) Other (EUA labia and resection of 
ileocolonic anastomosis) 
  
$- number of patients includes those who did not yet reach dependency on either first or second course of ADA
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7.6.8. Post induction and dose escalation in ADA dependency cohort 
When assessed at 4 weeks, 16 (47%) had a response, 12 (35%) were in remission and 
6 (18%) had no response. All 34 patients who received induction proceeded onto 
maintenance, most 30 (88%) on 40mg, two on 24mg/m2 and one each received 20mg and 
25mg fortnightly. 24 (70%) required increased frequency to weekly after a median of 0.4 
(range 0.1-5.4) years, 7 (32%) subsequently had this reversed. 6 (25%) required dose 
increase to 40mg in 2, 80mg in three and 30mg in one; one subsequently had this reversed.  
 
7.6.9. Outcome of dependency patients 
  At 6 months, 13(38%) were in remission, 12 (35%) in steroid free remission, 4 (12%) 
had mild disease and 5 (15%) had moderate disease. At 12 months, 11 (32%) were in 
remission, 10 (29%) in steroid free remission, 8 (24%) had mild and 5 (15%) had moderate 
disease.  At last follow up 25 (74%) continued ADA with 6 (24%) in steroid free remission, 8 
(32%) in remission, 6 (24%) with mild and 5 (20%) had moderate disease having received 
ADA for a median of 2.1 years (range 1.2-6.8) (see Figure 18).   
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9 (26%) stopped after 12 months due to loss of response in 2 (22%), planned 
withdrawal in 6 (67%) and primary non-response in 1 (11%). The mean time to 
discontinuation of ADA was 4.8 years (range 2.7, 3.6) (Figure 23) which was not affected by 
either immunomodulator usage (p=0.69) or by duration of disease prior to IFX commencing 
(p=0.76). 
 
7.6.10. Factors associated with dependency 
Lack of steroid use at baseline was the only significant factor associated with 

















Duration of ADA (years) 
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Table 26 Univariate associations with loss of response in Crohn’s disease in those 
who develop dependency 
Variable Univariable IFX 
HR (95%CI) 








(L3 and L4) 




use at baseline 
1.8 (0.4,7.3) 0.44 0.76 
(0.2,2.9) 
0.69 
Perianal disease 0.8 (0.4,1.6) 0.53 1.4 (0.4,5.8) 0.61 
Corticosteroid use 
at baseline 
2.1 (1.1,4.2) 0.03 1.0 (0.3, 3.9) 0.98 
Disease duration 
(<2yrs vs >2yrs) 




1.1 (0.5,2.4) 0.81 4.5 
(0.6,36.0) 
0.13 
Remission at 12 
months 
0.7 (0.4,1.4) 0.33 3.0 
(0.8,11.3) 
0.10 
HR- hazard ratio; CI- confidence interval 
 
7.6.1. Second course of IFX 
19 (10%) patients had a repeated induction course of IFX, 17 were then commenced 
on maintenance. One child stopped after induction due to primary non-response was 
changed onto ADA and developed dependency to ADA whilst another stopped after an 
allergic reaction to the first dose of their second course. 11 (58%) of those commenced on 
maintenance were still receiving IFX at 12 months, two then discontinued after 12 months 
due to loss of response. 4(24%) stopped before 12 months: 2 primary non-response, one 
loss of response and one planned drug withdrawal. 
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7.7. Infliximab safety 
Thirty patients (28 CD 2 UC) had 35 acute infusion reactions with 2 had anaphylaxis 
requiring adrenaline (Table 27a). Twenty-one patients had an adverse event including 
fourteen patients who experienced toxicity requiring hospitalisation (Table 27b)- one with 
a severe lupus like reaction who needed intensive care and one patient with lupus like joint 
disease that improved upon discontinuation of IFX. Other adverse events included 
paraesthesia (3) and non-productive cough (2) (Table 27c). Five had a serum sickness 
reaction occurring between 5 days and 8 weeks post IFX, common symptoms were rash, 
pruritus, facial oedema and arthralgia, all settled with no treatment. There were 25 
infections, 6 serious requiring hospital admission (2-21 days), most commonly infections 








Table 27 – Safety of Infliximab 
Table 27A- Acute infusion reactions with Infliximab 
Patient Type of IBD Age at 
diagnosis (yrs) 
Sex Method of IFX 
administration 
Number of 
infusions   




Long term IFX outcome 
1 Crohn’s 
disease 
11 M Maintenance 2 Dizziness AZA IFX continued Discontinued- loss of response 
2 Crohn’s 
disease 




9 F Episodic 4 Headache/dizziness/nausea/ 
flushed 




17 M Induction only 0 Hypotensive/felt clammy and 
tongue itchy 




11 F Maintenance 6 Hypotensive and short of breath CS/AZA IFX discontinued Discontinued- adverse event 
6 Crohn’s 
disease 
11 M Induction only 2 Cannula painful AZA IFX discontinued Discontinued-patient choice 
7 Crohn’s 
disease 
11 M Maintenance 4 Swollen lips/flushed and 
desaturated 
AZA IFX continued Discontinued- allergic reaction 
8 Crohn’s 
disease 
14 M Maintenance 1 Chest pain CS/AZA IFX continued Discontinued- long drug holiday 
9 Crohn’s 
disease 
10 M Episodic 3 Felt itchy CS/AZA IFX continued Discontinued- loss of response 
10 Crohn’s 
disease 




14 F Maintenance 1 Right arm parathesiae AZA IFX continued Discontinued- long drug holiday 
12 Crohn’s 
disease 




13.6 F Maintenance 9 Nausea and felt flushed MTX IFX continued IFX continued 
14 Crohn’s 
disease 
9.6 F Induction only 2 Shortness of 
breath/flushed/desaturated-  
AZA IFX discontinued Discontinued- allergic reaction 
15 Crohn’s 
disease 
4.9 F Induction only 2 Short of breath/ gasping/ 
tachypnoeic/urticarial- 
AZA IFX discontinued Discontinued- primary non-
response &allergic reaction 
16 Crohn’s 
disease 




5.7 M Maintenance 2 Dizziness AZA IFX continued IFX continued 
18 Crohn’s 
disease 











         
Patient Type of IBD Age at 
diagnosis (yrs) 
Sex Method of IFX 
administration 
Number of 
infusions   




Long term IFX outcome 
19 CD 11.9 M Maintenance 9 “anaphylactic” reaction MTX IFX stopped IFX discontinued due to allergic 
reaction 
20 CD 9.8 M Maintenance 4 Nausea/urticaria MTX IFX continued  IFX continued 
21 CD 12.1 F Maintenance 5 Facial oedema anaphylaxis with 
chest pain, short of breath  
CS/AZA IFX stopped IFX stopped due to allergic 
reaction and PNR 
22 CD 14.8 F Maintenance 15 Dizzy, chest pain, short of breath  IFX continued IFX discontinued due to allergic 
reaction 
23 CD 10.9 M Maintenance 8 Chest pain, short of breath, facial 
erythema 
MTX IFX stopped IFX discontinued due to allergic 
reaction 
24 CD 14.0 M Maintenance 0 Nausea AZA IFX continued IFX discontinued due to PDW 
25 UC 12.3 M Induction only 2 Headache, chest pain and 
“allergic” reaction 
CS/MTX IFX stopped IFX discontinued due to allergic 
reaction 
26 CD 14.2 F Maintenance 1 Felt weak, acute malaise, vacant 
and slurred vision 
AZA IFX continued IFX continued 
27 CD 10.4 F Maintenance 6 Chest pain, shortness of breath CS/AZA IFX continued IFX discontinued due to loss of 
response 
28 CD 6 F Maintenance 0 Nausea, short of breath, flushed 
and sweating 
AZA IFX stopped IFX discontinued due to loss of 
response 
29 CD 8.8 M Induction only 1 Nausea, chest pain, short of 
breath, cyanosis 
CS/MTX IFX stopped IFX discontinued due to primary 
non response 
30 UC 13.0 M Induction only 0 Dizzy and short of breath CS/AZA IFX stopped IFX discontinued due to allergic 
reaction 
CS- corticosteroids, AZA- Azathioprine, MTX- Methotrexate.  Reactions occurred after a median (range) of 2.5 (0-20) doses, 9 (50%) required treatment, usually with chlorphenamine, but no anaphylaxis occurred, and none required hospitalisation. Clinical features 










Table 27B. Toxicity whilst on Infliximab requiring hospitalisation 
Patient Age Gender Toxicity Management; 
 * hospitalisation for <24 hours 
Outcome Concomitant 
immunosuppression 
1 16 F Macular rash, 
varicella 
Treated with Varicella immunoglobulin and 
acyclovir which settled over 48 hrs hospital 
admission 
Stopped IFX due to adverse event AZA 
2 16 F Labial abscess Requiring drainage in theatre* Stopped IFX due to planned drug withdrawal MTX 
3 11 M Perianal sepsis Taken to theatre for incision and drainage* Stopped IFX due to planned drug withdrawal AZA, CS 
3 11 M Night sweats and 
fatigue 
Required admission for assessment- no treatment 
needed£ 
Stopped IFX due to planned drug withdrawal AZA, CS 
4 11 M Gastroenteritis Thought to be viral but required PN and admission 
to hospital for 21 days 
Stopped IFX due to loss of response Nil 
5 14 M Septic arthritis Required 5-day admission with IV gentamicin and 
flucloxacillin  
IFX continues MTX, CS 
6 13 M Shingles Rash spread for 2 weeks then stopped, treated 
with acyclovir but required 48 hours hospital 
admission 
IFX continues AZA, CS 
7 8 M Rectal stricture Required admission for dilatation  Stopped IFX due to rectal stricture CS, AZA 
8 14 M Rectal stricture Required admission for dilatation Continues of IFX CS, MTX 
9 17 M Impaired memory, 
headache 
Admitted for assessment- MRI normal then 
transitioned to adult services 
Stopped IFX due to planned drug withdrawal CS, AZA 
10 15 M Lupus like reaction Prolonged stay in intensive care*$ Stopped IFX due to adverse event AZA 
11 12 F Central line sepsis Treated with prolonged course of antibiotics post 
each episode 
Continues IFX  
12 9 M Gastroenteritis Likely infective, required IV fluids and admission Continues of IFX AZA 
13 12 M Gastroenteritis Likely infective, required IV fluids and admission Stopped IFX due to primary non-response MTX, CS 
14 14 F Rectal strictures Required admission for dilatation Stopped IFX due to loss of response MTX, CS 
  
CS- corticosteroids, AZA- Azathioprine, MTX- Methotrexate. £- patient had two separate toxicity episodes 
$Patient had his 4th dose of IFX then developed pyrexia, deranged liver function tests and coagulopathy in conjunction with raised inflammatory markers and immunoglobulins requiring in total a 36-day 
hospitalisation, including intensive care admission. The patient was initially treated with broad spectrum antibiotics, but his pyrexia continued and serositis developed, so he was commenced on 









Table 27C Other toxicity on IFX not requiring admission 
Patient Age Gender Event  Management;  
* hospitalisation required  
Outcome Concomitant 
immunosuppression 
1 15 M Paraesthesia Resolved IFX continues CS, MTX 
2 14 F Profuse diarrhoea hours 
after 1st dose 
Resolved IFX stopped due to primary non-response  CS, AZA 
3 14 F Diplopia and Paraesthesia Resolved IFX stopped due to primary non-response and 
adverse event 
CS, AZA 
4 6.9 M ? hallucinations Nil IFX continues CD/MTX 
5 6 M Perianal abscess Managed with oral antibiotics IFX stopped due to loss of response MTX 
6 12 F Non-productive cough Self -resolved IFX continues  
7 15.2 F Drug induced lupus Settled on withdrawal of IFX IFX stopped due to allergic reaction CS/AZA 
8 15 F Loss of sensation left lower 
ankle and sole of foot 
MRI brain and spine normal IFX stopped due to adverse event CS/AZA 
9 15 F Non-productive cough Self -resolved IFX continues MTX 
 










Table 27D Infections whilst on Infliximab 
Patient Age Gender Drug  Infection Management; 
 * hospitalisation required  
Outcome Concomitant 
immunosuppression 
1 15 F IFX Macular rash, 
varicella 
Treated with Varicella immunoglobulin and acyclovir 
which settled over 48 hrs hospital admission* 
Stopped IFX due to adverse event AZA 
2 12 M IFX Bacterial pharyngitis Infusion postponed 2 weeks Continues IFX MTX, CS 
3 13 M IFX Viral infection Settled with conservative management Continues IFX MTX, CS 
4 10 M IFX Shingles Rash spread for 2 weeks then stopped, treated with 
acyclovir but required 48 hours hospital admission* 
Stopped due to PDW AZA, CS 
5 12 F IFX labial abscess Requiring drainage in theatre Stopped IFX due to primary non-
response 
MTX 
5 12 F IFX Parotitis (viral) and 
lichenified rash 
Resolved IFX continues CS, AZA 
6 6 M IFX Tonsillitis Treated with amoxycillin, 3rd infusion postponed by 2 
weeks 
Stopped due to PDW MTX, CS 
7 12 F IFX Viral infection sore 
throat increased 
diarrhoea 
IFX already discontinued Stopped IFX due to primary non-
response 
MTX 
8 8 M IFX Perianal sepsis Taken to theatre for incision and drainage- no 
hospital admission 
Stopped IFX due to primary non-
response 
AZA 
9 12 M IFX Facial candidial 
infection 
Treated topically Stopped due to PDW AZA, CS 
10 10 M IFX Gastroenteritis Thought to be viral but required PN and admission to 
hospital for 21 days* 
Stopped IFX due to loss of 
response 
Nil 




Topical treatment for candida and dermatology 
referral for warts 
Continues IFX AZA, CS 
12 14 M IFX Septic arthritis Required 5-day admission with IV gentamicin and 
flucloxacillin * 
Continues IFX MTX, CS 
12 14 M IFX Viral infection Self-resolved Continues IFX MTX, CS 
13 11 F IFX Viral illness  IFX stopped due to primary non-
response  
CS, AZA 
14 17 F IFX Viral upset  Delayed 3rd dose but IFX 
continues 
MTX 
15 15 F IFX Feeling unwell, sore 
throat, coughing, no 
appetite 
 IFX stopped due to adverse event AZA, EEN 
16 16 F IFX Viral - raised temp, 
sore throat & 
lymphadenopathy  











       
Patient Age Gender Drug  Infection Management; 
 * hospitalisation required  
Outcome Concomitant 
immunosuppression 
17 14 F IFX Viral infection, sore 
throat, increased 
diarrhoea, around 
1/02/08, less than 1 
month from 
stopping IFX 
 IFX stopped due to PDW MTX 
18 12 M IFX Gastroenteritis Admitted for 1week after IFX for 3 days for IV 
rehydration 
IFX stopped PNR CS/MTX 
19 16 F IFX UTI Treated with oral antibiotics IFX continues CS/AZA 
20 14 M IFX Tonsillitis  IFX continues AZA 
21 14 F IFX Influenza A Self-resolved IFX stopped LOR MTX/CS 
22 12 F IFX Recurrent CVL 
infections 
Treated with broad=spectrum antibiotics IFX continues  AZA/CS 
23 5.3 M IFX Viral URTI Self-resolved IFX stopped PNR CS 
24 15.5 M IFX Acute EBV infection Self-resolved IFX stopped due to adverse event MTX 
25 13.2 M IFX Chronic colonisation 
with staph aureus 
 IFX stopped due to LOR AZA 
26 13.3 M IFX Patches of staph 
aureus infections 
behind knees 
 IFX stopped due to LOR AZA 
27 13.3 F IFX Recurrent UTIs not 
confirmed on 
microscopy 
 IFX continued CS/AZA 
28 15.5 M IFX Tonsillitis  Treated by GP IFX continued AZA/CS 
29 10.8 M IFX Recurrent tonsillitis  IFX stopped due to PDW AZA 










191 treated with IFX
30 (15%) Infusion 
reaction
-5 (38%) continued 20 (62%) 
discontinued
-1 (5%) patient 
choice
- 6 (30%) Primary 
non response
- 8 (40%) adverse 
reaction
-3 (15%) planned 
drug withdrawal
-2 (10%) loss of 
response
31 (15%) infections
- 12 (39%)  
continued 
19 discontinued
- 6 (32%) primiary 
non response
-4 21%) loss of 
response
-6 (32%) planned 
drug withdrawal





-3 (21%) planned 
drug withdrawal
- 5 (36%) adverse 
event
- 3 (21%) loss of 
response
-3 Primary non 
response








7.7.2 Adalimumab safety 
Table 28 Adverse events to Adalimumab 






of CD to 
ADA start 




Long term ADA 
outcome 
1 CD 4.9 F 4.0 Viral illness with cough MTX ADA stopped due to primary 
non-response 
2 CD 5.4 F 4.8 Neutropenia and leukopenia CS/AZA ADA stopped due to loss of 
response 
3 CD 12.4 F 0.16 Chronic right tympanic membrane 
perforation 
CS ADA continues 
4 CD 10.4 F 3.2 Paronychia MTX ADA continues 
5 CD 14.9 F 0.04 Impetigo CS ADA continues 
6 CD 8.6 M 6.5 Headaches - ADA continues 
7 CD 5.4 F 6.3 Neutropenia and leukopenia MTX ADA stopped due to loss of 
response 
8 CD 6.5 M 7.2 Perianal abscess required 
hospitalisation* 
CS/AZA ADA continues 
9 CD 7.4 F 8.3 Clostridium difficile infection required 
hospitalisation* 
MTX ADA continues 
10 CD 10.5 M 12.7 Recurrent microscopic haematuria and 
dysuria, no cause found but resolved 
- ADA continues 
11 CD 8.4 F 14.9 Vulval swelling/cellulitis required 
admission and IV antibiotics* 
MTX ADA stopped due to primary 
non-response 
12 CD 13.6 F 16.0 Buttock abscess treated with oral 
antibiotics 
CS ADA continues 
13 CD 4.9 M 9.2 Perianal shingles treated with IV 
acyclovir* 
MTX ADA continues 
14 CD 8.4 F 8.4 Gastroenteritis required IV fluids* MTX, EEN ADA continues 
15 CD 11.2 M 2.2 Impetigo requiring oral antibiotics CS, AZA ADA continues 
16 CD 4.7 M 6.9 Clostridium difficile infection  ADA continues 
CS- corticosteroids, AZA- Azathioprine, MTX- Methotrexate * hospitalisation required
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Fifteen had adverse effects, with 5 hospitalisations (1 perianal abscess, 1 Clostridium 
difficile infection, gastroenteritis, perianal shingles and vulval cellulitis) (Table 28).  
 
Figure 25 Outcomes of adverse events in those treated with Adalimumab who 





In this Scottish population-based cohort of children with all subtypes of PIBD treated 
with either IFX or ADA, both drugs were effective in inducing remission during ‘real life’ 
usage with remission rates of 58% for IFX (10-12 weeks) and 83% response/remission of 
ADA (4 weeks). Both were safe and well tolerated, however, 50% of ADA and 34% of IFX 
treated patients became dependent on anti-TNF therapy to maintain response. IFX and 
ADA were associated with improved linear growth which has been demonstrated in other 
population based cohorts for IFX (266, 267), however, to our knowledge this is the first 
population-based ADA study for ADA.  IFX improved linear growth in those who achieved 
remission, had disease duration for over 2 years at anti-TNF start and were in the early 
stages of puberty (Tanner stage 1-3). 
57 Treated with ADA
16 (28%) Adverse events
12 (75%) continued
4 (25%) discontinued
- 2 (50%) primary non 
response
-2 (50%) loss of response
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Effectiveness of ant-TNF therapy 
 CD post-induction remission rates reported in this study of 59% with IFX and 26% of 
ADA are low when compared with published rates of 34-85% (50, 247) and 61-70% (79, 
142) respectively. 12 month CD remission rates of 54% for IFX and 47% for ADA compare 
with published rates of 25-83% (50) and 41-49%(79, 142). A worrying result is the lack of 
durable response for many on CD maintenance IFX therapy; 66% discontinued for primary-
non-response/loss of response/adverse effects after a median of 0.83 years compared to 
36% in a recent single centre retrospective study from 2000-2013(247). Reasons for the 
lower efficacy from our multi-centre 11-year nationwide study with full accrual compared 
to some published literature, include more liberal use of anti-TNF in some centres (thus 
better effectiveness rates) than real-life UK practice, where local prescribing restraints and 
national advice led to a clear top-up policy in everyday practice, only progressing to 
biologicals if all other therapies failed or became inappropriate. The ability to dose escalate 
(immediately increasing drug cost) to reverse any loss of response was difficult in many UK 
centres compared to others worldwide which would influence efficacy. Dose optimisation 
as a strategy to prevent complete loss of response has been successful as illustrated in 
Toronto from 2000-2011 in CD which was based on patients symptoms and used in 50% of 
treated with IFX which resulted in loss of response of just 2-6% per year (68).  Most studies 
on anti-TNF arise from single academic centres, rather than population-based, therefore 
are subject to referral biases, potentially treating more severe disease, or having more 
liberal anti-TNF strategies.  The  retrospective study contains data from 2000 onwards, 
reflecting  how IFX/ADA were first used, with some centres early adopters of strategies 
now seen as routine for biological therapy (e.g. maintenance rather than episodic IFX 
dosing in 2000-2005, induction dosing followed  by maintenance when bridging to 
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immunosuppression, strong evidence of prolonged ‘deep remission’ on biological prior to 
planned treatment withdrawal, and dose optimisation to rescue loss of response).  
 
Dependency 
62% who commenced maintenance IFX became dependent with dose escalation in 
44% which was successful in 40%.  In a comparable Canadian study of children who were 
treated in a specialist referral centre from 2000-2011 with IFX, 50% required dose 
escalation which was successful in 86%.  28% of these children had risk factors for disabling 
disease at baseline, yet only 10% required alternate therapy by 12 months(68) contrasting 
with our results.  Factors which may explain our increased loss of response include the 
higher number of patients in this cohort with moderate to severe disease (70%) (median 
PCDAI was 32.5 in the Canadian cohort) or that the longer median duration of disease to 
start of IFX (1.3 years in Canada verses 2.8 years in Scotland) may reflect a more severe 
phenotype and aggressive disease.  
The concept of dependency in biological drugs was demonstrated with Infliximab in 
PIBD in 2006 by a Danish group who found that 71% of children improved with episodic IFX 
but 42% required further infusions to maintain clinical response(254).Further studies 
showed dependency rates between 56-60% in paediatrics which was associated with 
response after induction, inflammatory behaviour, perianal disease and fistulising disease 
(263, 264). In this cohort, similar rates were reported of perianal disease and inflammatory 
behaviour with remission post induction and MTX usage was associated with dependency 
at 12 months on multivariate regression. 
There are conflicting results, for co-immunosuppression, it is associated with a 
reduced risk of loss of secondary response to IFX(68) yet other studies have shown no 
difference in efficacy, loss rates and endoscopic scores(268). Evidence also differs for ADA 
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on co-immune suppression with the DIAMOND trial reporting no additional benefit to 
adding AZA over ADA monotherapy in a multicentre prospective randomised control 
trial(269). However, two systematic review and meta-analyses differed with one supporting 
co-immune suppression for induction of remission but with equal rates of remission at 12 
months(270) whilst the other reports no difference(271) . However, the adult literature has 
confirmed no effect of co-immunosuppression with MTX in time to remission(272).  
De Ridder found no difference in dependency rates if therapy started 1 or 2 years 
post diagnosis as was reported here, however, Kugathasan and Lionetti found longer 
duration of IFX treatment if diagnosed less than 2 and 1 years respectively (273, 274).The 
differences observed may relate to the disease severity or variations in treatment practices 
including dose escalation as this population based cohort reflects “real life” clinical 
practice. 
 
To our knowledge this is the first report of the concept dependency in paediatric 
ADA in a population-based cohort. 50% who commenced ADA had dependency requiring 
continued doses to maintain response and/or remission, similar to Imagine 2 with 46% still 
requiring ADA by week 240 to maintain response/remission(261). 89% in the dependency 
cohort received prior IFX demonstrating that despite failed response to IFX remission was 
achieved on ADA in those with moderate to severe CD contrasting with Imagine 2 trial 
where only 29% had prior IFX(261). 
 
Long term outcomes 
Remission rates reported at 12 months vary from 12-64% in those on maintenance 
IFX(65, 264) which decrease to 30-33% by 3 years reported however the number of 
patients included also decreases (63, 65, 266).  In this cohort dependency, 68% of patients 
Chapter 7- The natural history of anti-TNF therapy use for paediatric inflammatory bowel 
disease treatment in Scotland 
188 
 
were still in follow up at 12 months with 50% continuing IFX and 55% in remission.  By 3 
years, 33% in continuous remission with IFX was reported by Hyams with 90% on 
immunomodulators and 49% requiring dose optimisation compared to 11% who were dose 
optimised and 67% were on a form of immunomodulators with Assa. Dose optimisation 
and co-immunosuppression may explain the improved rates of response in the Hyams 
study with shorter disease duration, with the median time from diagnosis to start of IFX 
was 9 months (63, 65, 266). In this cohort 68% were still in follow up at 12 months, 50% of 
whom continued IFX with 55% in remission but, by 36 months only 37% of dependent 
patients remained in follow up with 56% of in remission, however, they may not have 
remained in continuous remission or had disease relapses. 
 The median follow up in the whole IFX cohort was 59 months which is significantly 
longer than 33 months for Assa and 32 months for Crombe(65, 266) but is similar to adult 
studies(275). The increased duration of follow up in this cohort may explain the increase in 
of loss of response and less planned withdrawal due to changes in practice from 2000 to 
2012 with focus now on regularly reviewing therapy and discontinuation if in remission. 
Adult data suggest that those on immunomodulators had a longer duration until loss of 
response to IFX(275) which has not been seen in paediatrics(66, 247). 
In the ADA dependency cohort, 72% remained in remission at last follow up with a 
median duration of ADA of 2.41 years. In ADHERE 42% and 50% were receiving every other 
week and weekly ADA were in remission(276) compared to 75% on every other week and 
57% on weekly in this cohort. In ADHERE, 51% of patients had been treated with prior IFX 
and 43% on immunomodulators compared with 89% prior IFX and 56% on 
immunomodulators in this cohort. Remission rates were similar with 49% in RESEAT, at 12 
months vs 41% in the BSPGHAN audit(79, 142). At 240 weeks in Imagine 2, 41% were in 
remission with 29% had receiving prior IFX(261). Differing long term remission rates may be 
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explained by the higher rate of co immunosuppression in PIBD, varying disease status at 
induction, increased frequency of dose escalation or differing criteria for 
response/remission.  
 
Second line anti-TNFs 
Loss of response 
The most common reason for discontinuation of maintenance IFX in those was loss 
of response in 36%, followed by planned withdrawal in 29% which is in contrast to the 
Hyams trial where, 46% had a planned withdrawal and 25% discontinued to due to loss of 
response(63). Significant differences between the 2 cohorts may explain the differing 
response rates including the prospective and multi centre design of the Hyams study with 
clear treatment protocols. By contrast, this study was retrospective population based and 
reflecting “real life” practice with varying treatment protocols by centres. Co-
immunosuppression with MTX was associated with dependency which is protective against 
loss of response in those treated with IFX (68, 277). 
Therapeutic drug monitoring has become standard practice with recent evidence 
supporting proactive monitoring with alteration of doses to ensure optimal drug levels (61). 
Loss of response may have been related to antibody formation or inadequate drug levels 
that could have been optimised, or switched to another therapy if high drug concentration 
or high antibody levels(278); this was only available latterly in some centres. 
The most common reason for discontinuation in ADA WAS loss of response in 27% 
with a mean time to loss of response of 3.6 years which was less common than for IFX, this 
is supported by the Imagine 2 where 22% stopped due to loss of response. However, other 
confounding factors may explain this difference including length of follow up or lack of 
drug/antibody levels.  
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Anti-TNF and growth 
Growth failure in this cohort is comparable to other population-based cohorts such 
as EPIMAD, the largest population-based multicentre inception cohort from Northern 
France. In this study, 18% had severe growth failure (HtSDS<-2), improving to 15% then 7% 
at 1 and 2 years respectively, this is worse than reported by EPIMAD, where around 10% 
had severe growth failure at diagnosis, improving only slightly to 8% at 1 year and 6.5% at 2 
years(266); however, no pubertal data were provided.  The increase in growth failure in the 
Scottish cohort can be explained by the differing median ages at first dose of IFX, in Scottish 
children the median age was 13.2 years verses 18 years in EPIMAD (data are collected both 
before and after transition to adult IBD services and time of transition is study end in the 
Scottish PIBD biologicals register). The younger age in the Scottish cohort may be due to a 
more severe phenotype who required biological therapy compared to all PIBD patients 
included in the EPIMAD cohort. Two other nationwide population-based study also 
examined IFX and growth with differing results; firstly De Ridder observed that in 6 CD 
patients with ht SDS <1 at initiation of IFX, 3 who remained on IFX post induction, 
subsequently resumed normal growth velocity (267). However, Wewer showed no 
improvement in height velocity in 10 CD patients who had IFX in part due to growth failure  
(no pubertal data or ht SDS were provided for this cohort) (254). Both studies have 
significantly smaller numbers than the Scottish cohort and the lack of pubertal data makes 
comparisons challenging. Although improvement was noted in linear height post IFX in this 
study, follow up was only 5.2 years for the whole cohort so impact on final adult height was 
not possible to ascertain as others have shown short term improvement but final adult 
height remained reduced from target (257). 
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The effect of pubertal stage on linear growth in children treated with IFX remains 
controversial. In this study, improvement was seen in Tanner 1 -3 in Δ height SDS and 
height velocity but not height SDS, this suggests improvement in growth is not influenced 
by pubertal progression as similar improvement is seen in pre-pubertal/pubertal children 
or that although certain growth parameters improve with IFX, these are insufficient to lead 
to improvement in height SDS. However, only half who were Tanner stage 1 at start of IFX 
remained so at 12 months. Malik also demonstrated improved HV SDS 6 months after IFX 
even after adjustment for pubertal staging(248). However, a large cohort of newly 
diagnosed patients in North America showed greater improvement in linear height in early 
puberty (33), yet another showed those in Tanner 1-3 grew  but at a suboptimal rate with 
no improvement in Tanner 4/5 compared to Tanner 1-3 (251). 
Growth improves with greater disease control as can be seen in these results with no 
improvement in those who did not achieve remission post induction, whilst in those that 
did, all measures of growth improved. Those in clinical remission whose growth parameters 
improved minimally may not have achieved full mucosal healing which could continue to 
adversely affect their height. Mucosal healing is associated with prolonged remission after 
induction treatment with IFX(279) and could potentially be associated with sustained 
improvement in linear growth.  Comparable results for growth in clinical remission are seen 
in the REACH study extension where a trend towards continued improvement in height SDS 
score was seen in those with sustained remission(280). Improvement in linear growth was 
observed in those receiving corticosteroids at induction in this cohort despite most 
evidence suggesting corticosteroid usage is associated with poor growth(281). Potential 
explanations include that these children had received steroids prior to anti-TNF therapy 
which were then able to be weaned leading to improved growth(33), or that corticosteroid 
usage combined with anti-TNF therapy resulted in remission earlier thereby improving 
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growth.  Alternative hypotheses are that IFX could promote catch up growth once the 
inflammatory process has been ‘switched off’ or merely prevents further deterioration in 
growth trajectory without improving overall height(282).  
Disease duration for ≥ 2years had improved height SDS, Δ height SDS and height 
velocity at 12 months compared to those with a shorter disease duration of less than 2 
years. This contrasts with current evidence which suggests shorter disease duration has 
better outcomes with anti-TNF, exemplars are the REACH study and ACCENT 1 trial. In the 
REACH study, children had a median duration of disease of 1.6 years prior to IFX with 88% 
response rate and 59% remission post-induction contrasting with a 66.7% response and 
39.1% remission rate in adults in ACCENT 1 trial where the median duration of disease was 
7 years prior to initiation of IFX(53, 57). A prospective multicentre North American study 
observed improved growth and clinical outcome at 12 months in those treated with early 
IFX (within 3 months of diagnosis) compared with early immunomodulator therapy or no 
therapy(283) differing for results observed here.  Improved growth in those with a longer 
disease course in our cohort could be related to inflammation being ‘switched off’ with 
anti-TNF therapy resulting in normal growth and/or pubertal development. 
This study, which included all subtypes of IBD, found a significant improvement in 
linear growth in those on combination therapy of AZA and IFX contrasting with other 
studies on the effect of AZA on growth. The only paediatric RCT on the use of AZA from 
2000 observed no significant difference in linear growth between those treated with AZA 
and placebo at 18 months (41). Pfefferkorn also found no improvement in height at 12 or 
24 months for AZA(33) yet a UK study did show improved height with AZA although this 
was not statistically significant. However, this UK study was retrospective,  before IFX was 
commonly used, growth data was only available for 44 patients with confounders including 
concurrent corticosteroid use, disease severity and pubertal staging data unavailable (284).  
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Improvement in growth with both MTX monotherapy and used in combination with IFX has 
been reported with 12 patients receiving MTX and IFX combination therapy showing 
improved linear growth(248) whilst MTX monotherapy consistently demonstrates 
improvement in height velocity (47). No mechanism has been proposed as to potential 
pathways which may explain improvement in growth for either AZA or MTX.  
Limited data exists on the effects of ADA on growth which is divided on efficacy. In 
this cohort no growth improvement was seen in Tanner stage 1 but significant 
improvement in Tanner stage 2/3 for Δ height SDS and height velocity was observed 
suggesting that development through puberty may at least partially explain the 
improvement in height. No improvement was seen in those in Tanner 4/5 which has been 
previously shown(259). The Imagine trial, only RCT published, found improvement in height 
velocity z scores at 6 and 12 months with higher and lower doses of ADA, however, no 
pubertal data was provided(78).  More comparable data is provided from a multicentre UK 
and Irish audit which demonstrated improved short term growth with an improvement in Δ 
height SDS at 6 months after initiating ADA (259) that continued to 12months but with no 
increase in height velocity; however, it did show improved growth for Tanner stage 1-3.   
Contrasting evidence is seen in a single centre study from Israel found no improvement in 
height at last follow up (median of 17.3 months) with no pubertal data provided (285). 
In this study no improvement was seen in those that achieved remission post 
induction, potentially related to smaller numbers involved with only 5 achieving remission 
post induction. However, others have reported greater improvement in height velocity if 
response at 4 weeks post induction was seen which persisted until week 52(260).  
UC 
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This study is the first to report on dependency to IFX in UC which was observed in 
14%. IFX was effective in induction and maintenance of paediatric UC and is used as rescue 
therapy in acute severe UC as previously reported (54) (25).  ADA was used in 4% of UC but, 
was unsuccessful at inducing or maintaining a remission with both patients requiring 
surgery receiving ADA for a median of 0.16 years. The reasons for the poor responses are 
unclear, both had moderate to severe disease at baseline having failed IFX for loss of 
response/allergic reaction and responded initially so not unresponsive to biological 
therapy. The lack of response may represent the severity of disease when the ADA was 
commenced or patient preference for the more definitive surgical option than continued 
medical therapy.  ADA has been shown in a small cohort adults of UC to be an effective 
treatment with 35% in remission at 2 years in those previously treated with IFX (77) which 
has been replicated in case series in PIBD(79).  
 
Planned withdrawal 
The STORI trial assessed response to planned drug withdrawal in adults with a 
multicentre prospective trial in those with stable CD/remission on eight weekly IFX AND 
stable doses of anti-metabolite medications (6 Mercaptopurine, Azathioprine and 
Methotrexate). 50% relapsed within two years of discontinuing therapy, most within the 
first year, although regained response when recommenced IFX but requiring dose 
intensification (265) . In this cohort, 43% of patients had a planned withdrawal, most in 
clinical remission at discontinuation of therapy and were males with CD. 15% restarted IFX 
after a median of 0.87 years similar to that seen by Molander(286).  
The UK anti-TNF withdrawal study group reported a third of patients will have a 
moderate/severe relapse by 12 months after stopping therapy increasing to 54% by two 
years but, reassuringly 90% who restarted IFX did so successfully(287). In a prospective 
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study by Molander, 19% relapsed after a median of 6 months who had been in clinical and 
endoscopic remission prior to discontinuation and had received anti-TNF for a minimum of 
12 months. 67% remained in remission at 12 months post planned withdrawal and 85% 
remained in endoscopic remission. Unfortunately, predictive factors for a sustained 
remission could not be elicited but re-introduction of anti-TNF therapy was successful(286). 
Due to transition, it is unclear how many patients had a relapse following planned drug 
withdrawal necessitating restarting anti-TNF, however, 4 patients (2 ADA and 2 IFX) had a 
second course having had a planned withdrawal on their first course. 
 
Safety  
No deaths or malignancy occurred in the anti-TNF cohort. IFX infusion reactions 
occurred in 18%,  with 15% reported in multiple pooled studies (50). Serious infections 
occurred in 3%, similar to pooled studies at 3.3%(50). 14 (7%) required hospitalisation due 
to IFX toxicity. ADA was well tolerated with 5 (9%) hospitalised for toxicity but mostly minor 
side effects, although serious infections of 3% were noted in other studies(50). 
 
Limitations of the study 
As a ‘real life’ clinical experience from a nationwide managed clinical network from 3 
different centres over a 13 year period there is significant heterogeneity in the data due to 
changing treatment practices as new evidence emerged and differing rates of uptake of 
change within these centres; example of these include episodic dosing with IFX in 2000-
2007(134) and induction only moving to  induction plus maintenance given improved 
outcomes in those that continued(55). No consensus guidelines existed on dosages, criteria 
for commencement of therapy or escalation/ de-escalation of treatment and PCDAI data  
was not routinely collected so PGA data was used instead which has a strong correlation 
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(144, 288). Only patients under 18 years treated in paediatric centres were included which 
may underrepresent the true numbers treated and could influence the efficacy and safety 
signals generated. 
Growth results should be interpreted with caution as only those treated with anti-
TNF therapy were reported which represents a more severe phenotype where a relatively 
higher rate of growth failure would be expected.  Satisfactory growth data was available for 
only 49% and full pubertal status in 71% of these. Now treatment algorithms have changed 
considerably with IFX is given earlier in treatment course if a severe phenotype such as 
those with widespread colonic deep mucosal ulceration, growth failure or severe perianal 
disease with episodic treatment abandoned and long-term maintenance being the norm. 
Other studies have shown the benefit to early aggressive treatment in altering the disease 
progression(57), so it is possible that if IFX is given earlier the somewhat modest 
improvement in growth seen in this study will become more pronounced.  
 
7.9. Conclusion  
 
This Scottish national experience is the only UK population-based study on biological 
outcomes in a PIBD in real-life clinical setting, and the first nationwide study ever on IFX in 
either UC or IBDU, and on ADA in all PIBD subtypes.   Biologicals are moderately effective in 
PIBD management, but many have limited duration of effect. Known safety signals were 
confirmed without any new types of adverse effect or deaths reported. Growth failure was 
relatively common, with 18% demonstrating severe growth failure at initiation of therapy. 
Infliximab and Adalimumab are both associated with improved linear growth after 12 
months of treatment. Most improvement was seen in those who achieved remission, had 
disease for longer than 2 years, received combination therapy with azathioprine, received 
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maintenance therapy and were Tanner stages 1-3.for IFX. For Adalimumab, improvement in 
growth in those who were Tanner stages 2 and 3.  
Dependency was commonly seen with IFX and ADA with 50% of ADA and 34% of IFX 
treated patients still on treatment at 12 months. MTX usage and remission post induction 
were associated with dependency but analysis is needed to examine these relationships 
more closely in a prospective trial.  35% of IFX treated patients had a planned drug 
withdrawal with only 15% restarted for disease relapse. Early identification of those in 
whom planned withdrawal will be successful has significant cost implications and needs to 
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8. Mortality and cancer in paediatric inflammatory 




Paediatric-onset inflammatory bowel disease (PIBD) has a more rapidly progressive 
phenotype which is often more extensive than adult-onset disease at diagnosis and has 
earlier use of immunosuppressant therapies including thiopurines and anti-TNF agents(16, 
266). Short and long term complications of immunosuppression include the risk of 
malignancy and opportunistic infections which compound the already established increase 
risk of colonic cancer(289). The exact incidence of cancer and mortality in PIBD is unknown 
with a paucity of published literature, those that have been published have short term 
follow up only(120) often due to transition to adult services, or are retrospective, single or 
multi centre performed in a single country with few population-based cohorts. A 
systematic review on mortality in PIBD reported the most common cause of death was 
cancer in 76.2%,  with other non-cancer deaths related to infection or gastrointestinal 
complications and those that died of sepsis, most 43.8%, were on dual immunosuppression 
(290).  
 
8.2.1. Aims and hypothesis 
The aim of this study was to characterise the risk of cancer and mortality in 
population-based cohort of PIBD patients within Scotland to provide relevant and 
appropriate information regarding risks of treatment for patients and their families. 
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8.3.1. Case identification 
In Scotland, specialist paediatric gastroenterology, hepatology and nutrition (PGHAN) 
is provided through three tertiary funded Scottish regional networks covering all four 
academic centres (Glasgow, Edinburgh, Aberdeen and Dundee), and all district general 
hospitals having paediatric units thus forming a virtual Scottish national network as 
described previously(92, 134). Patients were identified through review of the national 
Paediatric Inflammatory Bowel Disease in Scotland Audit (PISA) and request for information 
from lead clinicians for each of the three main centres (Glasgow, Edinburgh and Aberdeen). 
All cases of mortality and cancer in PIBD patients cared for in paediatric services (<18 years) 
in Scotland were collected retrospectively from 01.01.2003 to 31.12.13. In 2011, Scotland 
had a population under 16 years of just under 1 million and the incidence of PIBD 2003-
2013 was 9.4/100,000/year. 
Diagnosis of IBD was based on clinical symptoms, laboratory results, endoscopic, 
radiological and histological assessment in-line with the revised Porto criteria(13) and 
Lennard Jones(135) by the local specialist PIBD team. Patients were diagnosed as either 
Crohn’s disease (CD), Ulcerative Colitis (UC) or Inflammatory Bowel Disease Unclassified 
(IBDU).  
 
8.2.2. Data collection 
Further details were collected using standardised proformas on PIBD disease course, 
medications, cause of death/cancer and relation to IBD/IBD treatments 
(immunosuppressants, anti-TNF agents, corticosteroids) and outcome (death or outcome at 
Chapter 8- Mortality and cancer in paediatric inflammatory bowel disease in Scotland 2003-
2013-a nationwide retrospective study 
202 
 
last follow up). Data was collected from date of diagnosis until date of death or last 
paediatric follow up, whichever came first.  
 
8.2.3. Statistical methods 
Continuous variables were expressed as median and interquartile ranges. Cancer and 
mortality rates were calculated using assumptions and methodology adapted from the 
Porto group’s publication on mortality/cancer in PIBD (131). No Scottish prevalence data 
exists for this study periods, however, estimated PIBD prevalence rates were calculated 
based on the same assumptions as the Porto group of 30 per 100,000 (185, 291-293). The 
Porto group assumed a prevalence of 60 per 100,000 for 0-26 years but only ages 0-16 are 
covered in this study hence using 30 not 60 per 100,000. This assumption is supported by 
recent Scottish prevalence data from 2016 where prevalence was 58.9 per 100,000 at its 
highest in those 0-16 years(294). The incidence of PIBD increased from 7.82 per 100,000 in 
2003-08 to 12 per 100,000 in 2015-2017 so assuming a similar increase in prevalence 38 
per 100,000 would be the expected prevalence which is comparable with the Porto study. 
The total population covered was multiplied by the prevalence providing an estimation of 
the population at risk. then multiplied by 11 to calculate the exposure of the duration of 
the study. Incidence rates are reported based on the number of patient years.  
 
8.4. Results 
Four cases were identified within the study period, 2 males and 2 females. Three 
patients died, one male died of malignancy, one female died of IBD disease related 
complication and one female died of a non-disease related cause. 
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One male with CD died of gamma delta non-Hodgkin ‘s lymphoma. The patient was 
diagnosed with panenteric CD at 14.6 years of age and treated initially with corticosteroids 
then commenced azathioprine after 3 months. He had a disease relapse and underwent a 
left hemicolectomy but continued azathioprine which was stopped at age 17.2 years then 
was diagnosed with gamma delta non-Hodgkin’s lymphoma at aged 17.5 years. He 
underwent active treatment but unfortunately died aged 18 years, 3.4 years after his IBD 
diagnosis. He never received any anti-TNF agents and there was no family history of 
malignancy. 
One female with UC died aged 12.2 years of a volvulus post restorative proctectomy. 
She has been diagnosed with UC aged 9.4 years and underwent a colectomy for active 
disease. Her duration of disease was 2 years and 9 months having never received any 
thiopurines or anti-TNF agents. 
One female with IBDU died aged 11.7 years from a non-IBD related conditions. She 
had been diagnosed with IBDU aged 8.99 years and treated with corticosteroids only, never 
received thiopurines or anti-TNF agents. She had significant other underlying health issues 
and had chronic lung disease with home oxygen secondary to a left sided congenital 
diaphragmatic hernia. She died from a lower respiratory tract infection on the background 
of deteriorating lung function 2.7 years after her IBD diagnosis. Since the number of deaths 
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Two cases of malignancy were diagnosed as mentioned above, one male with 
gamma delta non-Hodgkin’s lymphoma and one acute myeloblastic leukaemia. The case of 
acute myeloblastic leukaemia was diagnosed in a male with CD aged 16.8 years. He was 
diagnosed with CD aged 15.5 years and treated with azathioprine for 13 months prior to his 
diagnosis of leukaemia. He was successfully treated and at last review with in remission 
from his CD on no active treatment. Since the number of cancers was 2 in 3829 patient 
years, the incidence of cancer was 522 per 1,000,000 patient years. 
8.5. Discussion 
Death and malignancy remain a rare occurrence in PIBD in Scotland with only 4 cases 
reported between 2003-2013 with 500 new cases diagnosed during this time was a 
mortality rate of 783 per 1,000,000 patient years and malignancy risk of 522 per 1,000,000 
patient years. One death was non-IBD related with the remaining two cases linked, one 
died from treatment related complications who developed lymphoma and one from 
disease related complications post restorative proctectomy. The final case of cancer was 
leukaemia following thiopurine therapy in a male with CD. After data collection ended, a 
further malignancy was reported in a 10-year-old male diagnosed aged 4 years with CD 
who lost response to AZA so escalated to MTX then developed acute myeloblastic 
leukaemia which was treated initially with chemotherapy then bone marrow 
transplantation. Further case was reported post transition to adult care of a young man 
previously treated with thiopurines who developed a fatal lymphoma.  
No serious infective complications were reported which could be related to the 
small numbers (4 versus 18) in ESPGHAN, or the levels of immunosuppression. Both fatal 
infections reported in UK/Irish audit of 72 children treated with ADA were on dual 
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immunosuppression and receiving parenteral nutrition (79), whilst 3/13 deaths due to 
sepsis in the ESPGHAN cohort had a central venous catheters(117). 
The risk of malignancy in PIBD is unknown, however, the largest case series to date 
reported retrospectively on 2 cases of lymphoma (both males treated with thiopurines) 
amongst 1374 patients over a 4.8 year follow up in a North American cohort providing an 
incidence amongst those exposed to thiopurines of 4.5 per 10,000 patient years(44); 
although this is non-population-based. In the adult CESAME study examining 5867 patients 
were treated with thiopurines, the highest risk was associated with  older age and longer 
disease duration(295) with a rate of 9 per 10,000 patient years. Population-based studies 
have reported 20 cancers in 9405 cases of childhood-onset IBD with colorectal, small bowel 
and liver cancers the most common with an increased risk of developing cancer of 3.3 per 
1000 years with PIBD compared to 1.5 per 1000 years if no IBD(121). No increase in cancer 
was observed in those treated with anti-TNF agents and only 15 cases of cancer associate 
with thiopurines which is supported by a paediatric systematic review which with no 
increase in lymphoma risk in those treated with anti-TNF compared to other 
therapies(296). 
The risk of lymphoma in PIBD appears to be treatment related with two key types, 
hepatosplenic T cell lymphoma and EBV driven lymphomas.  Hepatosplenic T cell 
lymphomas were reported in relation to IBD in 2007 with a case series of 8 young patients, 
all of whom were treated with azathioprine and infliximab(119). This rare cancer was 
associated with a poor survival rate with 6 out of 8 cases dying. Reports of this cancer lead 
changes in practice on the use of concurrent use of immunomodulator with anti-TNF drugs, 
specifically azathioprine. Controversy still exists now within paediatric gastroenterology 
over single agent use of anti-TNF or use in combination with other immunosuppressant, 
particularly in EBV naive patients where it is thought to contribute to lymphoma(297). The 
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combination therapy has the advantage of reducing immunogenicity and potentially 
prolonging the response to the anti-TNF agent(298), however, it must be balanced against 
the potential increased risk of malignancy and now of infection. An adult systematic review 
was performed to examine the risk of malignancy associated with anti-TNF therapy which 
found no increased risk (299) but concluded that most studies had a relatively short follow 
up period of 1 year, that was potentially insufficient to detect an increased risk. The 
DEVELOP registry aimed to explore the risk in the paediatric population and reported that 
IFX was no associated with an increased risk, however, thiopurine use was(130).  
Importantly, in this study 3/15 cases of cancer occurred in patients over 18 years which in 
most UK centres would be managed by adult gastroenterologists. 
Thiopurines have been implicated in the development of EBV driven 
lymphomas(300). In the CESAME study, 52% of lymphoproliferative disorders were EBV 
positive(295) with a reported incidence of 0.1 per 1000 patient years for primary EBV 
infection related lymphomas in EBV naive males under 35 years(301).  EBV exposure often 
occurs in childhood/adolescence and with the increased risk of EBV driven lymphomas 
practice in many centres is to screen prior to commencement of AZA and considering 
alternative in those naive. In the ESPGHAN study, 3 out of 11 who developed lymphoma 
were EBV positive, all received thiopurines so were thought to be treatment related(117), 
this was also reported in a large Dutch study where 92% of IBD patients diagnosed with 
EBV positive lymphoma had received prior thiopurines compared to 19% of EBV negative 
lymphomas(302).  
Cancer risk in PIBD may not become apparent until adult life, potentially related to 
the cumulative effects of disease severity, ongoing inflammation, medications including 
thiopurines and anti-TNF therapy, both in isolation or combination which may act 
synergistically. An adult nationwide study reported an increased risk of lymphoma in those 
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treated with AZA which became statistically significant after 4 years of use, , the risk then 
normalised after stopping for 4 years(303). Despite the more widespread use of anti-TNF 
agents, there is no decrease in malignancy with a suggestion that those diagnosed after 
2002 have an increase in gastrointestinal and melanoma skin cancers(121), however, it was 
not powered to detect statistically significant differences which would require more 
participants and a longer duration of follow up. A systematic review on the natural history 
of paediatric-onset IBD reported cancer in 14 patients, 12 of whom were diagnosed over 
the age of 19 years(116) which in the UK would be in adult practice with 8/14 had UC and 
7/14 had colonic adenocarcinoma suggesting the potential effects of uncontrolled 
inflammation on the risk of malignancy.  An adult population-based study confirms this 
hypothesis having reported an excess mortality of 14% in IBD patients related to 
inflammation of the gut, for both UC and CD, which was highest in the first 3 years after 
diagnosis but remained significantly elevated in the long term(304). 
Prospective European wide studies into mortality and morbidity are required with 
long duration of follow up which relies on prompt and full reporting from individual 
countries and clinicians within those countries for complete accrual. Transition age varies 
by country so cases may be seen and treated by adult gastroenterologists so not recorded 
in some countries for example, those over 16 years in Scotland are seen in adult practice 
whilst in France they would remain in paediatric practice until 19 years old. As is already 
known, environment has a role to play in the pathogenesis of IBD, it may also influence 
response to treatment, development of cancer and other adverse outcomes such as 
unusual infections (i.e. more likely in countries with a high prevalence of tuberculosis to 
have re-activation of this).  
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The strengths of this study lie with the robust nature of the nationwide data 
collection across Scotland and the managed network of care that exists ensuring that all 
new cases of PIBD and adverse events are recorded. All patients were treated in paediatric 
centres, so data collection was complete allowing appropriate information on treatments 
and risk factors to be identified over a 10-year period. The limitations of this study are that 
the numbers involved are low in comparison to other similar studies with only cases 
included who were treated within the paediatric service, potentially excluding those 
diagnosed and treated in adult services. Furthermore, the relatively short follow up period 
means that long term sequelae remain unknown as patients transitioned to numerous 
different adult hospitals so future collaboration with adult gastroenterologists is crucial. 
The use of anti-TNF agents has increased since the study ended so it is possible that more 
adverse events will be have occurred.  
 
8.6. Conclusions 
Cancer and mortality remain a rare occurrence in PIBD which is confirmed in this 
population-based nationwide cohort study with only three deaths, two related to IBD and 
two cases of malignancy, both related to azathioprine, one of whom died. The results of 
this study reassure clinicians as to the rarity of these devastating consequences which can 
be used when counselling families about commencing immunosuppression. Further 
prospective collection of data is required due to the relatively short follow up period of 10 
years, particularly as the use of immunosuppressant and anti-TNF agents are increasing in 
































9.1 Challenges of epidemiological research 
 Epidemiological research can provide information on the natural history of diseases 
and environmental associations that may be involved in pathogenesis. However, good 
epidemiological data is challenging to produce, firstly patients with the condition of 
interest must be identified. For PIBD, diagnostic approach varies between countries and, 
even within centres in the same country with not patients having endoscopic evaluation as 
per current guidelines(10) as exemplified within Scotland, where IBDU patients underwent 
differing procedures.  Furthermore, historically studies have divided into “probable” and 
“possible” IBD(187, 190, 193) with Scottish data prior to 1995 having no cases of IBDU, with 
2 being reclassified as UC before IBDU was a recognised IBD subtype. The varying 
classifications makes relating data from these studies difficult to correlate with the current 
literature and other historical data. 
Secondly, epidemiological databases collect information through coding from 
hospital/government/insurance databases which is dependent upon correct insertion by 
coders and is fraught with misclassification bias(305). Approximately 10-20% of patients 
classified via ICD coding algorithms with IBD using administrative databases do not actually 
have IBD(305). Scottish incident data was validated from 1981-1995 to confirm the 
diagnosis, however, the most recent cohorts have not which is planned for future work. A 
challenge for the Scottish PGHAN network is the different practices of the units, both retro 
and prospective data collections were done, as well as database managers in some but not 
all centres. Practice varied on reviewing diagnosis for reclassification and inclusion of 
prevalent cases which may occur, particularly if the patient relocates to a new area. Certain 
studies have performed validation techniques to ensure the robust nature of data collected 
through administrative databases (111, 113), however, not all(183). Therefore, it is 




plausible that rates of rise observed is over-estimations given the intrinsic difficulties 
collecting the data.  
Thirdly, there is a challenge of ensuring all eligible patients are captured, particularly 
cases which may have been treated and diagnosed in adult centres, a challenge for older 
adolescents or stand-alone children’s hospitals. Close collaboration with adult colleagues 
will ensure all relevant patients are included as well as well-established referral pathways. 
A further challenge is missing patients with a milder phenotype who may not require 
hospital admission, this is less problematic in paediatric practice in Scotland where children 
either undergo endoscopic assessment either under sedation or a general anaesthetic but 
may affect teenagers diagnosed in adult services. 
Fourthly, when comparing incidence rates of PIBD between countries, age range 
used which varies between countries and even within individual countries. North American 
centres will include patients up to 19 years so incidence studies present data from 14 to 19 
years(180, 189), which drives up incidence rates. In Scotland, patients under 16 years are 
managed in paediatric services, however, it is possible that patients on the cusp are seen in 
adult services dependent upon geographical location or mode of presentation (acute 
admission verses outpatient referral).  
Finally, epidemiological research can suggest environmental factors associated with 
the development of PIBD but cannot prove causation. Often studies are limited by recall 
bias and confounders as many are retrospective with a complex interaction of factors 
making clear causal factors difficult to extrapolate. Population-based research reduces 
variability of data collection allowing improved generalisability.  
 
 




9.2 Incidence and prevalence of paediatric-onset inflammatory bowel 
disease 
 
The incidence and prevalence systematic reviews (Chapters 3 and 4) both 
demonstrate an increase in PIBD, CD and UC. Temporal trends on incidence demonstrated 
a significant increase in PIBD in 11/12 studies, 11/14 for CD and 10/15 for UC which were 
predominately from Western Europe and North America. The lack of data from Africa, Asia 
and Eastern Europe provides challenges in determining the global impact of PIBD, however, 
inferences can be drawn from adult studies which suggest an increase in South America 
(Brazil, Uruguay and Barbados)(306) and Asia(101). Prevalence in adult-onset IBD in Asian 
countries such as Japan, South Korea and Hong Kong has increased so it can be 
hypothesised that PIBD may be rising in these countries (2, 87). However, caution should 
be used when interpreting the results of systematic review due to the wide variation in 
methodologies used, variety of age range used for cut off of paediatric patients from 14 
years or use of “possible” and probable” IBD diagnoses (2). Studies were not all population-
based including those gathered from insurance databases so may not be a true reflection of 
the incident cases within that geographical area (307). Four studies were identified (2 from 
the UK, 1 each from Denmark and Bosnia(154, 155)) (93, 132)which were not included 
within this previous review which would have provided a more global representation of 
PIBD. 
Potential environmental clues involved in PIBD aetiology may be revealed by 
exploring the incidence in developing countries which have not previously reported 
incidence data or those who have become “westernisation”(87). China reports higher 
incidences of IBD in areas with increased urbanisation(209, 308) supporting this hypothesis. 
Furthermore, incidence and prevalence rates from newly industrialised countries are 
similar to rates reported in Western Europe in the 1970s and 1980s(87). Recent inception 




cohorts from areas with a paucity of data will aid understanding of the increase such as the 
Asia-Pacific Crohn’s and Colitis Epidemiological study(308) and the ECCO-EpiCom 
study(108). The EpiCom study although based in countries in both Eastern and Western 
Europe (14 Western and 8 Eastern European countries) provides information on the 
incidence of IBD among migrants to 6 of these countries suggesting similar incidence 
between those born within the country and those who migrate there(309). 
There is a paucity of data on prevalence of PIBD (Chapter 4) with only 27 studies 
reporting from 12 countries compared to 174 studies on incidence from 35 countries 
included in the previous and current incidence systematic reviews. The practicalities of 
collecting prevalent data contribute to this as patient can migrate into and out of the area. 
A prospective registry would capture patients at diagnosis but requires regular monitoring 
to ensure it remains accurate and that non-IBD cases and those who have 
emigrated/transitioned are removed. 
Scottish incidence (Chapter 5) continues to increase over the last 45 years with the 
rise driven by paediatric-onset CD with an incidence of 10.6 per 100,000 for IBD, 6.6 per 
100,000 for CD, 2.7 per 100,000 for UC and 1.3 per 100,000 for IBDU. The only other 
country reporting higher incidence was Finland with 13 per 100,000(173). Finland provides 
a good comparator for population-based incidence having similar population sizes, another 
is Ireland who reported an incidence of 5.6 per 100,000(153). Data collection differed 
between these studies with Ireland collecting data retrospectively through case note 
review and Finland gathering via a national health insurance scheme where physicians 
register a medical certificate for the patient with the condition according to diagnostic 
guidelines, families then are reimbursed for medications. This national data collection 
system may explain the increased incidence in Finland as new cases are captured 




irrespective if diagnosed in paediatric or adult centres. Once validation work has been 
performed in Scotland, the incidence may increase more in line with Finland.  
Previous assertions that the increase was related to a milder phenotype being 
diagnosed seems unlikely given the same diagnostic approach used in the centres for the 
previous study by Henderson(92) here. Others have hypothesised the increase is due to 
more young people aged 14-16 years being seen and diagnosed in paediatric centres now 
who would have previously been seen in adult services however, referral patterns have 
remained stable from the previous cohort to this so it is unlikely to sufficiently explain the 
observed rise and may even suggest an underestimate.  
As PIBD increases, more attention focuses on potential causes and triggers. Genetics 
was initially thought to play a key role with the discovery of the NOD2/CARD15 gene which 
led to further exploration of the genome and the discovery of 163 loci thought to be 
involved in IBD(310).However, most risk alleles only increase the chance of developing IBD 
by a small magnitude supporting the role of environment in pathogenesis(186). 
Furthermore, genetics evolve over thousands of years so would not have had enough time 
to sufficiently change in the last 30 years to fully explain the increase. The current 
hypothesis is that in genetically susceptible hosts there is a dysregulated immune response 
to intestinal flora leading to the development of IBD. Disruption to the microbiome is 
associated with the development of IBD(311) and within IBD there are particular bacteria 
which are associated with IBD subtypes such as Escherichia coli in ileal CD(312) as well as 
reduced microbial diversity(229). Abnormalities in both the innate and adaptive immune 
responses are thought to contribute to abnormal intestinal responses in IBD. The results of 
GWAS studies has focused on mucosal innate immune responses such as defects in the 
epithelial barrier integrity, autophagy, innate microbial sensing and unfolded protein 
responses as leading to the development of IBD. 




In countries with increased industrialisation and “westernisation” reporting 
increasing incidence of PIBD(2, 87), exploring the “exposome” or environmental triggers 
are crucial to understanding the pathogenesis. Several risk factors have been identified 
including air pollution, smoking, rural living, pets at home and larger family size(201, 217, 
221). Environmental factors have been shown to cause epigenetic changes (233) which are 
then affect interaction with the intestinal microbiome(234) and immune response(235) 
potentially leading to the development of IBD. Epigenetic changes may explain the early 
onset of disease in childhood in certain patients given the significant overlap in 
susceptibility genes shared by both adults and children with IBD(313). Antibiotic usage may 
also contribute to PIBD with an increased risk in those treated with antibiotics in the first 
year of life developing PIBD(218), this assertion is further supported by a recent case 
control study which reported an increased risk of developing IBD in those who had received 
antibiotics between 3 months to 5 years prior to diagnosis of IBD,  with the risk was highest 
in those under 18 years(314). 
Diet has been implicated in PIBD with a recent systematic review reporting the only a 
consistent association between high dietary fibre and intake of fruit with a decreased rate 
of CD(227). Other studies have reported that a Mediterranean diet is protective(315) yet 
others report an association with lower intake of fruit and vegetables(228). Diet affects the 
microbiome as has been shown in PIBD patients treated with EEN(316) and in healthy 
children(317) which may then affect the risk of developing IBD. 
The current trend of ever-increasing incidence and prevalence of PIBD continues in 
countries which have reported data, however, understanding of the pathogenesis leaves 
more questions unanswered than information provided. It is likely a complex and difficult 
relationship between genetics, environment, immune function and microbiota which leads 
to the development of PIBD. 




9.3. Inflammatory bowel disease unclassified 
Much about IBDU is contentious and in evolution having been first formally 
classified in 2005(9). Significant work is now underway to understand the natural history, 
disease reclassification, diagnostic algorithms and treatment options of this least common 
subtype of IBD(138, 239, 245). IBDU as a distinct subtype of PIBD is supported by the 
results of this study; 41% remained IBDU despite endoscopic reassessment with a median 
follow-up of 2.8 years.  23% did change diagnosis after endoscopic re-evaluation, most 
commonly to CD, with a small number requiring four endoscopic reassessments before 
changing diagnosis. The high rate of reassessment in IBDU patients is likely to reflect the 
clinician’s discomfort with the diagnosis and keenness to reclassify as either CD/UC, yet 
despite these efforts, often patients remain IBDU reinforcing the assertion of a distinct 
subtype with its own disease course. However, treatment effects can complicate the 
interpretation of histology during reassessment so is likely to explain in part why some 
patients remain IBDU. 
An interesting comparator for our data is the Eurokids registry, a prospective study 
across Europe, North America and Israel where at diagnosis, 7.7% of cases were IBDU 
which fell to 5.6% at the end of 5 year follow up as children underwent re-evaluation, most 
changed to UC (23/117) but 67% remained IBDU (138). However, Eurokids has 
methodological challenges that limit the generalisability of the findings including, lack of 
standardised diagnostic work up and histological review as both were clinician dependent 
at the individual centre. 42/265 reported cases of IBDU in Eurokids had features 
incompatible with the diagnosis such as granulomas or radiological evidence of small bowel 
disease(138). Another comparator is an Israeli  population-based cohort of IBDU patients 
collected over 27 years with at least one year follow up, 45% changed to CD and 9% to 




UC(318) in this cohort. However, the authors do not report on when cases were diagnosed 
or what investigations were performed, although the terminal ileum was not seen in 7% of 
cases who then had small bowel imaging (318). The high number of patients reclassified 
poses the question as to the validity of the initial diagnosis which the authors do not 
validate as IBDU. Potentially cases were labelled as IBDU where there was initial doubt but 
with modern classification would be diagnosed as CD/UC. 
Current hypotheses are that IBDU affects younger patients with a more aggressive 
phenotype which contradicts our findings of a milder phenotype in older children with the 
commonest age group 11-15 years (Chapter 6). The incidence in Scotland increased over 13 
years unlike other studies that have shown a steady rate(138), this could relate to a more 
robust diagnostic evaluation in this cohort compared to historical cases and that performed 
in other centres. A more rigorous diagnostic assessment may explain why IBDU is 
commoner in children than adults(140) who do not routinely undergo a upper 
gastrointestinal endoscopy and colonoscopy. Serology has been used in discerning IBD 
subtype but a recent study found no clear associations for IBDU(319), however, genetics 
have shown that it is  different subtype differing from both UC, colonic and ileal CD 
suggesting a genetic continuum from ileal CD to UC(244). 
In this cohort, most patients received UC treatment (5-ASAs/corticosteroids) at 
induction with 87% achieving remission, however, one patient who was treated with EEN 
entered remission and remained IBDU which suggests a more complex phenotype.  Greater 
understanding will come from population-based studies of patients diagnosed using 
standard algorithms and regular monitoring via databases.  
 
 




9.4.  Anti-TNF therapy in Scotland 
In chapter 7, anti-TNF drugs infliximab and adalimumab were shown to be safe and 
effective with 59% of CD and 54% of UC patients achieving remission post induction with 
IFX and 68% achieving remission with ADA. 13% had an infusion reaction to IFX and 7% had 
an adverse reaction requiring hospitalisation with no deaths. ADA was also well tolerated 
with only 9% had an adverse event requiring hospitalisation with 26% having milder events 
including infections. A significant number of patients went on to develop dependency 
requiring extended courses occurring in 40% for IFX and 60% for ADA. Risk factors for 
dependency was lack of steroid use at baseline. IFX had improvement in linear growth for 
those who achieved clinical remission post induction, were in the early stages of puberty 
(Tanner 2 and 3) and those who had disease for under 2 years. Improvement was seen with 
adalimumab at 12 months in Tanner stages 2-3. 
Modern use of anti-TNF therapy in children has changed significantly from an 
episodic or “as needed” basis initially to maintenance therapy (53, 55) with dosing based 
on weight alone initially but now adjusted according to therapeutic drug levels (61).  
Current evidence supports a more personalised approach or “treat to target”, by 
proactively adjusting infliximab levels to a therapeutic range even when patients are well, 
which, results in reduced rates of treatment failure including the need for surgery, IBD 
related hospitalisation or serious infusion event(61). Additional benefits will come from 
cost savings related to decreased adverse events which may negate the higher costs 
incurred from increasing anti-TNF usage and doses.  A key strategy going forward is to 
identify early in the disease course those patients who would benefit from anti-TNF 
therapy and commence early which may alter disease course.  
 




9.5 Cancer and mortality in PIBD 
As demonstrated in Chapter 8, cancer and death remain an infrequent but 
devastating consequence in PIBD with a quoted risk of 5.3 per 10,000 patient years in a 
recent systematic review of children treated with infliximab(296). While not all deaths in 
this cohort were directly related to IBD and none to the use of infliximab, two cases of 
cancer were observed, both of which were treated with thiopurines, including a case of 
gamma delta non-Hodgkin’s lymphoma which proved fatal. 
It is challenging to quote the exact risk of malignancy or death given the lack of 
accurate prevalence data to use as a denominator and paucity of population-based studies 
although this is now improving(120, 304). Population-based studies have reported an 
increased mortality for both CD and UC in PIBD patients(122, 304), including an recent 
Danish study where CD mortality was 62% higher for those diagnosed under 19 years when 
compared to those diagnosed aged 60-79 years with a two-fold increase for UC patients 
diagnosed in childhood(122). Other nationwide cohort studies have not observed this 
increase, potentially related to the limited follow-up of 11 years(120). Swedish registry data 
reported an increase in cancer in PIBD occurring under 18 years and in adulthood, quoting 
a relative risk of 3.2 of UC and for 1.8 CD(320). They suggested no increased risk for 
thiopurines contrary to other published evidence, however, these results must be 
interpreted with caution, data is from 1964-2014, during which time significant advances 
have been made in the treatment of PIBD improving disease control as uncontrolled 
inflammation is a significant risk factor for development of gastrointestinal malignancy 
(321) the most common type of cancer reported. EPIMAD also reported a three-fold 
increase risk of malignancy with 2/9 cancers colonic in origin. ESPGHAN reports 6/25 
deaths related to infection and 8 to cancer. suggesting that immunosuppression is a key 
risk factor in these deaths. However, the increased risk of cancer precedes the widespread 




use of anti-TNF drugs and azathioprine(120). A recent systematic review on the natural 
history of PIBD reported in 12/14 patients who developed cancer had either small bowel or 
colonic adenocarcinoma, after 19 years when most paediatric patients would be followed 
up in adult practice(116). 
 In adult-onset IBD, routine screening is advised for cancer surveillance which begins 
8 years post diagnosis and is repeated every 2-3 years(322). Recent colonoscopy was 
associated with a  reduced incidence of colorectal cancer and in those diagnosed a reduced 
mortality(323). Screening for colorectal cancers is not routine in paediatric practice, 
however, given the increased risk and evidence of improved outcomes, a potential strategy 
would be routine colonoscopy prior to transition in those who had not undergone in the 
last 3 years. 
Cancers may be classed as disease related and secondary to chronic inflammation 
such as colonic or cholangiocarcinoma or treatment related such as lymphomas. The 
increased risk of colonic cancer associated with IBD is well established(324, 325) with 
cancers such as EBV positive lymphomas thought to be treatment related(117, 302).  
Studies in adults with UC have shown a 4-fold increase in risk of lymphoma in those 
being treated with thiopurines which increases each year it is given reaching statistical 
significance after 4 years before reverting to baseline once the drug has been 
discontinued(303).  This increased risk is supported by a multicentre prospective registry 
which reported no increased risk of malignancy with anti-TNF agents compared to those 
not treated with a biological yet an increased risk of malignancy in those treated with 
thiopurines with or without a biologic(130). Based on these result, deeper consideration to 
discontinuation of therapy should be discussed with patients and families, however, many 
paediatric gastroenterologists would be cautious about stopping treatment while potential 
adverse effects on growth, pubertal development and schooling exists(326). Therefore, a 




balance is needed between treatment to control IBD symptoms affecting quality of life 
versus the risks of uncontrolled inflammation leading to colonic dysplasia and immune 
dysregulation leading to impaired tumour surveillance(118). Newer drugs being developed 
need to reduce bowel inflammation with no increased risk of infection and sepsis. 
Prospective national registries recording cancer and mortality in both adult and paediatric-
onset IBD would aid clinicians in counselling patients and families. France and Finland have 
such databases to follow patients from diagnosis in childhood to adulthood so not lost to 
follow up, a key limitation in many studies on mortality.   
 
9.6. Future directions and research agenda 
Incidence in Scotland of PIBD has been collected for 45 years with validation of the 
cohort until 1995 ensuring the robust nature of the data obtained with non-IBD cases 
removed. A key success for PIBD in Scotland has been the introduction of managed clinical 
networks and strong relationships between tertiary and secondary care allowing patients 
to access high quality care close to home. Once the validation has been performed and 
relevant ethical permissions obtained, further temporal trend analysis can be performed on 
the North-South divide which has been demonstrated already. 
A prevalent database is needed to ensure adequate provision of services for children 
and their families for this is a chronic lifelong condition which impacts upon growth, 
nutrition, psychological wellbeing and educational attainment. Financially this will allow the 
Scottish government to accurately understand the disease burden and cost involved to 
ensure high standards of care as per UK IBD standards. Once the validation work has been 
performed, this can be used to create a prevalent database for each of the lead centres. 
After the prevalent database is established, a database manager or researcher, would visit 
each centre on a regular basis to add in prospectively new incident cases, review changes 




of diagnosis with the clinical team, remove those who have either transitioned or moved 
out of the area and add in those who have relocated. 
The increase in mortality in adults who were diagnosed in childhood in other 
population-based cohorts is concerning, particularly given the increasing number of young 
people with IBD making it is critical to follow these children into adulthood. Once a 
prevalent database is established, it would allow cohort studies to be performed and 
explore in more depth mortality and morbidity of PIBD using data linkage via Information 
Services Division Scotland. Data linkage of patients with PIBD diagnosed from 1981-2014 
(once validation work completed) could be matched (age, deprivation, geographical 
location and gender) to controls using a case control study design then access data on 
admissions (SMR01- covers inpatient admissions and morbidity), cancer registry (SMR06) 
and death (National Records for Scotland) using existing Scottish government held records. 
Similar methodology could be used to gather information on cardiovascular disease and 
thromboembolic events and to explore environmental risk factors including rural/urban 
location and latitude. However, an easier process would be the electronic transfer of 
information to adult hospitals where data could then be captured differentiating these 
cases from prevalent adult cases, consequently outcomes for these patients could be more 
easily identified.  
The Scottish biologicals registry has now been established and by continuing to input 
data for all patients nationwide, long term data n the effects of these drugs including 
malignancy and mortality can be captured. Anti-TNF drugs have only been widely used in 
the last 10 years in paediatric practice and 15 years in adult practice so further longitudinal 
data will enhance knowledge and expertise in optimal management. The registry could be 
expanded to collect data on drug levels, co-immunosuppression and drug escalation and 
de-escalation pathways. An additional benefit will be the ability to capture data on newer 




drugs including vedolizumab, ustekinumab and tofacitinib to gain further insight into 
efficacy/side effects to support or refute   their use in PIBD using “real life” clinical data 
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